Document:

<PAGE>
                                                                   Exhibit 10.52

                                BOTOX(R) -- JAPAN

                                LICENSE AGREEMENT

                                 BY AND BETWEEN

                                 ALLERGAN, INC.

                               ALLERGAN SALES, LLC

                                       AND

                               GLAXO GROUP LIMITED

<PAGE>

                       BOTOX(R) -- JAPAN LICENSE AGREEMENT

     THIS BOTOX(R) -- JAPAN LICENSE AGREEMENT including the exhibits and
schedules referred to herein and attached hereto, (collectively, the
"Agreement"), dated September 30, 2005 (the "Effective Date"), is made and
entered into by and between ALLERGAN, INC., a Delaware corporation having a
place of business at 2525 Dupont Drive, Irvine, California 92612, and ALLERGAN
SALES, LLC, a Delaware Limited Liability Company having a place of business at
2525 Dupont Drive, Irvine, California 92612, (ALLERGAN, INC. and ALLERGAN SALES,
LLC are collectively referred to herein as "ALLERGAN") and GLAXO GROUP LIMITED,
a private limited company incorporated in England and Wales, having its
registered office at Glaxo Wellcome House, Berkeley Avenue, Greenford,
Middlesex, England UB6 0NN ("GSK").

                                    RECITALS

     A. ALLERGAN Controls (as defined in Article 1 below) the ALLERGAN Patent
Rights (as defined in Article 1 below), ALLERGAN Know-How (as defined in Article
1 below) and ALLERGAN Trademarks;

     B. GSK desires to obtain from ALLERGAN, and ALLERGAN is willing to grant to
GSK, certain licenses under the ALLERGAN Patent Rights, ALLERGAN Know-How and
ALLERGAN Trademarks under the terms and conditions herein; and

     C. ALLERGAN will have Product manufactured and supplied to GSK under the
terms of the Supply Agreement (as defined in Article 1 below).

     NOW, THEREFORE, in consideration of the mutual covenants and obligations
set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, ALLERGAN and GSK hereby agree as
follows:

1.   DEFINITIONS

     As used in this Agreement, the following terms will have the meanings
indicated:

     1.1 An "Affiliate" of a Party or Person means any Person, whether de jure
or de facto, that directly or indirectly, controls, is controlled by, or is
under common control with such Party or Person, as applicable. Solely as used in
this definition, "control" means (a) direct or indirect ownership of more than
fifty percent (50%) of the equity (or such lesser percentage which is the
maximum allowed to be owned by a foreign corporation in a particular
jurisdiction)

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

<PAGE>

having the power to vote on or direct the affairs of such Party or Person, as
applicable, or (b) the possession, directly or indirectly, of the power to
direct or cause the direction of the policies and management of such Party or
Person, as applicable, whether by the ownership of stock, by contract, or
otherwise.

     1.2 "Agreement" will have the meaning set forth in the preamble.

     1.3 "ALLERGAN" will have the meaning set forth in the preamble.

     1.4 "ALLERGAN Corporate Trademarks" will have the meaning set forth in
Section 1.9.

     1.5 "ALLERGAN Know-How" means any and all know how, information, data
(including, without limitation, pre-clinical data, toxicology information and
clinical trial data), documents, materials, and software (including, but not
limited to, marketing information, technical information, regulatory
information, clinical information, processes, procedures, methods, formulae,
protocols, and techniques) relating to Product (including, without limitation,
Product Improvements and Enhancements) but not including ALLERGAN Manufacturing
Information, which exists as of the Effective Date or during the Term and is
Controlled by ALLERGAN or its Affiliates.

     1.6 "ALLERGAN Manufacturing Information" means any and all confidential
documents and information Controlled by ALLERGAN and/or its Affiliates and
relating to the manufacture of Product.

     1.7 "ALLERGAN Patent Rights" means any and all patent applications and
patents generically or specifically claiming or covering the use, sale, offer
for sale and/or import of Product (including without limitation the active
pharmaceutical ingredient in Product and its dosage forms and formulations),
that are Controlled by ALLERGAN or its Affiliates as of the Effective Date or
during the Term in the Territory, including without limitation the following:
(a) patent applications and patents set forth on Exhibits A and A-1, such
Exhibits to be updated by ALLERGAN at least one (1) time in each Calendar Year
during the Term and also within thirty (30) calendar days after GSK's written
request, which request will not be made by GSK more than one (1) time in any
Calendar Year during the Term; (b) divisions, continuations,
continuations-in-part, renewals, and substitute applications of any patent
applications described in (a); (c) patents that may issue from any patent
applications described in (a) or (b); (d) reissues, reexaminations, and
extensions or restorations of patents described in (a) or (c) by existing or
future extension or restoration mechanisms, including without limitation, patent
restoration and supplementary protection certificates or the equivalent thereof;
and (e) any other form of government-issued right in the Territory substantially
similar to any of the foregoing. Notwithstanding anything to the contrary,
ALLERGAN Patent Rights will not include any patent applications or patents
claiming or covering any processes for manufacture of Product. For clarity,
ALLERGAN Patent Rights includes those patents and patent applications which are
Controlled by ALLERGAN or any of its Affiliates in the Territory, which
generically or specifically cover the use, sale, offer for sale and/or import of
any Product Improvements and

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       2
<PAGE>

Enhancements made by or on behalf of ALLERGAN. For further clarity, ALLERGAN
Patent Rights do not include any GSK Patent Rights.

     1.8 "ALLERGAN Product Trademarks" will have the meaning set forth in
Section 1.9.

     1.9 "ALLERGAN Trademarks" means any trademarks, applications to register
trademarks, intent-to-use applications, or other registrations or applications
related to trademarks, common-law trademarks and rights, service marks, trade
dress, logos, trade names, corporate names, all rights arising from the use of
or existing in connection with domain names, and all goodwill associated with
the foregoing and all registrations and applications for registration of any of
the foregoing, all to the extent Controlled by ALLERGAN or its Affiliates in the
Territory as of the Effective Date or during the Term that are (a) specific to
and only used with Product, as set forth in Exhibit B (the "ALLERGAN Product
Trademarks") or (b) used in connection with, but are not specific to or used
exclusively with, Product (including without limitation Housemarks of ALLERGAN),
as set forth in Exhibit C (the "ALLERGAN Corporate Trademarks").

     1.10 "Allowable Standard Cost" means an increase in the Standard Cost of no
greater than, (a) during each Calendar Year commencing with the first (1st)
Calendar Year and continuing through the end of *** and (b) from and after ***,
***. When calculating the Allowable Standard Cost for each Calendar Year after
the first (1st) Calendar Year, the 'Standard Cost' referred to in this Section
1.10 will be the lower of the Allowable Standard Cost for the immediately
preceding Calendar Year or the Standard Cost, as recalculated by ALLERGAN in the
immediately preceding Calendar Year as provided in Section 1.55.

     1.11 "Applicable Law" means all applicable provisions of any and all
federal, national, state, provincial, and local statutes, laws, rules,
regulations, administrative codes, ordinances, decrees, orders, decisions,
injunctions, awards, judgments, permits and licenses of or from any governmental
authorities relating to or governing the use or regulation of the subject item
or action.

     1.12 "Calendar Quarter" means each of the three (3) month periods ending
March 31, June 30, September 30, and December 31; provided, however, that the
first (1st) Calendar Quarter under this Agreement will be the period beginning
on the Effective Date and ending on the end of the Calendar Quarter in which the
Effective Date is encompassed.

     1.13 "Calendar Year" means, for the first Calendar Year, the period
beginning on the Effective Date and ending December 31, 2005, and for each
Calendar Year thereafter, each successive period beginning on January 1 and
ending twelve (12) consecutive calendar months later on December 31; provided,
however, that the last Calendar Year of the Term will be the period beginning on
January 1 and ending on the effective date of expiration or termination of the
Term.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       3

<PAGE>

     1.14 "Closing Date" means the earlier of (a) the date on which the
applicable waiting period under Article 16 of the Anti-Monopoly Law of Japan
expires or terminates early; or (b) the date on which the Parties agree in
writing that all requests to the Parties by the JFTC with regard to the
transaction contemplated by this Agreement have been satisfactorily met and no
objection on the part of the JFTC remains.

     1.15 "Co-Development Agreement" will have the meaning set forth in Section
4.1.2(b).

     1.16 "Commercially Reasonable Efforts" means efforts and resources normally
used by a Party in the Territory in the exercise of its reasonable business
discretion relating to a prescription pharmaceutical product owned by it or to
which it has co-exclusive rights, which is of similar market potential at a
similar stage in its development or product life, taking into account issues of
patent coverage, safety and efficacy, product profile, the competitiveness of
the marketplace, the proprietary position of the compound or product, the
regulatory structure involved, the profitability of the applicable products, and
other relevant factors, including without limitation technical, legal,
scientific, and/or medical factors.

     1.17 "Competing Product" will have the meaning set forth in Section 7.5.2.

     1.18 "Confidential Information" will have the meaning set forth in Section
10.1.

     1.19 "Control" means, with respect to the subject item, the ability and
authority of a Party or its Affiliate, whether arising by ownership, possession
or pursuant to a license or sublicense, to grant licenses or sublicenses to the
other Party under or to the subject item as specified in this Agreement, without
breaching the terms of any agreement with any Third Party and/or its Affiliates.

     1.20 "Co-Promotion Option" will have the meaning set forth in Section 2.5.

     1.21 "Co-Promotion Term" will have the meaning set forth in Section 2.5.

     1.22 "Cosmetic Indication" means the treatment, minimization, and/or
eradication of, or the appearance of, glabellar lines, crow's feet, or any lines
or wrinkles on the face.

     1.23 "Current Indications" means those Indications for which ALLERGAN or
any of its Affiliates, as of the Effective Date, has received Regulatory
Approval in the Territory to use Product for the treatment, prevention or
palliation of such Indications, which Indications include blepharospasm (benign
essential blepharospasm and essential blepharospasm), hemifacial spasm, and
cervical dystonia (spasmodic torticollis).

     1.24 "Distribution Agreement" will have the meaning set forth in Section
4.1.1(b).

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       4

<PAGE>

     1.25 "Effective Date" means the date on which this Agreement is mutually
executed by authorized representatives of each Party, which date will be that
which is set forth in the preamble.

     1.26 "Extended Term" will have the meaning set forth in Section 9.2.1.

     1.27 "Field of Use" means any and all uses of Product for the Current
Indications, Cosmetic Indication, and Future Indications.

     1.28 "Force Majeure Event" will have the meaning set forth in Section
11.13.

     1.29 "Future Indications" means all treatment, prevention or palliation of
Indications other than the Cosmetic Indication and Current Indications.

     1.30 "Good Clinical Practice" means the ministerial ordinance number 28
issued by the MHLW on March 27, 1997, as amended by the ministerial ordinance
number 106 issued on June 12, 2003, by the MHLW relating to the standard for
performance of clinical trials and its amendments related rules and regulations.

     1.31 "Good Post-Marketing Study Practice" means the ministerial ordinance
number 171 issued by the MHLW on December 20, 2004, relating to the standard of
post-marketing investigation and study and its amendments related rules and
regulations.

     1.32 "Good Vigilance Practice" means the ministerial ordinance number 135
issued by the MHLW on September 22, 2004, relating to the standard of
post-marketing safety management of drugs and its amendments related rules and
regulations.

     1.33 "GSK" will have the meaning set forth in the preamble.

     1.34 "GSK Distribution Commencement Date" means the effective date of the
Distribution Agreement, which date will not be more than fourteen (14) calendar
days after the Effective Date.

     1.35 "GSK Patent Rights" means any and all patents and patent applications
Controlled by GSK or its Affiliates, which generically or specifically claim or
cover the making, having made, use, sale, offer for sale, and/or import of
Product (including, for example, any Product Improvements and Enhancements
inside and outside of the Territory, which are made by or on behalf of GSK
pursuant to this Agreement and relate to Product in the Field of Use), which
includes, without limitation, the following: (a) divisions, continuations,
continuations-in-part, renewals, and substitute applications of any such patent
applications; (b) patents that may issue from any such patent applications; (c)
reissues, reexaminations, and extensions or restorations of patents described in
(b) by existing or future extension or restoration mechanisms, including without
limitation, patent restoration and supplementary protection certificates or the
equivalent thereof; and (d) any other form of government-issued right inside or
outside of the Territory

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       5

<PAGE>

substantially similar to any of the foregoing. For clarity, GSK Patent Rights do
not include any ALLERGAN Patent Rights.

     1.36 "GSK Sales Commencement Date" means the date of invoice of the first
commercial sale of Product in the Field of Use in the Territory by GSK (or its
Affiliates or sublicensee) to a Third Party once GSK or its Affiliate in the
Territory has become the MAH for Product in the Territory.

     1.37 "Housemarks" means the names of a Party or its Affiliates, or
variations of the names, and all related trade dress, logotypes, symbols, and
other trademarks used by a Party or its Affiliates in connection with its
products in the Territory.

     1.38 "Indication" means any distinct disease or medical condition. For the
purpose of clarification, any label expansion or other extension into a
different segment of any Current Indication will not be considered a different
Indication.

     1.39 "Initial Term" will have the meaning set forth in Section 9.1.

     1.40 "JFTC" means the Japan Fair Trade Commission, or any successor entity
thereto.

     1.41 "MAH" or "Marketing Authorization Holder" means a Person who possesses
all Regulatory Approvals in the Territory in such Person's name and who will
manage all interactions with Regulatory Authorities regarding such Regulatory
Approvals.

     1.42 "Manufacturer" means Allergan Pharmaceuticals Ireland, a Cayman
Islands corporation doing business at Carrowberg, Castlebar Road, Westport,
County Mayo, Ireland, a wholly owned Affiliate of ALLERGAN, or such other Person
as may be appointed to supply Product to GSK pursuant to the Supply Agreement.

     1.43 "Material Regulatory Interruption" means any action or omission of any
Regulatory Authority, including, without limitation, any mandatory recall of
Product, which prevents GSK or its Affiliates or sublicensees from being able to
use, sell, offer for sale and/or import Product in the Field of Use in the
Territory, which is not caused by GSK or its Affiliates or sublicensees being in
breach of their respective obligations to such Regulatory Authority.

     1.44 "Material Supply Interruption" means a breach by the Manufacturer of
its obligation to Manufacture (as defined in the Supply Agreement) Product in
accordance with the terms and conditions of the Supply Agreement.

     1.45 "MHLW" means the Japanese Ministry of Health, Labour and Welfare or
any successor agency thereto.

     1.46 "Net Sales" means, as to GSK or ALLERGAN and with respect to a given
period of time, gross invoiced sales of Product to Third Parties by either Party
or its Affiliates or

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       6

<PAGE>

sublicensees in such period, less the following deductions from such gross
amounts which are actually incurred, allowed, paid, accrued or specifically
allocated: (a) credits or allowances actually granted for damaged Product,
returns or rejections of Product, price adjustments, and billing errors; (b)
governmental and other rebates (or equivalents thereof) granted to managed
health care organizations, pharmacy benefit managers (or equivalents thereof),
national, state/provincial, local, and other governments, their agencies and
purchasers, and reimbursers, or to trade customers; (c) such Party's normal and
customary trade, cash and quantity discounts, allowances, and credits actually
allowed or paid; (d) commissions allowed or paid to Third Party distributors,
brokers, or agents other than sales personnel, sales representatives, and sales
agents employed by such Party; (e) transportation costs, including insurance,
for outbound freight related to delivery of Product to the extent included in
the gross amount invoiced; (f) sales taxes, value added taxes (VAT), and other
taxes directly linked to the sales of Product to the extent included in the
gross amount invoiced; (g) the actual amount of any write offs for bad debt
directly relating to sales of Product in the period; and (h) any other items
actually deducted from gross invoiced sales amounts as reported by such Party in
its financial statements in accordance with, in the case of GSK's Net Sales, the
International Financial Reporting Standards, applied on a consistent basis, and,
in the case of ALLERGAN's Net Sales, the U.S. generally accepted accounting
principles applied on a consistent basis. Sales between or among either Party
and its Affiliates or sublicensees will be excluded from the computation of such
Party's Net Sales, but the subsequent final sales to a Third Party by such
Affiliates or sublicensees will be included in the computation of such Party's
Net Sales.

     1.47 "Other Territories" means those countries in the world other than
those in the Territory, where ALLERGAN has granted, as of or after the Effective
Date, certain licenses to GSK and its Affiliates to use, sell, offer for sale
and import Product in such countries.

     1.48 "Party" means either GSK or ALLERGAN, and "Parties" means both of
them.

     1.49 "Person" means an individual, corporation, partnership, association,
trust, or any other entity or organization, including without limitation any
government or political subdivision or any agency or instrumentality thereof.

     1.50 "Product" means any pharmaceutical composition intended for
administration to humans containing botulinum toxin type A, regardless of
formulation, dosage, or form, and manufactured and supplied by the Manufacturer
in accordance with the Supply Agreement. For clarity, Product includes any
Product Improvements and Enhancements.

     1.51 "Product Improvements and Enhancements" means any and all improvements
and enhancements of Product, including, for example, research leading to
formulations, assays, and preclinical models in support of Indications,
invented, developed, or acquired by or on behalf of ALLERGAN and/or GSK, as
applicable, during the Term.

     1.52 "Regulatory Approval" means an approval, license, registration, and/or
authorization necessary for the use, sale, offering for sale, or importation of
a prescription

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       7

<PAGE>

pharmaceutical product in the Territory, including, without limitation, the
Shonin and the New Drug Application.

     1.53 "Regulatory Approval Applications" means an application for obtaining
a Regulatory Approval, together with all documents, data, and information
included with such application.

     1.54 "Regulatory Authority" means any or all national, supranational,
regional, state, or local regulatory agency, department bureau, commission,
council, or other government entity involved in the granting of Regulatory
Approval for a pharmaceutical product in the Territory.

     1.55 "Standard Cost" means the Manufacturer's internal standard cost,
comprising direct and indirect fully allocated costs to Manufacture (as such
term is defined in the Supply Agreement) botulinum toxin type A at the
Manufacturing Facility (as such term is defined in the Supply Agreement), for
supply to GSK or any of the Manufacturer's other customers (be they Third
Parties or Affiliates), including without limitation the net standard cost of
raw materials, active pharmaceutical ingredients, components, labor, and
overhead attributed to the production, processing, quality control, labeling,
and packaging of Product, determined in accordance with Applicable Law and U.S.
generally accepted accounting principles using methodology consistently applied
by the Manufacturer.

     1.56 "Stock Product" will have the meaning set forth in Paragraph 5(a) of
Exhibit G.

     1.57 "Supply Agreement" means the agreement for the manufacture and supply
of Product by the Manufacturer to GSK for the purposes of this Agreement, which
will be executed by GSK and the Manufacturer contemporaneously with this
Agreement.

     1.58 "Tail Period" means the *** period following (a) the expiration of
this Agreement as provided in Section 9.1 or Section 9.2.3; or (b) the
termination of this Agreement by GSK solely as provided in Section 9.3.1.

     1.59 "Tail Period Payments" will have the meaning set forth in Section 3.4.

     1.60 "Term" means the Initial Term; however, if GSK exercises its option to
extend the Initial Term as provided in Section 9.2, the "Term" will mean the
Initial Term and the Extended Term.

     1.61 "Territory" means Japan and its territories and possessions.

     1.62 "Third Party" means any Person other than ALLERGAN or GSK or either of
their respective Affiliates.

     1.63 "Third Party Payments" will have the meaning set forth in Section
3.2.2(b).

     1.64 "Transition Period" will have the meaning set forth in Section 4.1.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       8

<PAGE>

     1.65 "Unit" means each separate stock keeping unit of a product with a
distinct product number or item code.

2.   LICENSES

     2.1 Product Rights.

          2.1.1 Subject to the terms and conditions of this Agreement, ALLERGAN
hereby grants to GSK a co-exclusive (with ALLERGAN and its Affiliates) license,
including a right to grant sublicense rights, as further described in Section
2.4, but not to assign except as provided in Section 11.3, under the ALLERGAN
Patent Rights, other than those that are identified on Exhibit A-1, and ALLERGAN
Know-How, to use, sell, offer for sale, and import Product in the Field of Use
in the Territory. For purposes of clarification, the license granted by ALLERGAN
to GSK pursuant to this Section 2.1.1 includes, without limitation, the right to
develop, as further described in Section 2.1.4, promote, commercialize, market,
and distribute Product in the Field of Use in the Territory, but will not
include any right to make or have made any Product.

          2.1.2 Subject to the terms and conditions of this Agreement, ALLERGAN
hereby grants to GSK an exclusive option to obtain a co-exclusive (with ALLERGAN
and its Affiliates) license, including a right to grant sublicense rights, as
further described in Section 2.4, but not to assign except as provided in
Section 11.3, under the ALLERGAN Patent Rights that are set forth on Exhibit A-1
to use, sell, offer for sale, and import Product for any Future Indications in
the Territory. This option may be exercised by GSK as to any of the patents and
patent applications at any time after the *** of the Term, upon providing prior
written notice to ALLERGAN and, subject to Section 3.8, payment to ALLERGAN of
***. Upon GSK's exercise of the option as provided in this Section 2.1.2 as to
any patent and/or patent application, such patent and/or patent application will
be moved from Exhibit A-1 and placed on Exhibit A.

          2.1.3 Subject to the terms and conditions of this Agreement, GSK
hereby grants to ALLERGAN and its Affiliates a royalty-free, worldwide,
non-exclusive, perpetual (subject to Section 9.4.2) license, including a right
to grant sublicense rights, but not to assign except as provided in Section
11.3, under the GSK Patent Rights, to make, have made, use, sell, offer for
sale, and import Product in the Field of Use. For purposes of clarification, the
license granted by GSK to ALLERGAN pursuant to this Section 2.1.3 will include
the right to develop, promote, commercialize, market, and distribute Product in
the Field of Use.

          2.1.4 ALLERGAN acknowledges and agrees that the licenses granted to
GSK under Section 2.1.1 include without limitation:

               (a) The right of GSK to conduct human clinical trials and submit
clinical data packages to Regulatory Authorities for Product in the Field of Use
in the Territory;

               (b) The right of GSK to manage all communications with Regulatory
Authorities relating to Product,***; and provided, further that any
communications

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       9

<PAGE>

with Regulatory Authorities relating to the drug master file (DMF) will be
managed by ALLERGAN after good faith consultation with GSK unless the Parties
agree in writing that any such communications will be managed by GSK;

               (c) Access by GSK to any data developed by ALLERGAN that is
useful for GSK to develop Product in the Field of Use for use, sale, offering
for sale and import in the Territory; and

               (d) Rights to other ancillary clinical development information
Controlled by ALLERGAN or its Affiliates that is useful to GSK in using,
selling, offering for sale and importing Product in the Field of Use in the
Territory.

     2.2 Trademark Rights.

          2.2.1 ALLERGAN Product Trademarks. ALLERGAN hereby grants to GSK a
co-exclusive (with ALLERGAN and its Affiliates) license, including a right to
grant sublicense rights as further described in Section 2.4, but not to assign
except as provided in Section 11.3, to use ALLERGAN Product Trademarks solely in
connection with the use, sale, offering for sale, and import of Product in the
Field of Use in the Territory. All representations of ALLERGAN Product
Trademarks that GSK intends to use if not previously approved by ALLERGAN as
provided in this Section 2.2.1, will first be submitted to ALLERGAN for
approval, such approval not to be unreasonably withheld. ALLERGAN will have
thirty (30) calendar days to review the representation of the ALLERGAN Product
Trademarks. If ALLERGAN does not provide written notice of its approval or
disapproval (together with its reasons for such disapproval) within such thirty
(30) calendar day period, ALLERGAN will be deemed to have approved such
representation. For the avoidance of doubt, ALLERGAN will retain no right to use
ALLERGAN Product Trademarks in the Territory for any purpose other than
co-promotion pursuant to the terms of this Agreement without GSK's prior written
consent.

          2.2.2 ALLERGAN Corporate Trademarks. ALLERGAN hereby grants to GSK a
co-exclusive license (with ALLERGAN and its Affiliates) including a right to
grant sublicense rights as further described in Section 2.4, but not to assign
except as provided in Section 11.3, to use ALLERGAN Corporate Trademarks as
trademarks solely in connection with the use, sale, offering for sale, and
import of Product in the Field of Use in the Territory. All representations of
ALLERGAN Corporate Trademarks that GSK intends to use, if not previously
approved by ALLERGAN as provided in this Section 2.2.2, will first be submitted
to ALLERGAN for approval, such approval not to be unreasonably withheld.
ALLERGAN will have thirty (30) calendar days to review the representation of the
ALLERGAN Corporate Trademarks. If ALLERGAN does not provide written notice of
its approval or disapproval (together with its reasons for such disapproval)
within such thirty (30) calendar day period, ALLERGAN will be deemed to have
approved such representation.

          2.2.3 Except for any Housemarks of GSK, ALLERGAN will own all
trademarks used in connection with Product in the Field of Use in the Territory.
Except for any Housemarks of GSK, GSK will not own any of the trademarks that it
may use in connection with the use, sale,

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       10

<PAGE>

offering for sale and importing of Product in the Field of Use in the Territory
and except for its use of the Housemarks of GSK, GSK will only use ALLERGAN
Trademarks as trademarks in connection with any and all Product in the
Territory.

          2.2.4 ALLERGAN and its Affiliates will have no right to use in any way
whatsoever any representation of a Housemark of GSK, whether in connection with
Product or otherwise, without obtaining the prior written consent of GSK.

     2.3 Ownership; Reservation of Rights.

          2.3.1 Except as expressly provided in this Agreement, ALLERGAN and its
Affiliates have and will retain sole and exclusive Control of the ALLERGAN
Patent Rights, ALLERGAN Know-How, and ALLERGAN Trademarks. Except as expressly
provided herein, no right, title, or interest is granted by ALLERGAN to GSK in,
to, or under the ALLERGAN Patent Rights, ALLERGAN Know-How, and/or ALLERGAN
Trademarks, and, except as expressly provided herein, GSK will have no right to
assign to any Third Party any right or interest received under the ALLERGAN
Patent Rights, ALLERGAN Know-How, or ALLERGAN Trademarks under the terms of this
Agreement.

          2.3.2 Except as expressly provided in this Agreement, GSK and its
Affiliates have and will retain sole and exclusive Control of the GSK Patent
Rights and GSK Housemarks. Except as expressly provided in this Agreement, no
right, title, or interest is granted by GSK to ALLERGAN in, to, or under the GSK
Patent Rights and/or GSK Housemarks, and, except as expressly provided herein,
ALLERGAN will have no right to assign to any Third Party any right or interest
received under the GSK Patent Rights or GSK Housemarks under the terms of this
Agreement.

     2.4 Conditions Precedent to Sublicense. GSK will have the right to grant
sublicenses to Third Parties and Affiliates to its license and option rights
under the ALLERGAN Patent Rights, ALLERGAN Know-How, and/or ALLERGAN Trademarks,
provided that (a) GSK has obtained the prior written consent of ALLERGAN, not to
be unreasonably withheld, as provided below in this Section 2.4, (b) each
sublicensee has agreed to be bound by all applicable terms and obligations of
the rights and licenses granted by ALLERGAN to GSK under this Agreement
(including without limitation GSK's confidentiality and royalty obligations),
(c) the terms and conditions of each such sublicense are consistent with, and no
less restrictive than, the terms and conditions of this Agreement, (d) ALLERGAN
is designated as a third party beneficiary of such sublicense and, consistent
with the terms and conditions of this Agreement, entitled to enforce the terms
and conditions of such sublicense with respect to such sublicensee in the event
that GSK elects not to enforce such terms and conditions of this Agreement, and
(e) GSK provides to ALLERGAN a copy of those terms and conditions contained in
each such sublicense which demonstrate compliance with the requirements in (b),
(c), and (d) of this Section 2.4. Notwithstanding anything to the contrary, GSK
agrees that GSK will not grant to any sublicensee a right to grant sublicense
rights under ALLERGAN Patent Rights, ALLERGAN Know-How, or ALLERGAN Trademarks.
ALLERGAN will have *** within which to consent

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       11

<PAGE>

to any requests from GSK or its Affiliates to sublicense any of its and their
rights under this Agreement to the ALLERGAN Patent Rights, ALLERGAN Know-How,
and/or ALLERGAN Trademarks, as provided above. If ALLERGAN does not provide its
written consent or refusal to consent (together with its reasons for such
disapproval) to any such sublicense within such *** period, ALLERGAN will be
deemed to have consented to such request to sublicense from GSK or its
Affiliate. ALLERGAN's consent pursuant to (a) of this Section 2.4 will not be
required for grants of sublicenses by GSK to Affiliates of GSK, but the
requirement in (b), (c), and (d) of this Section 2.4 will apply to any such
grants of sublicenses by GSK to Affiliates of GSK. Notwithstanding the
foregoing, the Parties acknowledge and agree that this Section 2.4 will in no
way apply to GSK's sublicense of any of its rights under Section 2.1.1 to any
Affiliate or Third Party that is providing services to GSK relating to this
Agreement (e.g., a Clinical Research Organization (CRO) or distributor) and that
GSK will have the right at any time during the Term, without complying with any
of the requirements set forth in (a) through (e) of this Section 2.4, to
sublicense any of its rights under Section 2.1.1, with the right to grant
further sublicenses in accordance with this Section 2.4, to any Affiliate or
Third Party that is providing services to GSK or its Affiliates relating to this
Agreement; provided, however, that any such Third Party or Affiliate (or
sub-contractor thereof) shall use those rights solely for the purpose of
providing such services to GSK; and further provided, however, that GSK will
remain fully and unconditionally obligated and responsible for the full and
complete performance of all of its obligations under the terms and conditions of
this Agreement whether or not such performance is carried out by GSK or its
Affiliates or Third Parties.

     2.5 Co-Promotion Option. At any time during such period of the Term that is
after thirty (30) months after the GSK Sales Commencement Date, ALLERGAN will
have the non-sublicenseable, non-assignable right, but not an obligation,
exercisable by giving not less than ninety (90) calendar days' prior written
notice to GSK, to co-promote Product in the Field of Use in the Territory,
directly or through its Affiliates, in accordance with the key terms set out in
Exhibit D (the "Co-Promotion Option"). Upon exercise of such Co-Promotion
Option, ALLERGAN will actively detail and promote Product in the Field of Use in
the Territory during the Co-Promotion Term as directed by the Territory Joint
Commercial Committee and in accordance with the key terms set out in Exhibit D.
The "Co-Promotion Term" will be the period beginning on the date of ALLERGAN's
exercise of the Co-Promotion Option as provided in this Section 2.5 and ending
on the earlier of (a) the expiration of this Agreement, (b) the termination of
this Agreement for any reason, (c) the termination of ALLERGAN's co-promotion
rights relating to Product as provided in this Agreement by ALLERGAN for any
reason, or (d) the termination of ALLERGAN's co-promotion rights relating to
Product as provided in this Agreement by GSK as a result of a material breach by
ALLERGAN of its co-promotion obligations as provided in this Agreement
(including, without limitation, Exhibit D), which breach is not cured by
ALLERGAN within sixty (60) calendar days after written notice thereof from GSK.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       12

<PAGE>

3.   PAYMENTS

     3.1 Upfront Payment. In consideration for the licenses granted by ALLERGAN
to GSK pursuant to Article 2 and subject to Sections 3.6.4, 3.7, and 3.8, GSK
will pay to ALLERGAN a nonrefundable payment of *** within fifteen (15) calendar
days after the Closing Date.

     3.2 Royalty Payments.

          3.2.1 In further consideration for the licenses granted by ALLERGAN to
GSK pursuant to Article 2 and subject to Sections 3.2.2, 3.3, 3.6.1. 3.6.3(a),
3.6.4(a), 3.7, and 3.8, during each Calendar Year after the GSK Sales
Commencement Date, GSK will pay to ALLERGAN the following percentages of GSK's
Net Sales for each such Calendar Year, or portion thereof if applicable, as
provided below:

               (a) ***

               (b) ***

               (c) ***

GSK acknowledges and agrees that GSK will be solely responsible for paying all
royalties owed to ALLERGAN on account of Net Sales by any and all of GSK's
Affiliates and sublicensees. ALLERGAN acknowledges and agrees that GSK will not
be obligated in any way to pay any royalties as provided in this Section 3.2.1
or any other payments of any kind whatsoever to ALLERGAN on GSK's or its
Affiliates' sales to any Person of Stock Product, including, without limitation,
if such sales of Stock Product occur on or after the GSK Sales Commencement
Date.

          3.2.2 Royalty Adjustments.

               (a) During each Calendar Year of the Co-Promotion Term in which
ALLERGAN employs a sales force of at least *** fully-trained (as directed by the
Territory Joint Commercial Committee), full-time sales representatives who
actively detail and promote Product in the Field of Use in the Territory in at
least a secondary detail position, which will be defined by the TJCC, and in
accordance with all of the terms set forth in Exhibit D, and subject to Sections
3.6.1, 3.6.3(a), 3.6.4(a), 3.7, and 3.8, GSK will pay ALLERGAN an additional ***
royalty on GSK's Net Sales in each such Calendar Year, or portion thereof if
applicable.

               (b) The Parties acknowledge that, during the Term, one (1) or
more royalty-bearing licenses may be necessary from one (1) or more Third
Parties in order for GSK and its Affiliates to use, sell, offer for sale, and
import Product in the Field of Use in the Territory, without infringing the
intellectual property rights of one or more patent rights of such Third Parties
in the Territory. In such an event, GSK will have the right but not the
obligation, and only after prior consultation with ALLERGAN, to use Commercially
Reasonable Efforts to

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       13

<PAGE>

obtain and maintain such Third Party licenses solely with respect to the
Territory. If, as a result of GSK obtaining and maintaining such Third Party
licenses, it is necessary for GSK to make royalty payments and/or license fee
payments to such Third Party (collectively, the "Third Party Payments") in order
for GSK to practice the rights granted hereunder to the ALLERGAN Patent Rights
and ALLERGAN Know-How without infringing such Third Party's rights, GSK will be
entitled to offset *** of all such Third Party Payments against any royalties
owed to ALLERGAN under this Agreement during the Term.

               (c) If, in any Calendar Year, the Standard Cost exceeds the
Allowable Standard Cost, ALLERGAN will credit against the royalty payable under
Section 3.2.1 of this Agreement in such Calendar Year, an amount equal to the
difference between (i) the Standard Cost plus *** and (ii) the Allowable
Standard Cost plus ***, multiplied by the number of Units of Product purchased
by GSK during such Calendar Year; provided such difference was actually incurred
by GSK.

     3.3 GSK Royalty Term. Subject to Section 9.5.1(a), the obligation of GSK to
pay royalties owed to ALLERGAN under Section 3.2.1 will commence on the GSK
Sales Commencement Date and continue until the expiration, pursuant to Section
9.1 or Section 9.2.3, or earlier termination, pursuant to Section 9.3, of the
Term. The obligation of GSK to pay the additional royalty owed to ALLERGAN under
Section 3.2.2(a) will, if all conditions are satisfied by ALLERGAN as provided
in Section 3.2.2(a), commence at the beginning of the Co-Promotion Term and
continue until the expiration or earlier termination thereof as provided in
Section 2.5.

     3.4 Tail Period Payments. Commencing on first (1st) day of the Tail Period
and continuing until the expiration thereof, subject to Sections 3.6.2,
3.6.3(b), 3.6.4(b), 3.7, and 3.8, ALLERGAN will pay the following payments (the
"Tail Period Payments") to GSK:***. For purposes of this Section 3.3, "year"
will mean each 365-calendar day period beginning on the first (1st) day of the
Tail Period or the relevant anniversary thereof.

     3.5 Product Improvement and Enhancement Reimbursement Payments.

          3.5.1 During the Term, ALLERGAN will conduct the Product Improvement
and Enhancement activities described in Exhibit E. ALLERGAN will have no
obligation to engage in any activities related to Product Improvements and
Enhancements other than as set forth on Exhibit E or existing or planned
activities in which ALLERGAN and its Affiliates engage outside the Territory for
ALLERGAN's own purposes.

          3.5.2 In consideration for ALLERGAN's conduct of the Product
Improvement and Enhancement activities as provided in Section 3.5.1 and subject
to Sections 3.6.4(a), 3.7, and 3.8, GSK will make research support payments to
ALLERGAN to reimburse ALLERGAN for a portion of its costs and expenses of
conducting such activities, which research support payments will not exceed the
amounts set forth on the schedule in Exhibit F for the applicable Calendar Year.
At the end of each six (6) month period beginning on January 1 or July 1 after
the Effective Date, continuing until December 31, 2009, ALLERGAN, within thirty
(30) days after

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       14

<PAGE>

the end of such six (6) month period, will provide to GSK a written report
detailing the Product Improvement and Enhancement activities showing progress on
delivering some or all of such Product Improvement and Enhancement activities
outlined in Exhibit E conducted by ALLERGAN during the just-ended six (6) month
period and an invoice for GSK's share of the costs and expenses of conducting
such activities during such six (6) month period. Within thirty (30) days after
receipt by GSK of (i) such report and such invoice and (ii) a letter from a
manager of ALLERGAN confirming that ALLERGAN's total global expenditures in
conducting such Product Improvement and Enhancement activities in the just-ended
six (6) month period ***, GSK will pay to ALLERGAN the amount corresponding to
such invoice. ALLERGAN covenants and agrees that it will use such payments
solely to cover a portion of the costs and expenses incurred by ALLERGAN and its
Affiliates in conducting the Product Improvements and Enhancements activities
set forth on Exhibit E. In the event that ALLERGAN does not incur any costs and
expenses in conducting Product Improvement and Enhancement activities in a six
(6) month period, no payments will be due for such six (6) month period to
ALLERGAN from GSK pursuant to this Section 3.5.2.

          3.5.3 If ALLERGAN and GSK mutually agree in writing that ALLERGAN will
engage in Product Improvement and Enhancement activities in addition to the
activities set forth in Exhibit E for the benefit of GSK in the Territory, GSK
will provide compensation to ALLERGAN in addition to that set forth in Exhibit F
for such additional activities under terms and conditions to be negotiated in
good faith by the Parties.

     3.6 Payment Terms.

          3.6.1 Quarterly Payments of Royalties. Within sixty (60) days after
the last day of each Calendar Quarter, GSK will pay to ALLERGAN all royalties
due and payable on GSK's Net Sales in the immediately preceding Calendar
Quarter, or portion thereof if applicable, in accordance with Section 3.2.

          3.6.2 Quarterly Payments of the Tail Period Payment. Within sixty (60)
calendar days after the last day of each Calendar Quarter during the Tail
Period, ALLERGAN will pay to GSK all payments due and payable on ALLERGAN Net
Sales as provided under Section 3.4 in the immediately preceding Calendar
Quarter, or portion thereof if applicable.

          3.6.3 Annual Reconciliations.

               (a) Subject to Section 9.5.1(a), within sixty (60) calendar days
after the last day of each Calendar Year during the Term, or portion thereof if
applicable, GSK will calculate the royalty payments due to ALLERGAN pursuant to
Sections 3.2.1 and, if applicable, 3.2.2(a) for such Calendar Year. In the event
the total payment due pursuant to Section 3.2.1 and, if applicable, 3.2.2(a) in
any Calendar Year is greater than the total for each such amount that GSK has
paid under Section 3.6.1 in such Calendar Year, the difference will be paid by
GSK to ALLERGAN within sixty (60) days after the last day of such Calendar Year,
or portion thereof if applicable. In the event the total payment due pursuant to
Section 3.2.1 and, if applicable, 3.2.2(a) in any Calendar Year is less than the
total for each such amount that GSK

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       15

<PAGE>

has paid under Section 3.6.1 in such Calendar Year, the difference will be paid
by ALLERGAN to GSK within sixty (60) days after the last day of such Calendar
Year, or portion thereof if applicable.

               (b) Within sixty (60) calendar days after the last day of each
Calendar Year during the Tail Period, or portion thereof if applicable, ALLERGAN
will calculate the Tail Period Payments due to GSK pursuant to Section 3.4 for
such Calendar Year. In the event the total payment due pursuant to Section 3.4
in any Calendar Year is greater than the total amount that ALLERGAN has paid
under Section 3.6.2 in such Calendar Year, the difference will be paid by
ALLERGAN to GSK within sixty (60) days after the last day of such Calendar Year,
or portion thereof if applicable. In the event the total payment due pursuant to
Section 3.4 in any Calendar Year is less than the total amount that ALLERGAN has
paid under Section 3.6.2 in such Calendar Year, the difference will be paid by
GSK to ALLERGAN within sixty (60) days after the last day of such Calendar Year,
or portion thereof if applicable.

          3.6.4 All payments made under this Agreement will be made in U.S.
dollars. All payments will be made by check or wire transfer in immediately
available funds to the following bank account or to such other bank account
designated in writing by ALLERGAN:

               ***

For sales of Product in Japanese Yen or in any currency other than U.S. dollars:

               (a) With respect to payments made by GSK to ALLERGAN under this
Agreement, GSK's Net Sales, as defined in Section 1.46, will be calculated in
accordance with the International Financial Reporting Standards consistently
applied. GSK Net Sales will be converted into U.S. dollars using the average
exchange rates as calculated and utilized by GSK's group reporting system and
published accounts. The current method uses spot exchange rates sourced from
Reuters/Bloomberg and if changed, GSK will notify ALLERGAN of the revised method
in advance of it being applied.

               (b) With respect to payments made by ALLERGAN to GSK pursuant to
Section 3.4, ALLERGAN's Net Sales, as defined in Section 1.46, will be
calculated in accordance with U.S. generally accepted accounting principles
consistently applied. Net Sales will be converted into U.S. dollars using the
average exchange rates as calculated and utilized by ALLERGAN's reporting
systems and published accounts. The current method uses the monthly average of
daily exchange rates obtained from Bloomberg to convert sales in local currency
into U.S. dollars. If this methodology is changed ALLERGAN will notify GSK of
the revised methodology in advance of it being applied.

     3.7 Late Payment Interest. Any payment due and payable under the terms and
conditions of this Agreement, including without limitation any royalty payment
and any Tail Period Payments, made by GSK or ALLERGAN after the date such
payment is due and payable, will bear interest as of the day after the date such
payment was due and payable, and will continue to accrue such interest until
such payment is made, at rate equal to *** per month. The

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       16

<PAGE>

payment of such interest will not limit either Party from exercising any other
rights it may have as a consequence of the lateness of any payment.

     3.8 Taxes. To the extent a statutory tax withholding obligation is imposed
by a governmental authority upon any payment made by a Party (the "Payor") to
the other Party (the "Payee") under this Agreement, including, for example,
royalty payments, due and payable by the Payor to the Payee under the terms and
conditions of this Agreement, the Payor will be entitled to withhold from such
payment the amount, if any, of any tax assessed against the Payee and actually
withheld, provided that such tax is only for the account of the Payee and
evidence of the payment of such tax is promptly provided to the Payee. The Payor
will pay the amount of such tax to the proper taxing authority and will be
entitled to deduct the amount of such tax from the payment to be made by the
Payor to the Payee. The Payor will advise the Payee of any tax payment made for
the benefit of the Payee pursuant to this Section 3.8 and provide the Payee with
copies of tax receipts for all taxes paid and deducted from the payment due and
payable to the Payee, together with copies of all pertinent communications from
or with governmental authorities with respect thereto. At a Party's reasonable
request and subject to the requesting Party reimbursing any costs and expenses,
each Party will reasonably assist the requesting Party in any effort by a Party
in claiming any exemption from such deductions or withholdings under any double
taxation or similar agreement or treaty from time to time in force, and in
minimizing the amount required to be so withheld or deducted. ALLERGAN warrants
that ALLERGAN is resident for tax purposes in United States and that ALLERGAN is
entitled to relief from United Kingdom income tax under the terms of the double
tax agreement between the United Kingdom and the United States. ALLERGAN will
notify GSK immediately in writing in the event that ALLERGAN ceases to be
entitled to such relief. Pending receipt of formal certification from the United
Kingdom Inland Revenue, GSK may pay royalty income and any other payments under
this Agreement to ALLERGAN by deducting tax at a rate specified in the double
tax treaty between the United Kingdom and the United States. ALLERGAN agrees to
indemnify and hold harmless GSK against any loss, damage, expense, or liability
arising in any way from a breach by ALLERGAN of the warranties in this Section
3.8 or any future claim by a United Kingdom tax authority or other similar body
alleging that GSK was not entitled to deduct such withholding tax on such
payments at source at the treaty rate.

     3.9 Records and Reports. Any and all payments made by either Party to the
other pursuant to this Agreement will be accompanied by a written statement
setting forth in reasonable detail the calculation of such Party's Net Sales,
and, if applicable, the calculation of the average exchange rate utilized by
such Party to convert a local currency payment to U.S. dollars. Each Party will
maintain, and will require its Affiliates, and sublicensees, to maintain
complete and accurate records sufficient to enable accurate calculation of any
payments due by a Party to the other Party hereunder, including, without
limitation payment of any royalties and the Tail Period Payment. Such records
and books of account will be preserved by each Party and its respective
Affiliates and sublicensees, as applicable, for a period of three (3) years
after the end of the period covered by such records and books of account, which
obligation will survive the expiration or earlier termination of this Agreement.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       17

<PAGE>

     3.10 Audit Rights.

          3.10.1 GSK will permit an ALLERGAN auditor, or an independent public
accountant designated by ALLERGAN and reasonably acceptable to GSK, to have
access, no more than once in each Calendar Year, during regular business hours
and upon at least sixty (60) calendar days' prior written notice, to GSK's
records and books, and GSK's Affiliates' and sublicensees' records and books, to
the extent necessary to determine the accuracy of GSK's Net Sales reported, and
payments made, by GSK to ALLERGAN pursuant to this Article 3 within the two (2)
year period immediately preceding such an audit. If such examination results in
a determination that GSK's Net Sales or payments owed to ALLERGAN by GSK have
been understated, unpaid amounts due will be paid by GSK to ALLERGAN promptly.
If such examination results in a determination that GSK's Net Sales or payments
owed to ALLERGAN by GSK have been overstated, overpaid amounts due will be
re-paid by ALLERGAN to GSK promptly. The fees and expenses of such auditor or
accountant will be paid by ALLERGAN unless GSK's Net Sales have been
understated, or that payments owed to ALLERGAN by GSK have been underpaid, by
more than *** for the period examined, in which case GSK will pay all reasonable
costs and expenses of the auditor or accountant incurred by ALLERGAN in the
course of making such determination.

          3.10.2 ALLERGAN will permit a GSK auditor, or an independent public
accountant designated by GSK and reasonably acceptable to ALLERGAN, to have
access, no more than once in each Calendar Year, during regular business hours
and upon at least sixty (60) calendar days' prior written notice, to ALLERGAN's
records and books, and ALLERGAN's Affiliates' and sublicensees' records and
books, to the extent necessary to determine the accuracy of ALLERGAN's Net Sales
reported, and payments made, by ALLERGAN to GSK pursuant to this Article 3
within the two (2) year period immediately preceding such an audit. If such
examination results in a determination that ALLERGAN's Net Sales or payments
owed to GSK by ALLERGAN have been understated, unpaid amounts due will be paid
by ALLERGAN to GSK promptly. If such examination results in a determination that
ALLERGAN's Net Sales or payments owed to GSK by ALLERGAN have been overstated,
overpaid amounts due will be re-paid by GSK to ALLERGAN promptly. The fees and
expenses of such auditor or accountant will be paid by GSK unless ALLERGAN's Net
Sales have been understated, or that payments owed to GSK by ALLERGAN have been
underpaid, by more than *** for the period examined, in which case ALLERGAN will
pay all reasonable costs and expenses of the auditor or accountant incurred by
GSK in the course of making such determination.

4.   TRANSITION ACTIVITIES

     4.1 Transition Period. The Parties acknowledge that due to Applicable Law,
during the period from the Effective Date and continuing until the date on which
Regulatory Authorities approve GSK or its Affiliate in the Territory becoming
the MAH for Product in the Territory (the "Transition Period"), ALLERGAN will
continue to be the MAH for Product in the Territory. Accordingly, the Parties
agree that the principles set forth in this Section 4.1 will guide the

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       18

<PAGE>

clinical development and commercialization activities for the Product in the
Territory during the Transition Period and thereafter with respect to study 909.

          4.1.1 Commercialization of Product.

               (a) During the period commencing on the Effective Date and
continuing until the GSK Distribution Commencement Date, ALLERGAN will use
Commercially Reasonable Efforts to promote, sell, offer for sale and distribute
Product in the Field of Use in the Territory and ALLERGAN will be entitled to
book all Net Sales of ALLERGAN during such time.

               (b) Promptly after the Effective Date, the Parties or their
respective Affiliates will enter into good faith negotiations for an agreement
(the "Distribution Agreement"), which will set forth the roles and
responsibilities of GSK relating to the commercialization of Product in the
Field of Use during the Transition Period. Such Distribution Agreement will be
executed not later than fourteen (14) calendar days after the Effective Date and
will include the principles set forth on Exhibit G.

               (c) The Parties acknowledge and agree that the TJCC will oversee
all activities of ALLERGAN pursuant to Section 4.1.1(a) and all activities of
the Parties pursuant to the Distribution Agreement.

               (d) Upon expiration of the Distribution Agreement, ALLERGAN will,
if so requested by GSK, use Commercially Reasonable Efforts to transfer and
assign to GSK all contracts relating to the Product, including, without
limitation, post-marketing surveillance contracts, excluding, however, any
contracts relating to study 909 as provided in Exhibit H.

          4.1.2 Co-Development Activities.

               (a) During the period commencing on the Effective Date and
continuing until such time as set forth in Exhibit H, the Parties will
co-develop the Product in the Territory in accordance with the terms set forth
on Exhibit H.

               (b) The Parties or their respective Affiliates in the Territory
may, within a reasonable period of time after the Effective Date, mutually
determine to enter into a separate agreement setting forth their respective
obligations with respect to the co-development of Product in the Territory,
which agreement must include the terms set forth on Exhibit H (the
"Co-Development Agreement"). In the event of a conflict between the terms of any
such agreement and this Agreement, this Agreement will control.

     4.2 Regulatory Approval Transfer. During the Transition Period, ALLERGAN or
its Affiliate in the Territory will work diligently with GSK to enable GSK to
become the MAH for the Product in the Territory and in addition become
responsible for all Regulatory Approval Applications in the Territory for
Product, including, without limitation, those Regulatory

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       19

<PAGE>

Approval Applications in the Territory for Product for the Cosmetic Indication.
Notwithstanding the foregoing, the Parties acknowledge and agree that prior to
the Closing Date, they will not, and will cause their respective Affiliates not
to, communicate in any way with the Regulatory Authorities (whether orally or in
writing) regarding the transfer of Regulatory Approvals for Product in the
Territory from ALLERGAN to GSK so as to enable GSK to become the MAH. As soon as
possible but in no event later than thirty (30) calendar days after the date of
notification by the MHLW that GSK is the MAH for Product in the Territory,
ALLERGAN will at its own cost and expense (a) deliver, or cause its Affiliates
to deliver, to GSK copies of each Regulatory Approval and Regulatory Approval
Application held by ALLERGAN its Affiliates or agents relating specifically to
Product in the Field of Use in the Territory, (b) certify in writing that the
copies of such Regulatory Approval Applications and filings are true and
complete copies thereof, and (c) do all other things that are required pursuant
to any Applicable Law in the Territory to ensure that the Regulatory Approvals
and Regulatory Approval Applications are duly transferred into the name of GSK
or its nominee in a timely manner

     4.3 Notification by the MHLW. Once the Regulatory Approvals and Regulatory
Approval Applications for Current Indications are transferred to GSK and GSK
receives notification by the MHLW that GSK is the MAH, the Transition Period
will immediately terminate, the Distribution Agreement will immediately
terminate, and GSK will become legally responsible for all communications with
MHLW relating to Product in the Territory. Further, all legal responsibility for
releasing Product in Japan, quality assurance/quality control, post-marketing
surveillance, and pharmacovigilance relating to Product in the Territory will
transfer to GSK at such time. Notwithstanding the foregoing, the Co-Development
Agreement will immediately terminate upon the later to occur of (a) the date on
which the Regulatory Approvals and Regulatory Approval Applications for Current
Indications are transferred to GSK and GSK receives notification by the MHLW
that GSK is the MAH or (b) the date on which the study 909 database is locked,
as described in Exhibit H.

     4.4 Disclosure of ALLERGAN Know-How; Transfer of Materials.

          4.4.1 Within thirty (30) calendar days after the Effective Date,
ALLERGAN or its Affiliate, will at its or their sole cost and expense disclose
the ALLERGAN Know-How to GSK and will provide to GSK all documents that recite,
are directed to, or concern ALLERGAN Know-How. Notwithstanding anything to the
contrary contained in this Article 4, ALLERGAN will thereafter during the Term
promptly disclose to GSK any ALLERGAN Know-How that comes into ALLERGAN's
possession and will provide to GSK all documents that are directed to such
ALLERGAN Know-How.

          4.4.2 ***.

     4.5 Maintenance of Documentation. Except as provided herein or as otherwise
required or appropriate under Applicable Law, the documents and materials
provided by ALLERGAN to GSK under this Section 4.5 may be copies of original
documents and materials, provided that such copies will be of the highest
quality possible and, if such quality is inadequate

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       20

<PAGE>

for GSK's needs, ALLERGAN will permit GSK to have access to the original
documents and materials. In the event that ALLERGAN elects to provide original
documents and materials, GSK will permit ALLERGAN to have access to such
original documents and materials for use by ALLERGAN for purposes consistent
with the terms and conditions of this Agreement. Such original documents and
materials will be provided to GSK in accordance with the following:

          4.5.1 GSK will maintain original documents and materials under safe
and secure conditions typically used by GSK to maintain its own similar
documents and materials. Specifically, GSK will maintain such original documents
and materials in files located in a GSK facility or at another secure facility
used to store GSK's own original documents. If GSK chooses to transfer such
original documents and materials to any other secure facility, GSK will notify
ALLERGAN in writing sixty (60) calendar days in advance of such transfer.

          4.5.2 If a Regulatory Authority requires ALLERGAN, or an Affiliate of
ALLERGAN, to provide the Regulatory Authority with access to any of the original
documents or materials transferred by ALLERGAN or its Affiliate to GSK as
provided in this Article 4, GSK will permit ALLERGAN, its employees, agents, or
independent contractors, and/or officials or representatives of the Regulatory
Authority, as appropriate, access to the original documents and materials. Such
access will be provided at the site where the original documents and materials
are maintained by GSK, during normal business hours (Monday through Friday
between 9 a.m. and 5 p.m.) after receipt of reasonable written notice (being at
least five (5) calendar days where practicable but in any case not less than
twenty-four (24) hours advance written notice from ALLERGAN (seventy-two (72)
hours if such notice arrives on a Friday, Saturday, or Sunday), or at such other
facility and during such hours as agreed upon by GSK, ALLERGAN, and/or the
Regulatory Authority. The term "access" will mean, for the purposes of this
Section 4.5.2, that ALLERGAN and/or the Regulatory Authority, as appropriate,
will have possession of the original documents and materials at the GSK facility
where the original documents and materials are maintained, or at such other
facility as agreed upon by ALLERGAN and GSK and/or the Regulatory Authority, for
sufficient time to allow ALLERGAN to review the original documents in detail
and/or to allow the Regulatory Authority to complete its review. Prior to the
grant of access, ALLERGAN will provide GSK with a copy of the relevant written
Regulatory Authority communication or a copy of ALLERGAN's written contact
report of an oral request by the Regulatory Authority for such access, if such
letter or contact report exists.

          4.5.3 Upon expiration or termination of this Agreement, GSK will
return to ALLERGAN all documents and materials provided by ALLERGAN to GSK as
provided in this Article 4 in accordance with Section 9.4.3.

     4.6 Further Assistance by ALLERGAN. ALLERGAN, on GSK's or GSK's Affiliate's
request, will provide consulting services regarding specific issues in
connection with pre-clinical and clinical development and commercialization of
Product in the Field of Use ("Consultations") as set forth in this Section 4.6.
For clarity, Consultations will not include any efforts or activities conducted
by employees and/or agents of ALLERGAN in connection with

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       21

<PAGE>

the activities and obligations involved under the Distribution Agreement, in the
transfer of Regulatory Approvals and ALLERGAN Know-How and materials pursuant to
this Article 4, in connection with ALLERGAN's participation in the TJDC and TJCC
as provided in Article 5, and in connection with global Product strategic
marketing support.

          4.6.1 During the period commencing on the Effective Date and
continuing for a period of ***, Consultations will occur at mutually agreeable
times and places, and will not exceed *** hours of total employee time,
excluding travel, per month.

          4.6.2 As of and after the date of the expiration of the *** period
referenced in Section 4.6.1 and continuing for *** thereafter, Consultations
will occur at mutually agreeable times and places, and will not exceed *** hours
of total employee time, excluding travel, per month.

          4.6.3 In the event that GSK or an Affiliate of GSK requests
Consultations in excess of the total employee time per month set forth in
Section 4.6.1 or 4.6.2, respectively, ALLERGAN will use Commercially Reasonable
Efforts, but will have no obligation, to provide such Consultations. In the
event that ALLERGAN and GSK agree that Consultations in excess of the total
employee time per month set forth in Section 4.6.1 or 4.6.2 will be provided,
GSK will pay ALLERGAN a full time equivalent (FTE) rate of *** per person per
day on which Consultations are actually provided and will reimburse ALLERGAN for
any documented reasonable and properly incurred out-of-pocket costs or expenses
that ALLERGAN incurs in connection with such Consultations, including without
limitation all reasonable and properly incurred travel and hotel accommodation
costs and expenses (which will be pre-agreed with GSK).

          4.6.4 Notwithstanding anything to the contrary, there will be no time
limit on communications to ALLERGAN from GSK pertaining to the acquisition of
development or regulatory documents or data identified as missing after the
transfer of Regulatory Approvals and ALLERGAN Know-How was, in the opinion of
ALLERGAN, complete, nor will there be a charge for ALLERGAN supplying such
documents or data; provided that such documents or data are in ALLERGAN's
possession or are in the possession of an ALLERGAN contractor or investigator
and are retrievable upon exercise by ALLERGAN of Commercially Reasonable
Efforts.

5.   PRODUCT DEVELOPMENT AND COMMERCIALIZATION

     5.1 In General. GSK, at GSK's sole expense (subject to ALLERGAN's
performance of its obligations as set forth in Article 4 and Exhibits G and H),
will use Commercially Reasonable Efforts to commercialize Product in the
Territory, as provided in Section 5.5. Additionally, as provided in Section 5.3,
GSK will develop Product for at least one (1) Future Indication. Notwithstanding
the above, ALLERGAN covenants and agrees that it will cause the Manufacturer to
supply Product for such development and commercialization activities (under the
terms of the Supply Agreement) and, at GSK's request and at GSK's expense,
subject to ALLERGAN's obligations as set forth in Article 4 and Exhibits G and
H, cooperate with GSK

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       22

<PAGE>

and to provide assistance as reasonably necessary in connection with any such
development and commercialization activities in the Field of Use in the
Territory.

     5.2 Territory Joint Development Committee.

          5.2.1 Within thirty (30) calendar days after the Effective Date, the
Parties will form a Territory Joint Development Committee ("TJDC") to manage and
review the development process and Regulatory Approval Application submissions
for Product in Territory. The responsibilities of the TJDC will include, without
limitation:

               (a) Reviewing co-development activities for Product during the
Transition Period as set forth in Article 4 and Exhibit H;

               (b) Reviewing the ongoing development activities for Product in
the Field of Use during the Term in accordance with the clinical development
plan in the Territory as described in Section 5.9.1;

               (c) Reviewing the progress of GSK's development of Product in the
Territory after the expiration of the Transition Period, including, without
limitation, Product Improvement and Enhancement activities, as provided in
Section 3.5;

               (d) Reviewing the progress of ALLERGAN's Product Improvement and
Enhancement activities as set forth in Section 3.5;

               (e) Acting as a forum for the Parties to exchange information
concerning the development and routine regulatory maintenance of Product in the
Field of Use in the Territory after the Transition Period, including
communications and correspondence to and from Regulatory Authorities;

               (f) Reviewing and discussing pharmacovigilance activities,
post-marketing surveillance activities, and manufacturing/CMC topics; and

               (g) Performing such other responsibilities as agreed to by the
Parties.

          5.2.2 The TJDC will meet periodically every Calendar Year as agreed to
by the Parties, but in no event less than once during each Calendar Quarter of
each Calendar Year during the Term, in person in the Territory not more than
twice per Calendar Year, or by video teleconference or teleconference as
mutually agreed, to discuss matters within its purview.

          5.2.3 ALLERGAN will designate two (2) members and GSK will designate
three (3) members to comprise the TJDC. Such individuals will be executives with
responsibility for the clinical development of and/or regulatory matters
relating to the Product in the Territory. In addition, the TJDC may from time to
time include additional non-voting, ad-hoc representatives from either Party on
specific issues as the need arises. Each Party will identify its members on

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       23

<PAGE>

the TJDC within thirty (30) days after the Effective Date. Chairmanship of the
TJDC will reside with a GSK member. The chairman will be responsible for
preparing minutes of each TJDC meeting and distributing such minutes to members
of the TJDC within thirty (30) days after each meeting for review and comment.
Such minutes will be approved as the first order of business at the immediately
succeeding TJDC meeting.

          5.2.4 Each Party will bear all expenses it incurs in regard to
participating in such TJDC meetings, including, without limitation, all travel
and living expenses.

          5.2.5 At least one (1) representative from each Party must be present
at any meeting of the TJDC to represent a quorum for voting purposes, with each
member on the TJDC having one (1) vote.

          5.2.6 All decisions related to Product portfolio management and
routine regulatory maintenance of Product in the Territory, initiation, conduct
and termination of clinical trials for Product, subject to Section 5.2.8,
budgeting for all such development and regulatory activities, and selection of
Indications for which Product may be developed, will be made by majority vote of
the TJDC, which decision will be final and binding on the Parties.

          5.2.7 All decisions related to other aspects of clinical development
or Regulatory Approval not specified in Section 5.2.6 will be made by unanimous
vote of the TJDC, which decision will be final and binding on the Parties. If
the TJDC cannot reach unanimous agreement, any disputes will be submitted for
resolution to a senior clinical development executive of each Party, or his/her
designee, for the Territory. If the senior clinical development executives of
each Party, or their respective designees, for the Territory cannot resolve such
any disputes within thirty (30) calendar days after the first (1st) interaction
(whether in writing, via telephone or in person) between the senior clinical
development executives of each Party or their respective designees, such dispute
will be decided by GSK, which decision of GSK will be final and binding on the
Parties.

          5.2.8 Notwithstanding the foregoing, any development plan or clinical
trial ***. GSK or its Affiliate will provide ALLERGAN with written notice prior
to proceeding with any matter set forth in this Section 5.2.8, and within thirty
(30) calendar days of receipt of such written notice from GSK or its Affiliate,
ALLERGAN will provide written notice to GSK or its Affiliate of whether ALLERGAN
consents to GSK or its Affiliate progressing with such matter. If ALLERGAN does
not refuse consent, or does not provide any response to GSK or its Affiliate, in
each case within such thirty (30) calendar day period, ALLERGAN will be deemed
to have consented to GSK or its Affiliate proceeding with the matter as
presented in GSK's or its Affiliate's written notice to ALLERGAN.

          5.2.9 For the avoidance of doubt, the TJDC's role will only be with
respect to development and regulatory activities of the Parties relating to
Product in the Territory as provided herein and, unless provided otherwise by
this Agreement, the TJDC will have no authority to (a) modify any term or
condition of this Agreement, including without limitation

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       24

<PAGE>

ALLERGAN's right pursuant to Section 2.5, or (b) create, provide for, or
eliminate any financial obligation of either Party under this Agreement.

     5.3 Development Responsibilities of GSK.

          5.3.1 Cosmetic Indications. Provided that GSK or any of its Affiliates
is the Marketing Authorization Holder and subject to Section 5.2.8, GSK will use
Commercially Reasonable Efforts to initiate and complete development and
regulatory activities that are reasonably required to obtain Regulatory Approval
for Product for Glabellar Lines in the Territory. Upon GSK becoming the
Marketing Authorization Holder, and except to the extent ALLERGAN's cooperation
is required in order to comply with regulatory requirements in the Territory,
and further subject to the Manufacture (as defined in the Supply Agreement) by
the Manufacturer of Product for use in such development activities in accordance
with the terms and conditions of the Supply Agreement, full responsibility for
any activities to obtain Regulatory Approvals of Cosmetic Indications for
Product in the Territory will be the sole responsibility of GSK.

          5.3.2 Future Indication Development Requirements and Diligence.

               (a) Provided that GSK or any of its Affiliates is the MAH and
subject to Section 5.2.8, GSK, at GSK's sole expense, will use Commercially
Reasonable Efforts to develop Product in the Territory and, in connection with
such Commercially Reasonable Efforts, undertake Product development activities
directed toward obtaining Regulatory Approval for Product for ***. Future
Indication, as reviewed by the TJDC. Such Product development activities may
include, without limitation, preclinical, clinical, and regulatory activities.

               (b) GSK will commence and continue such development of Product
for *** Future Indication as provided in Section 5.3.2(a) above until the
earlier of (A) the end of the *** of the Term; or (B) GSK obtaining Regulatory
Approval for the *** Future Indication for Product in the Territory.

               (c) If GSK ceases all development of Product during the ***
period set forth in Section 5.3.2(b) prior to obtaining *** Regulatory Approval
for Product for a Future Indication, all rights related to Future Indications
will revert to ALLERGAN.

For the avoidance of doubt, failure to use Commercially Reasonable Efforts to
perform any material development responsibilities in accordance with this
Section 5.3.2 will be considered a material breach of this Agreement provided
that in the event of a breach by ALLERGAN of its representations, warranties,
covenants or obligations under this Agreement, a Material Supply Interruption or
Material Regulatory Interruption, other scientific, medical or technical reason
outside GSK's control, and/or a Force Majeure Event in the Territory, the
failure of GSK to perform any of the development responsibilities as provided in
this Section 5.3.2(a) through 5.3.2(c) will not be considered a material breach
of this Agreement.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       25

<PAGE>

          5.4 Territory Joint Commercial Committee.

          5.4.1 Not later than thirty (30) calendar days after the Effective
Date, the Parties will form a Territory Joint Commercial Committee ("TJCC") to
oversee GSK's commercialization, sales, and promotion activities relating to
Product in the Field of Use in the Territory. The responsibilities of the TJCC
will include, without limitation:

               (a) Overseeing the Parties' respective commercialization
activities during the Transition Period pursuant Section 4.1.1(a) and the
Distribution Agreement, and managing the transition of such activities to GSK
once GSK or any of its Affiliates becomes the MAH;

               (b) Reviewing, on an annual basis, GSK's then-current marketing
plans, sales forecasts, and launch plans for Product in the Field in the
Territory;

               (c) Reviewing the progress and status of GSK's commercialization
of Product in the Territory;

               (d) Acting as a forum for the Parties to exchange information
concerning the commercialization of Product;

               (e) Coordinating ALLERGAN's co-promotion activities during the
Co-Promotion Term; and

               (f) Performing such other responsibilities as agreed to by the
Parties.

          5.4.2 The TJCC will meet periodically every Calendar Year as agreed to
by the Parties, but in no event less than once during each Calendar Quarter of
each Calendar Year during the Term, in person in the Territory not more than
twice per Calendar Year, or by video teleconference or teleconference as
mutually agreed, to discuss matters within its purview.

          5.4.3 ALLERGAN will designate two (2) members and GSK will designate
three (3) members to comprise the TJCC. Such individuals will be senior
management executives with responsibility for Product commercialization in the
Territory. In addition, the TJCC may from time to time include additional
non-voting, ad-hoc representatives from either Party for specific issues as the
need arises. Each Party will identify its members on the TJCC within thirty (30)
days after the Effective Date. Chairmanship of the TJCC will reside with a GSK
member. The chairman will be responsible for preparing minutes of each TJCC
meeting and distributing such minutes to members of the TJCC within thirty (30)
days after each meeting for review and comment. Such minutes will be approved as
the first order of business at the immediately succeeding TJCC meeting.

          5.4.4 Each Party will bear all expenses it incurs in regard to
participating in such TJCC meetings, including, without limitation, all travel
and living expenses.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       26

<PAGE>

5.4.5 At least one (1) representative from each Party must be present at any
meeting of the TJCC to represent a quorum for voting purposes, with each member
on the TJCC having one (1) vote..

          5.4.6 The TJCC will strive to make all decisions by consensus vote,
however, any disputes will be decided by a majority vote of the members of the
TJCC, which decision will be final and binding on the Parties.

          5.4.7 For the avoidance of doubt, the TJCC's role will only be with
respect to commercialization activities of the Parties relating to Product in
the Territory and, unless provided otherwise by this Agreement, the TJCC will
have no authority to (a) modify any term or condition of this Agreement,
including without limitation ALLERGAN's right pursuant to Section 2.5, or (b)
create, provide for, or eliminate any financial obligation of either Party under
this Agreement.

     5.5 Commercialization Responsibilities of GSK. Provided that GSK or any of
its Affiliates is the Marketing Authorization Holder, GSK, at GSK's sole
expense, will use Commercially Reasonable Efforts to commercialize Product in
the Field of Use in the Territory as directed by the TJCC.

     5.6 Adverse Event and Serious Adverse Event Reporting. GSK will be solely
responsible for and will comply with all applicable medical event reporting
requirements for the Product in the Territory and any countries in the Other
Territories. ALLERGAN will solely be responsible for and will comply with all
applicable medical event reporting requirements in all countries outside the
Territory and the Other Territories where the Product is being marketed, under
investigation, or pending registration. Adverse event information will be
exchanged between the Parties in such a manner as to ensure that their
respective regulatory obligations are met. Both Parties will agree in a separate
Pharmacovigilance Agreement on the detailed procedures including timeframes and
formats of adverse event information exchange specific to clinical trial and
spontaneous serious adverse events and non-serious adverse events and other
regulatory safety information. The drug safety groups for both Parties will have
standard operating procedures outlined in the Pharmacovigilance Agreement
relating to the receipt, processing, evaluation, and reporting of all adverse
events. Mechanisms for training and assessing compliance with these procedures
will also be identified in the Pharmacovigilance Agreement. The Parties will
negotiate and execute the Pharmacovigilance Agreement, which will include the
core principles set forth on Exhibit I as well as such other terms and
conditions agreed to by the Parties, within sixty (60) calendar days of the
Effective Date. GSK will be responsible for submitting all required
pharmacovigilance information to Regulatory Authorities in the Territory.
ALLERGAN will have access to such information provided by GSK and will be free
to use such information outside the Territory and Other Territories for any
purpose in connection with the sale of Product. GSK will provide reports to
ALLERGAN regarding all such pharmacovigilance information in the development
reports provided to ALLERGAN pursuant to Section 5.9.1.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       27

<PAGE>

     5.7 Product Recall. If any Regulatory Authority in the Territory orders or
requires the recall of any Product in the Territory, or if in GSK's opinion a
recall is necessary in the Territory, GSK will promptly notify ALLERGAN and
provide such information regarding such recall order or other information as may
be reasonably requested by ALLERGAN. GSK will, unless prohibited by Applicable
Law, consult ALLERGAN on the need for a recall and take all ALLERGAN submissions
into account when making a decision of whether to instigate or recall (such
decision not to be unreasonably made). GSK will be responsible for conducting
any recall in the Territory and ALLERGAN will co-operate with GSK by providing
all such information and assistance as may be reasonably required to implement
such recall. To the extent that any recall of the Product is implemented as a
result of Manufacturer's failure to Manufacture (as defined in the Supply
Agreement) Product in accordance with the terms and conditions of the Supply
Agreement, ALLERGAN will (a) bear all direct expenses incurred by GSK in
connection with such recall, (b) indemnify the GSK Indemnitees (as defined in
Section 8.1) from any and all Liabilities (as defined in Section 8.1) incurred
by the GSK Indemnitees to the extent that these are proven to be attributable to
the Manufacturer's failure to Manufacture Product in accordance with the terms
and conditions of the Supply Agreement, and (c) either, at GSK's sole option,
replace or credit GSK for the cost of the relevant Lots (as defined in the
Supply Agreement) of Product subject to the recall. If a recall is required due
to any negligence or willful misconduct of a GSK Indemnitee, GSK will bear all
such costs and expenses incurred in connection with such recall and will
indemnify the ALLERGAN Indemnitees (as defined in Section 8.2) from and against
any and all Liabilities incurred by the ALLERGAN Indemnitees that are proven to
be attributable solely to the negligence or willful misconduct of GSK. If any
Regulatory Authority outside the Territory orders or requires the recall of any
of the Products outside the Territory then ALLERGAN will promptly notify GSK and
provide such information regarding such recall order or other information as may
be reasonably requested by GSK. Except as set forth in Article 8, each Party's
sole and exclusive remedies for recalled Product shall be limited to the
remedies provided in this Section 5.7.

     5.8 Product Flow Outside of Territory. Each Party will implement reasonable
safeguards so that country-specific Products are sold only in its respective
territory and are not sold in any country outside such territory. Each Party
will sell Product only in its respective territory and will not, directly or
indirectly, offer Product to any Third Party that such Party reasonably believes
is going to market, distribute, or sell such Product, directly or indirectly,
outside such territory, unless mutually agreed upon by both Parties. If a Party
becomes aware that any of its customers has illegally imported Products from
outside its territory or exported Products to outside its territory, or has
reason to believe that a customer intends to illegally import Products from
outside its territory or exported Products to outside its territory, such Party
will take Commercially Reasonable Efforts to cause such customer to cease such
illegal import/export activities. If such Party reasonably believes that such
customer has not ceased such activities, then such Party will immediately cease
sale or distribution of any Product to such customer, to the full extent
permitted by Applicable Law. In addition, ALLERGAN will continue to implement
during the Term and during the Tail Period, and GSK will use Commercially
Reasonable Efforts to implement during the Term, ALLERGAN's product integrity
plan, the principles of which are set forth on Exhibit J to protect the safety
of patients,

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       28

<PAGE>

maintain the loyalty of physician customers, preserve value, and assure that
safe Product is available to patients seeking treatment and appropriately
handled for safe and effective treatment. Accordingly, GSK will designate one
(1) Person in the Territory to monitor the foregoing activities and concerns
(the "Product Integrity Manager"), and the Parties will use Commercially
Reasonable Efforts to ensure that: (a) Product will be promoted or sold solely
to authorized medical professionals through legitimate distribution channels;
(b) in order to guard against counterfeiters and illegal imports/exports, all
sales personnel of the Parties will be trained to recognize Product brand
packaging and help customers to determine and guard against counterfeiting or
illegal imports/exports; and (c) detection of illegal importers/exporters and
counterfeiters will be reported to the Product Integrity Manager by employees or
agents of the Parties as soon as possible.

     5.9 Reports. GSK will deliver to ALLERGAN the following written reports in
English summarizing GSK's activities and progress in its development and
commercialization of Product in the Territory.

          5.9.1 Development Reports.

               (a) If GSK or any of its Affiliates becomes the MAH and GSK (or
its Affiliate), in its sole discretion, undertakes to develop the Product in the
Field of Use in the Territory in accordance with Section 5.3 but subject to
Section 5.2.8, GSK will deliver to ALLERGAN a preliminary clinical development
plan listing major activities to be conducted within twelve (12) weeks after the
effective date of each such undertaking. Thereafter, not later than thirty (30)
calendar days after the end of each Calendar Year, GSK will update each such
clinical development plan and deliver to ALLERGAN a written report summarizing
progress in development of Product in the Field of Use during such Calendar
Year. Each such report will summarize all regulatory activities and development
progress made by GSK in development of Product in the Field of Use as of the
date of such report and, in addition, GSK's plans for the continuing such
development of Product in the Field of Use during the immediately following next
Calendar Year. Each such report will include information with respect to the
Product Improvement and Enhancements development programs since the prior
report, such as: (i) current status (for example, planning, enrollment, and
completion) of any clinical trial under the development program; (ii) efforts
toward and progress of enrolling patients in any clinical trial under the
development programs; and (iii) clinical trial synopsis for any clinical trial
under the development programs that is to be undertaken. The synopsis will
include, for example: (A) a description of the patient population, number of
patients to be enrolled, inclusion and exclusion criteria, study design,
description of endpoints, general statistical analyses plans, and formulation
and presentation to be utilized; (B) efforts undertaken in preparing a
Regulatory Approval Application relating to the development programs and status
of the efforts to prepare such application; (C) information submitted to the
local regulatory authorities relating to the development programs, including
without limitation regulatory updates and matters pertaining to Product
labeling; and (D) information received from the local regulatory authorities
relating to the development programs, including, for example, records of meeting
minutes of any other correspondence.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       29

<PAGE>

          5.9.2 Commercialization Reports.

               (a) Beginning on the date that is *** after the date of
initiation of clinical studies with a Product intended by GSK to be the subject
of a Regulatory Approval Application, GSK will deliver to ALLERGAN, within
thirty (30) calendar days after such date and, thereafter, within ***, a written
marketing plan with respect to commercialization by GSK of Product in the Field
of Use in the Territory that is the subject of the Regulatory Approval
Application.

               (b) Approximately *** prior to the anticipated date of
commercialization of a Product in such Field of Use, GSK will deliver to
ALLERGAN a complete marketing plan including market analysis and marketing and
sales activities in the Territory, the date anticipated by GSK that such
marketing and sales activities will begin, and, after Regulatory Approval for
Product has been obtained for such Field of Use, marketing and sales information
with respect to such Product for such Indication in the Territory; provided,
however, that GSK will not be required to generate extensive commercial analysis
solely for the purpose of reporting. Such annual reports will be in addition to
the written reports concerning progress in development described in Section
5.9.1. GSK may delete proprietary and sensitive information describing GSK's
customer and marketing strategies from reports to be provided to ALLERGAN under
this Section 5.9.2.

               (c) After the GSK Sales Commencement Date, GSK shall provide to
ALLERGAN, within *** after the end of each ***, a written report of GSK's
estimated Net Sales in the Territory during the immediately preceding ***.

               (d) Within *** after the end of each ***, GSK shall provide to
ALLERGAN a written report of the estimated Net Sales of GSK in the Territory
during the immediately preceding ***, broken down into two (2) categories:
aggregate Net Sales for the Cosmetic Indications and aggregate Net Sales for all
Indications other than the Cosmetic Indications.

               (e) ALLERGAN acknowledges and agrees that the written reports
received from GSK in accordance with Sections 5.9.2(c) and (d): (i) are
estimates of Net Sales only, and thus by definition may contain inherent errors,
and will not be binding upon and/or create any diligence obligation on GSK
and/or any of its Affiliates or sublicensees for any purpose under this
Agreement; (ii) are being provided to ALLERGAN solely for information purposes
and that as a result, neither GSK nor any of its Affiliates or sublicensees will
be liable for, and ALLERGAN will indemnify and hold GSK, its Affiliates and
sublicensees harmless from and against, any liabilities, damages, losses, costs
and/or expenses of any kind whatsoever incurred by ALLERGAN, its Affiliates, its
sublicensees or any Person relating to the use of such written reports by
ALLERGAN, its Affiliates and/or its sublicensees whether internally or publicly,
subject to Section 5.9.5; (iii) may be amended by GSK, its Affiliates or
sublicensees at any time and for any reason whatsoever; and (iv) are not subject
to being audited by ALLERGAN or its Affiliates or sublicensees. Further ALLERGAN
acknowledges and agrees

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       30

<PAGE>

that it cannot obligate GSK to alter or amend in any way any written report
received from GSK in accordance with Sections 5.9.2(c) and (d).

          5.9.3 Forecasts.

               (a) GSK will provide to ALLERGAN the following financial
forecasts relating to Product sales in the Territory: (i) by *** of each
Calendar Year, a rolling forecast of GSK's Net Sales for such Calendar Year,
broken down by Quarter and by all Cosmetic Indications and all Indications other
than Cosmetic Indications, and for *** (annual totals only); (ii) by *** of each
Calendar Year, an updated forecast of GSK's Net Sales for the remainder of such
Calendar Year, broken down by Quarter and by all Cosmetic Indications and all
Indications other than Cosmetic Indications; and (iii) by *** of each Calendar
Year, an updated forecast of GSK's Net Sales for the *** (annual totals only).
The Parties acknowledge and agree that GSK will in no way be obligated to
provide any assumptions along with any forecasts provided pursuant to this
Section 5.9.3.

               (b) ALLERGAN acknowledges and agrees that the forecasts received
from GSK in accordance with Section 5.9.3(a): (i) are estimates of Net Sales
only, and thus by definition may contain inherent errors, and will not be
binding upon and/or create any diligence obligation on GSK and/or any of its
Affiliates or sublicensees for any purpose under this Agreement; (ii) are being
provided to ALLERGAN solely for information purposes and that as a result,
neither GSK nor any of its Affiliates or sublicensees will be liable for, and
ALLERGAN will indemnify and hold GSK, its Affiliates and sublicensees harmless
from and against, any liabilities, damages, losses, costs and/or expenses of any
kind whatsoever incurred by ALLERGAN, its Affiliates, its sublicensees or any
Person relating to the use of such forecasts by ALLERGAN, its Affiliates and/or
its sublicensees whether internally or publicly, subject to Section 5.9.5; (iii)
may be amended by GSK, its Affiliates or sublicensees at any time and for any
reason whatsoever; and (iv) are not subject to being audited by ALLERGAN or its
Affiliates or sublicensees. Further ALLERGAN acknowledges and agrees that it
cannot obligate GSK to alter or amend in any way any forecast received from GSK
in accordance with Section 5.9.3(a).

          5.9.4 Data and Information Reports. GSK will disclose to ALLERGAN in
written reports delivered to ALLERGAN at each meeting of the TJDC or TJCC, as
applicable, any and all information and/or data generated or otherwise acquired
by GSK during the Term in connection with GSK's activities relating to Product
in the Field of Use in the Territory, for use by ALLERGAN and its Affiliates for
any purpose outside the Territory. In addition, after GSK has obtained
Regulatory Approval for a Product for a Field of Use in the Territory, GSK will
deliver to ALLERGAN a single written report each Calendar Year covering GSK's
development activities and marketing and sales activities in the immediately
preceding Calendar Year with respect to Product in the Field of Use covered by
such Regulatory Approval, such annual reports to be delivered within thirty (30)
days after December 31 of each Calendar Year.

          5.9.5 ALLERGAN agrees to treat written reports received from GSK
pursuant to this Section 5.9 as Confidential Information of GSK and in
accordance with Article 10.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       31

<PAGE>

6.   PATENT AND TRADEMARK MAINTENANCE AND ENFORCEMENT

     6.1 Patent Maintenance and Prosecution.

          6.1.1 ALLERGAN will file, prosecute, and maintain the ALLERGAN Patent
Rights after taking into account GSK's reasonable interests and requests after
reasonable consultation with GSK. As relevant to the activities and interests of
GSK under this Agreement, ALLERGAN will promptly inform GSK in writing of any
change in the status of the ALLERGAN Patent Rights. GSK will reimburse ALLERGAN
for *** of all of ALLERGAN's costs and expenses in prosecuting and maintaining
the ALLERGAN Patent Rights in the Territory, including the costs of oppositions,
interferences, and similar proceedings, and any appeals arising therefrom.
Should ALLERGAN elect not to file, prosecute, or maintain any patent or patent
application included within the ALLERGAN Patent Rights, ALLERGAN will provide
(a) GSK with written notice as soon as reasonably possible after making such
election but in any event no later than sixty (60) calendar days before GSK
would be faced with a possible loss of rights, (b) give GSK the right, at GSK's
discretion and sole expense, to file, prosecute and maintain such patents and/or
patent applications, and (c) offer reasonable assistance in connection with such
filing, preparation, and maintenance at no cost to GSK except for reimbursement
for reasonable out-of-pocket expenses incurred by ALLERGAN. In the event that
GSK elects to file, prosecute and maintain any patent and/or patent application
included within ALLERGAN Patent Rights as provided herein, such patent and/or
patent application will not be regarded as an ALLERGAN Patent Right for the
purpose of Section 6.3.2(a), but rather GSK will have the initial right to
initiate, maintain and control any enforcement actions relating to such patent
or patent application as provided in Section 6.3.2(b).

          6.1.2 GSK will file, prosecute, and maintain the GSK Patent Rights in
at its sole cost and expense; provided, however the Parties acknowledge and
agree that GSK will have no obligation whatsoever to file, prosecute, or
maintain any GSK Patent Rights. Should GSK elect not to file, prosecute or
maintain any patent or patent application included within the GSK Patent Rights,
GSK will provide (a) ALLERGAN with written notice as soon as reasonably possible
after making such election but in any event no later than sixty (60) calendar
days before ALLERGAN would be faced with a possible loss of rights, (b) give
ALLERGAN the right, at ALLERGAN's discretion and sole expense, to file,
prosecute and maintain such patents and/or patent applications, and (c) offer
reasonable assistance in connection with such filing, preparation, and
maintenance at no cost to GSK except for reimbursement for reasonable
out-of-pocket expenses incurred by GSK.

     6.2 Trademark Maintenance and Prosecution. ALLERGAN, at its sole discretion
but after taking into account GSK's reasonable interests and requests after
reasonable consultation with GSK, will at its own cost and expense file,
prosecute, and maintain the ALLERGAN Product Trademarks in the Territory,
including the costs of oppositions, interferences, and similar proceedings, and
any appeals arising therefrom.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       32

<PAGE>

     6.3 Enforcement.

          6.3.1 Notice. Each Party will notify the other promptly of any
apparent, threatened, or actual infringement by a Third Party of any patent
within the ALLERGAN Patent Rights, any trademark within the ALLERGAN Product
Trademarks or any patent within the GSK Patent Rights, in each case in the Field
of Use in the Territory, of which the Party becomes aware. The notifying Party
will promptly furnish the other Party with all known evidence of such
infringement (an "Infringement Notice").

          6.3.2 Enforcement Actions. As between ALLERGAN and GSK:

               (a) ALLERGAN will have the initial right, but not an obligation,
at its expense and in its own name or in the name of any of its Affiliates, to
initiate, maintain, and control any legal action on account of any infringement
of any patent within the ALLERGAN Patent Rights or trademark within the ALLERGAN
Product Trademarks by a Third Party, by counsel of its own choice. ALLERGAN will
notify GSK in writing within sixty (60) calendar days after giving or receiving
an Infringement Notice of its intention to initiate legal action against a Third
Party for infringement of a patent within the ALLERGAN Patent Rights or a
trademark within the ALLERGAN Product Trademarks in the Field of Use in the
Territory. If ALLERGAN exercises its first right, GSK will thereafter have a
right, in GSK's sole discretion and at GSK's expense, to join or otherwise
participate or not to join or otherwise participate in such legal action in the
Territory with legal counsel selected by GSK. If ALLERGAN does not exercise its
first right, GSK will thereafter have the right, but not the obligation, at its
expense and in its own name or in the name of any of its Affiliates, to
initiate, maintain, and control such legal action on ALLERGAN's behalf by
counsel of its choice. In the event that GSK initiates and thereafter maintains
such legal action against infringement of a patent within the ALLERGAN Patent
Rights or a trademark within the ALLERGAN Product Trademarks by a Third Party in
the Field of Use in the Territory, ALLERGAN, at GSK's expense, will provide GSK
cooperation as reasonably necessary, including agreeing to be named as a party
to such legal action.

               (b) GSK will have the initial right, but not an obligation, at
its expense and in its own name or in the name of any of its Affiliates, to
initiate, maintain, and control any legal action on account of any infringement
of any patent within the GSK Patent Rights by a Third Party, by counsel of its
own choice. GSK will notify ALLERGAN in writing within sixty (60) calendar days
after giving or receiving an Infringement Notice of its intention to initiate
legal action against a Third Party for infringement of a patent within the GSK
Patent Rights in the Field of Use in the Territory. If GSK exercises its first
right, ALLERGAN will thereafter have a right, in ALLERGAN's sole discretion and
at ALLERGAN's expense, to join or otherwise participate or not to join or
otherwise participate in such legal action in the Territory with legal counsel
selected by ALLERGAN. If GSK does not exercise its first right, ALLERGAN will
thereafter have the right, but not the obligation, at its expense and in its own
name or in the name of any of its Affiliates, to initiate, maintain, and control
such legal action on GSK'S behalf by counsel of its choice. In the event that
ALLERGAN initiates and thereafter maintains such legal action against
infringement of a patent within the GSK Patent Rights by a Third Party in the
Field of Use in the Territory, GSK, at ALLERGAN's expense, will provide

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       33

<PAGE>

ALLERGAN cooperation as reasonably necessary, including agreeing to be named as
a party to such legal action.

               (c) Any recovery received by a Party from legal action initiated
pursuant to this Section 6.3 in the Territory, whether by judgment, award,
decree, or settlement, will be used ***.

     6.4 Third Party Action. In the event of the institution of any suit by a
Third Party against ALLERGAN, GSK or their respective Affiliates or sublicensees
for patent infringement involving the use, sale, offering for sale or import of
Product in the Field of Use in the Territory, the Party sued will promptly
notify the other Party in writing. GSK will have the first right, but not the
obligation, to defend such suit at its own expense. ALLERGAN and GSK will
provide reasonable assistance to one another and reasonably cooperate in any
such litigation at the other's request without expense to the requesting Party.

     6.5 Cooperation. In any suit, proceeding, or dispute as described in this
Article 6, the Parties will provide each other with reasonable cooperation, and,
upon the request and at the expense of the Party bringing suit, the other Party
will make available to the Party bringing suit, at reasonable times and under
appropriate conditions, all relevant personnel, records, papers, information,
samples, specimens, and the like in its possession. Notwithstanding any other
provision of this Article 6, neither Party will make any settlements of any
suit, proceeding, or action as described in this Article 6 that would adversely
affect the other Party, materially affect the rights and licenses granted
hereunder, require the other Party to be subject to an injunction, or require
the other Party to make any monetary payment without first obtaining such other
Party's prior written consent, such consent not to be unreasonably withheld or
delayed.

7.   REPRESENTATIONS, WARRANTIES, AND COVENANTS

     7.1 Representations and Warranties of ALLERGAN. ALLERGAN represents and
warrants that, as of the Effective Date:

          7.1.1 ALLERGAN is a corporation duly organized, validly existing, and
in good standing under the laws of the state of Delaware;

          7.1.2 The execution, delivery, and performance of this Agreement by
ALLERGAN have been duly authorized by all requisite corporate action and do not
require any shareholder action or approval;

          7.1.3 The execution, delivery, and performance by ALLERGAN of this
Agreement and its compliance with the terms and provisions hereof do not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (a) any agreement with a Third Party, including
but not limited to a loan agreement, guaranty, financing agreement, agreement
affecting a Product, or other agreement or instrument binding or affecting it or
its property; (b) the provisions of its charter or operative documents or
bylaws; or

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       34

<PAGE>

(c) any order, writ, injunction, or decree of any court or governmental
authority entered against it or by which any of its property is bound;

          7.1.4 ALLERGAN has taken customary and reasonable steps, consistent
with industry practice, to protect the confidentiality of the ALLERGAN Know-How;

          7.1.5 ALLERGAN has the right and authority to grant the licenses
granted to GSK and its Affiliates pursuant to the terms and conditions set forth
in this Agreement in the Territory;

          7.1.6 Neither ALLERGAN nor its Affiliates has granted any right,
license, or interest in, to, or under the ALLERGAN Patent Rights, ALLERGAN
Know-How or ALLERGAN Trademarks in the Territory that is inconsistent with the
rights, licenses, and interests granted under the terms and conditions set forth
in this Agreement;

          7.1.7 ALLERGAN is the registered proprietor of the ALLERGAN Trademarks
that are registered in the Territory and the applicant in respect of those
ALLERGAN Trademarks which are applications at the Effective Date in the
Territory and, to the knowledge of ALLERGAN, the use of the ALLERGAN Trademarks
by GSK as contemplated by this Agreement will not infringe the intellectual
property rights of any Third Party in the Territory;

          7.1.8 ALLERGAN Controls the ALLERGAN Patent Rights and the ALLERGAN
Know-How and, the ALLERGAN Patent Rights have been properly filed, prosecuted,
and maintained and all fees and other charges due have been paid, in the
Territory;

          7.1.9 To the knowledge of ALLERGAN, the patents in the ALLERGAN Patent
Rights are not invalid and their exercise would not infringe the patent or other
intellectual property rights of any Third Party in the Territory, and there has
been no written notice of any claim or objection that the use of the ALLERGAN
Patent Rights and the ALLERGAN Know-How infringes, misappropriates, or otherwise
violates or makes unauthorised use of, or has infringed, misappropriated, or
otherwise violated or made unauthorised use of, the intellectual property or
know-how rights of any Third Party in the Territory and there is no fact or
circumstance which may give rise to any such claim or objection;

          7.1.10 To the knowledge of ALLERGAN, no Third Party is, infringing, or
otherwise violating or making unauthorised use of the ALLERGAN Patent Rights in
the Territory;

          7.1.11 To the knowledge of ALLERGAN, there are no pre-clinical or
clinical data or other information concerning Product in the Territory that it
has not provided to GSK prior to the Effective Date that demonstrates or
suggests that there is or may exist material quality, toxicity, safety, and/or
efficacy concerns that may impair the utility and/or safety of the Product in
the Territory;

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       35

<PAGE>

          7.1.12 To the knowledge of ALLERGAN, each Regulatory Approval in the
Territory has been validly issued by the appropriate Regulatory Authority and is
in full force and effect, ALLERGAN and its Affiliates and agents have been and
are in material compliance with all regulatory requirements of all competent
Regulatory Authorities in the Territory with respect to Product, and there are
no material facts or circumstances that might be expected to cause any
Regulatory Approval in the Territory to be revoked or not renewed;

          7.1.13 To the knowledge of ALLERGAN, all information and data provided
to GSK relating to the sales of the Products in the Territory is accurate in all
material respects and ALLERGAN and its distributors and agents have continued to
conduct their business in relation to the Product in the Territory in the
ordinary course and in accordance with Applicable Law since the date of the last
such information and data;

          7.1.14 To the knowledge of ALLERGAN, the information provided by
ALLERGAN to GSK for due diligence purposes in relation to this Agreement is
accurate in all material respects and ALLERGAN has not omitted to supply GSK
with any material information in its possession concerning Product in the
Territory or the transactions contemplated by this Agreement that would be
material to GSK's decision to enter into this Agreement and undertake the
commitments and obligations set forth in this Agreement. ALLERGAN acknowledges
that GSK has relied on the information in its material respects so provided by
ALLERGAN in deciding to enter into this Agreement;

          7.1.15 To the knowledge of ALLERGAN, all Products sold by ALLERGAN in
the Territory prior to the Effective Date were in material compliance with the
registered Product specifications, were manufactured in accordance with
Applicable Law, including requirements of current Good Manufacturing Practice
(cGMP), complied with any representation or warranty, express or implied, given
in respect of them, and were promoted, marketed, and sold in accordance with all
Applicable Law in the Territory; and

          7.1.16 To the knowledge of ALLERGAN, there are no material legal
proceedings or regulatory or governmental claims pending against ALLERGAN or its
agents in the Territory in relation to the Product.

     7.2 Covenants of ALLERGAN. ALLERGAN covenants that:

          7.2.1 Neither ALLERGAN nor its Affiliates will grant, during the Term,
any right, license, or interest in, to, or under the ALLERGAN Patent Rights,
ALLERGAN Know-How, or ALLERGAN Trademarks in the Field of Use in the Territory
that is inconsistent with the rights, licenses, and interests granted to GSK
hereunder or ALLERGAN's Control in such ALLERGAN Patent Rights, ALLERGAN
Know-How or ALLERGAN Trademarks;

          7.2.2 ALLERGAN will at all times comply with all Applicable Laws
relating to its activities under this Agreement;

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       36

<PAGE>

          7.2.3 ALLERGAN will not, and will cause all of its Affiliates and
sublicensees not to, either on its or their own or with any Third Party, conduct
any development activities or conduct clinical trials relating to Product, or
seek Regulatory Approvals for Product, in the Territory during the Term, except
as provided in Section 4.1;

          7.2.4 ALLERGAN will not, and will cause all of its Affiliates and
sublicensees not to, either on its or their own or with any Third Party, use,
sell, offer for sale or import (including, without limitation, distribute)
Product in the Territory during the Term, except as provided in Section 4.1 and
with respect to ALLERGAN's co-promotion activities during the Co-Promotion Term
as provided in Section 2.5, or as otherwise authorized by GSK in writing; and

          7.2.5 Prior to the GSK Distribution Commencement Date, ALLERGAN will,
and will use Commercially Reasonable Efforts to cause its Affiliates,
sublicensees, employees, and agents to, continue to develop and sell Product in
the Territory, and conduct business in relation to the Product in the Territory
in the ordinary course of business and in accordance with all Applicable Law,
including, without limitation, (a) preserving intact the market for Product in
the Territory and the goodwill associated with Product, (b) continuing to
maintain its (or their) relationships with distributors, customers and others
having material business relationships with it (or them) related to Product in
the Territory, (c) continuing to distribute Product in accordance with past
practice and, in particular, not to accelerate or increase the quantity of
Product distributed to the trade and not at prices below ALLERGAN's (or its
Affiliate's) average normal prices over the immediately preceding three (3)
consecutive months, and (d) take all reasonable steps to retain the services of
employees of ALLERGAN (or its Affiliate) to assist in the transition activities
set forth in Article 4.

     7.3 Representations and Warranties of GSK. GSK represents and warrants
that, as of the Effective Date:

          7.3.1 GSK is a private limited company duly organized, validly
existing, and in good standing under the laws England and Wales;

          7.3.2 The execution, delivery, and performance of this Agreement by
GSK has been duly authorized by all requisite corporate action and does not
require any shareholder action or approval;

          7.3.3 The execution, delivery, and performance by GSK of this
Agreement and its compliance with the terms and provisions hereof does not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (a) a loan agreement, guaranty, financing
agreement, agreement affecting a Product, or other agreement or instrument
binding or affecting it or its property; (b) the provisions of its charter or
operative documents or bylaws; or (c) any order, writ, injunction, or decree of
any court or governmental authority entered against it or by which any of its
property is bound; and

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       37

<PAGE>

          7.3.4 GSK has the right and authority to grant the rights and licenses
granted pursuant to the terms and conditions set forth in this Agreement.

     7.4 Covenants of GSK. GSK covenants that:

          7.4.1 GSK will at all times comply in all material respects with all
Applicable Law relating to its activities under this Agreement;

          7.4.2 GSK will take customary and reasonable steps, consistent with
industry practice, to protect the confidentiality of the ALLERGAN Know-How;

          7.4.3 GSK will not grant any right, license, or interest in, to, or
under any GSK Patent Rights that are inconsistent with the rights, license, and
interests granted under the terms and conditions set forth in this Agreement;

          7.4.4 GSK will use Commercially Reasonable Efforts to ensure that all
aspects of its regulatory, development, regulatory, and commercialization
activities with respect to Product in the Field of Use in the Territory,
including for example clinical trial design, pharmacovigilance, and clinical and
regulatory management activities, will be conducted in accordance with Good
Clinical Practice, Good Vigilance Practice, and Good Post-Marketing Study
Practice and professional standards consistent with the standards utilized by
GSK, including the relevant JPMA (Japan Pharmaceutical Manufacturers
Association) code, in GSK's commercialization efforts for Product in the Field
of Use in the Territory.

     7.5 Restrictive Covenant of GSK.

          7.5.1 The Parties acknowledge that:

               (a) As of the Effective Date, neither GSK nor its Affiliates have
any current or future intention of making, having made, using, offer for sale or
importing a Competing Product (as defined in Section 7.5.2) in the Field of Use
in any country of the world; and

               (b) During the Term, GSK will obtain certain Confidential
Information of ALLERGAN relating to the development, manufacture and
commercialization Product, which is valuable and highly confidential to ALLERGAN
and critical to the competitive success of ALLERGAN's business worldwide.

          7.5.2 To the extent permitted under Applicable Law, during the Term
and for a period of *** after the effective date of the expiration of this
Agreement pursuant to Sections 9.1 or 9.2.3, or the termination of this
Agreement for any reason other than by GSK pursuant to Sections 9.3.1 or 9.3.2
(the "Restrictive Period"), neither GSK nor any Affiliate of GSK will
manufacture, market, distribute, sell, promote, or detail any pharmaceutical
product in the Territory, which ***, other than Product (a "Competing Product")
in the Field of Use; provided, however, that:

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       38

<PAGE>

               (a) If GSK or any of its Affiliates manufactures, initiates
clinical studies, markets, distributes, sells, promotes, or details
(collectively, "commercialization") a Competing Product in *** during the Term,
GSK will (i) notify ALLERGAN immediately upon becoming aware of such
commercialization, and (ii) cease commercialization of such Competing Product
within *** after the date that GSK became aware of such commercialization. If
GSK does not cease such commercialization within *** after becoming aware of
such commercialization, ALLERGAN, at any time thereafter, will have a right to
terminate this Agreement and any other agreement between the Parties relating to
Product in the Other Territories, which termination by ALLERGAN of this
Agreement will be deemed a termination by ALLERGAN pursuant to Section 9.3.1.
During the period between the date that GSK becomes aware of commercialization
of a Competing Product as provided in this Section 7.5.2(a) and the earlier of
the date on which GSK ceases such commercialization and expiration of the
Restrictive Period, GSK will pay to ALLERGAN *** of all of GSK's or its
Affiliates' net sales of such Competing Product (which net sales will be
calculated in the same manner that Net Sales are calculated herein).
Notwithstanding the foregoing, if GSK or any of its Affiliates has used
ALLERGAN's Know-How or Confidential Information in connection with the
commercialization of a Competing Product as provided in this Section 7.5.2(a),
ALLERGAN will have the right to immediately terminate this Agreement and any
other agreement between the Parties relating to Product in the Other Territories
upon thirty (30) calendar days' prior written notice to GSK, which termination
by ALLERGAN of this Agreement will be deemed a termination by ALLERGAN pursuant
to Section 9.3.1.

               (b) Notwithstanding anything contained in this Section 7.5.2,
nothing herein will, expressly or impliedly, preclude or restrict GSK, or any of
its Affiliates, in any way from (i) acquiring a majority of the voting stock, or
all or substantially all of the assets of, a Business Entity (as defined below);
(ii) being acquired by a Business Entity; or (iii) merging, amalgamating, taking
over, or consolidating (or engaging in any similar transaction) with a Business
Entity (hereinafter, the actions referred to in (i), (ii), and (iii) of this
Section 7.5.2(b) are collectively referred to as "Merger" or "Merging").

                    The term "Business Entity" as used in this Section 7.5.2(b)
means any Person, which, at the time of such Merger, is commercializing (as such
term is defined in Section 7.5.2(a)) a Competing Product in ***, including, for
example, the Persons listed on Exhibit K.

                    In the event that GSK or any of its Affiliates Merges with a
Business Entity during the Term, GSK will divest or cause the divestiture of the
Competing Product being commercialized by the Business Entity within *** after
the date of the public announcement of such Merger ("Merger Date"). During such
*** period, (A) neither GSK nor any of its Affiliates will use any ALLERGAN
Know-How or Confidential Information in connection with the commercialization of
such Competing Product; and (B) GSK will continue to comply with the terms of
this Agreement in all respects. If GSK does not divest or cause the divesture of
such Competing Product within *** after the Merger Date, ALLERGAN, at any time
thereafter, will have a right to terminate this Agreement and any other
agreement between

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       39

<PAGE>

the Parties relating to Product in the Other Territories, which termination by
ALLERGAN will be deemed a termination by ALLERGAN pursuant to Section 9.3.1. In
the event that GSK does not divest or cause the divesture of such Competing
Product within the *** period as provided in this Section 7.5.2(b), GSK will pay
to ALLERGAN *** of all of GSK's or its successor's net sales of such Competing
Product after such *** period (which net sales will be calculated in the same
manner that Net Sales are calculated herein) and continuing until the earlier of
the date on which GSK or its successor divests such Competing Product or the
expiration of the Restrictive Period.

     7.6 Disclaimer. EXCEPT AS EXPRESSLY PROVIDED FOR IN THIS ARTICLE 7,
ALLERGAN MAKES NO, AND HEREBY DISCLAIMS ANY AND ALL, REPRESENTATIONS AND
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO THE ALLERGAN PATENT
RIGHTS, ALLERGAN KNOW-HOW, AND/OR ALLERGAN TRADEMARKS, INCLUDING WITHOUT
LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND
NONINFRINGEMENT OF ANY THIRD PARTY'S PROPRIETARY RIGHTS.

8.   INDEMNIFICATION AND INSURANCE

     8.1 Indemnification by ALLERGAN. ALLERGAN will indemnify, defend, and hold
GSK and its Affiliates and their directors, officers, employees, and agents
(each and collectively a "GSK Indemnitee") harmless from and against any and all
liabilities, damages, losses, costs and expenses, investigations, and reasonable
attorneys' fees incurred hereunder (each and collectively a "Liability")
resulting from or arising out of a claim, suit, or proceeding brought by a Third
Party against a GSK Indemnitee arising out of or related to:

          8.1.1 the research, development, manufacture, promotion, sale,
distribution, importation and/or use of Product in the Field of Use in the
Territory prior to the GSK Distribution Commencement Date;

          8.1.2 the research, development, manufacture, promotion, sale,
distribution, importation and/or use of Product in any country outside of the
Territory and the Other Territories;

          8.1.3 the promotion, sale, distribution, importation and/or use of
Product in the Territory for the Current Indications after the GSK Distribution
Commencement Date;

          8.1.4 the promotion, sale, distribution, importation and/or use of
Stock Product in the Territory;

          8.1.5 the research and development of Product in the Territory for the
Cosmetic Indications which is conducted or sponsored by an ALLERGAN Indemnitee
(as defined in Section 8.2) up to and continuing until the date on which the
study 909 is locked;

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       40

<PAGE>

          8.1.6 the employment (and/or termination) of any employees of ALLERGAN
and/or its Affiliates in the Territory, including, without limitation,
Liabilities relating to pensions and other defined benefits, severance payments
and/or wrongful dismissal claims;

          8.1.7 any violation of Applicable Law by any ALLERGAN Indemnitee in
performing ALLERGAN's obligations under this Agreement; and

          8.1.8 any material breach by any ALLERGAN Indemnitee of ALLERGAN's
representations, warranties and/or obligations under this Agreement;

provided, however, with respect to Sections 8.1.3, 8.1.4, 8.1.7 and 8.1.8,
except to the extent that any such Liabilities are the responsibility of GSK
under Section 8.2; and provided further with respect to Section 8.1.3, to the
extent that any such Liabilities occur during the first (1st) Calendar Year
after the Effective Date.

     8.2 Indemnification by GSK. GSK will indemnify, defend, and hold harmless
ALLERGAN and its directors, officers, employees, agents, and consultants (each
and collectively an "ALLERGAN Indemnitee") from and against any and all
Liabilities resulting from or arising out of a claim, suit, or proceeding
brought by a Third Party against an ALLERGAN Indemnitee arising out of or
related to:

          8.2.1 the research, development, promotion, sale, distribution,
importation and/or use of Product in the Field of Use in the Territory after the
Effective Date;

          8.2.2 any violation of Applicable Law by any GSK Indemnitee in
performing GSK's obligations under this Agreement; and

          8.2.3 any material breach by any GSK Indemnitee of GSK's
representations, warranties and/or obligations under this Agreement;

provided, however, with respect to Sections 8.2.1, 8.2.2 and 8.2.3, except to
the extent such Liabilities are the responsibility of ALLERGAN under Section
8.1.

     8.3 Procedure. For purposes of Sections 8.1 and 8.2, the Person asserting a
claim for indemnification pursuant to either Section 8.1 or 8.2 (the
"Indemnified Person") will notify the Party responsible for such indemnification
(the "Indemnifying Party") in writing of any claims, suits, or proceedings by
Third Parties that may give rise to any claim for which indemnification may be
required under this Article 8 as follows: (a) within fifteen (15) calendar days
after receipt of service of process of the commencement of suit or (b) for
non-litigated matters, within thirty (30) calendar days after receipt of notice
thereof; provided, however, that failure to give such notice will not relieve
the Indemnifying Party of its obligation to provide indemnification hereunder
except if, and to the extent that, such failure materially and adversely affects
the ability of the Indemnifying Party to defend the applicable claim, suit, or
proceeding. The Indemnifying Party will be entitled to assume sole control over
the defense of any such claim at its own cost and expense; provided, however,
that the Indemnified Person will have the right to

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       41

<PAGE>

be represented by its own counsel at its own cost in such matters. Neither the
Indemnifying Party nor the Indemnified Person will settle or dispose of any such
matter in any manner that would adversely affect the rights or interests of the
other, require the other to be subject to an injunction, or require the other to
make any monetary payment, in each case without the prior written consent of the
other, which will not be unreasonably withheld or delayed. The Indemnifying
Party and Indemnified Person will reasonably cooperate with the other and its
counsel in the course of the defense of any such suit, claim, or demand, such
cooperation to include without limitation using reasonable efforts to provide or
make available documents, information, and witnesses.

     8.4 Limitation of Liability. With respect to any claim by one Party against
the other arising out of the performance or failure of performance of the other
Party under this Agreement, the Parties expressly agree that the liability of
such Party to the other Party for such breach will be limited under this
Agreement or otherwise at law or equity to direct damages only and in no event
will a Party be liable for indirect, special, punitive, exemplary, or
consequential damages. The limitations set forth in this Section 8.4 will not
apply with respect to the obligations of either Party to indemnify the other
under Sections 8.1 or 8.2 in connection with a claim of a Third Party.

     8.5 Insurance. Each Party, at its own expense, will maintain commercial
general (public liability)/ product liability insurance, including coverage for
clinical trials, with a minimum limit of liability per occurrence of, or the
equivalent of, *** and *** in the annual aggregate, or self insure for any such
amounts, and will provide the other Party with a certificate of such insurance.
Each Party will provide at least thirty (30) calendar days' written notice to
the other Party prior to cancellation or material change in the relevant Party's
policy or coverage.

9.   TERM AND TERMINATION

     9.1 Term. The initial term of this Agreement will commence on the Effective
Date and continue for a period of twenty (20) years (the "Initial Term"), unless
extended pursuant to Section 9.2 or terminated at an earlier date in accordance
with Sections 9.3 or 11.16. If GSK does not elect to extend the Initial Term as
provided in Section 9.2 below, unless earlier terminated as provided in Sections
9.3 or 11.16, this Agreement will expire at the end of the Initial Term.

     9.2 Options to Extend Initial Term.

          9.2.1 If, by the end of the Initial Term, cumulative GSK Net Sales,
based on the price of Product on the GSK Sales Commencement Date, of Product is
equal to or greater than ***, or the equivalent of *** in Japanese Yen using the
currency exchange rate for purchase of U.S. dollars as published in The Wall
Street Journal (Western edition) on the GSK Sales Commencement Date, GSK will
have the option to extend the Initial Term for an additional five (5) years
(such five (5) year period referred to as the "Extended Term"), for a total
duration of the Term equal to twenty-five (25) years, upon providing written
notice to ALLERGAN prior to the expiration of the Initial Term. Any reduction in
price of Product over the Initial Term of ***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       42

<PAGE>

or more from the price of Product on the GSK Sales Commencement Date, or any
similar reduction in the reimbursement rate of Product from that on the GSK
Sales Commencement Date, will reduce the Net Sales minimum threshold of *** set
forth in this Section 9.2.1 by *** reduction of price of Product or
reimbursement rate.

          9.2.2 Notwithstanding the foregoing, if during the Initial Term there
is a Material Supply Interruption or Material Regulatory Interruption, of GSK's
or its Affiliates' or sublicensees' ability to commercialize Product in the
Territory is materially disrupted due to a Force Majeure Event, the Net Sales
minimum threshold of *** will not apply and the Parties will negotiate in good
faith a new threshold which appropriately reflects GSK's inability to meet the
threshold of *** due to each such interruption or disruption.

          9.2.3 If GSK exercises its option to extend the Initial Term as
provided in this Section 9.2, unless earlier terminated as provided in Section
9.3, this Agreement will expire at the end of the Extended Term.

     9.3 Early Termination.

          9.3.1 Termination for Material Breach. In the event of a material
breach or default of this Agreement by either Party that is not cured within ***
after receipt of notice thereof from the other Party, the non-breaching Party
will be entitled to terminate this Agreement by giving written notice to the
other Party, such termination to take effect immediately. The right to terminate
this Agreement will not be affected in any way by a waiver of, or failure to
take action with respect to, any previous default.

          9.3.2 Termination for Bankruptcy. Either Party will have the right to
terminate this Agreement effective upon written notice to the other Party in the
event the non-notifying Party becomes insolvent or makes an assignment for the
benefit of creditors, or in the event bankruptcy or insolvency proceedings are
instituted against the non-notifying Party or on the non-notifying Party's
behalf.

          9.3.3 Termination for Safety or Quality Reasons; Material Regulatory
Interruption. GSK will have the right to immediately terminate this Agreement
upon providing thirty (30) calendar days' written notice to ALLERGAN, if (a)
there is a Material Regulatory Interruption which has lasted for at least ***
during the Term; or (b) GSK reasonably determines, after consultation with
ALLERGAN, that there are significant safety or quality concerns relating to
Product that GSK considers (in accordance with its corporate policies and
procedures) justifying that Product not be sold in the Territory.

          9.3.4 Termination for Commercial or Development Reasons. GSK may
terminate this Agreement on not less than six (6) months' prior written notice
to ALLERGAN in the event that GSK decides that based on a reasonable
determination, using the same standards as it would use to determine whether or
not to continue the commercialization of its own prescription pharmaceutical
products, that the intellectual property, medical, scientific, technical,
regulatory, and/or commercial profile of the Product does not justify the
continued

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       43

<PAGE>

commercialization of the Product in the Territory. During the period subsequent
to GSK providing notice of termination pursuant this Section 9.3.4 and until the
effective date of such termination, GSK will use Commercially Reasonable Efforts
to develop and commercialize Product in the Field of Use in the Territory as
provided in this Agreement.

     9.4 Effect of Expiration or Termination.

          9.4.1 In the event of the expiration of this Agreement in accordance
with Sections 9.1 or 9.2.3, or termination of this Agreement for whatever
reason, effective as of the date of expiration or such termination, all of GSK's
rights hereunder to ALLERGAN Patent Rights, ALLERGAN Know-How, and/or ALLERGAN
Trademarks will terminate and revert to ALLERGAN, and GSK will have no further
rights thereto.

          9.4.2 In the event of the termination of this Agreement by GSK
pursuant to and in accordance with Sections 9.3.1 or 11.16, all of ALLERGAN's
rights under the GSK Patent Rights pursuant to Section 2.1.3 will terminate and
revert to GSK, and ALLERGAN will have no further rights thereto.

          9.4.3 In the event of expiration of this Agreement in accordance with
Sections 9.1 or 9.2.3, or termination of this Agreement for whatever reason,
each Party will promptly return, or at the other Party's request destroy, any
Confidential Information of such other Party in such Party's possession or
control at the time of termination and, if destroyed, certify such destruction
to such other Party; provided that each Party may, at such Party's expense, make
and retain one (1) copy of the other Party's Confidential Information for legal
archival purposes only.

          9.4.4 In the event of termination of this Agreement for whatever
reason, each Party will retain any and all rights or remedies such Party may
have in law or in equity, subject to Section 8.4 of this Agreement.

          9.4.5 In the event of the expiration of this Agreement in accordance
with Sections 9.1 or 9.2.3, or the earlier termination of this Agreement by
either Party for any reason, each Party will pay to the other Party, any payment
hereunder that accrued prior to the effective date of such expiration or
termination, but has not been paid.

          9.4.6 Upon expiration of this Agreement in accordance with Sections
9.1 or 9.2.3, or the earlier termination of this Agreement for any reason, GSK
will, to the extent permitted under Applicable Law and at ALLERGAN's sole cost
and expense, transfer or assign to ALLERGAN or a Person designated by ALLERGAN
(or have reissued in the name of ALLERGAN or a Person designated by ALLERGAN, if
applicable), for use by ALLERGAN as ALLERGAN may determine (a) all Regulatory
Approvals, and Regulatory Approval Applications existing at the Effective Date
and transferred to GSK by ALLERGAN under this Agreement, and (b) except in the
event of termination of this Agreement by GSK pursuant to Section 9.3.1, all
data, Regulatory Approvals, and Regulatory Approval Applications obtained by GSK
in connection with GSK's activities related to Product in the Territory during
the Term.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       44

<PAGE>

GSK will cooperate fully with ALLERGAN to effect any such transfer or
assignment, or reissuance, if applicable.

          9.4.7 Upon expiration or termination of this Agreement, GSK will
return to ALLERGAN all documents and materials provided by ALLERGAN pursuant to
Article 4 to GSK in accordance with Section 9.4.3, and in addition approvals and
rights.

     9.5 Survival.

          9.5.1 Termination or expiration of this Agreement for any reason will
terminate all outstanding obligations and liabilities between the Parties
arising from this Agreement except those described in:

               (a) Sections 2.1.1, 2.2, 2.4, 3.2, 3.3, 3.6.1, 3.6.3(a),
3.6.4(a), 3.7, 3.8, 3.9, 3.10.1, 5.5, 5.8, 9.5.1(a) and 11.6, all with regard to
GSK's post termination/expiration sales of Product pursuant to Section 8.5 of
the Supply Agreement; and

               (b) Sections 2.1.3 (subject to Section 9.4.2), 2.3, 3.4, 3.6.2,
3.6.3(b), 3.6.4(b), 3.7, 3.8 (for clarity, the last sentence of Section 3.8 will
survive indefinitely), 3.9, 3.10, 5.6, 5.7 (4th and 5th sentences only),
5.9.2(e), 5.9.3(b), 7.5, 9.4, 9.5.1(b), 9.5.1(c), 9.5.2, 11.1, 11.3, 11.4, 11.5,
11.6, 11.7, 11.8, 11.10 and 11.11, and Articles 8 and 10, all of which will
survive termination or expiration of this Agreement for the longer of (A) the
duration of the Tail Period if such Sections and Articles are specifically
applicable to the Tail Period, or (B) the time period specified in such Sections
and Articles; provided, however, that if such Sections and Articles are not
specifically applicable to the Tail Period or no such time period is specified
in such Sections and Articles, they will all survive termination or expiration
of this Agreement indefinitely; and

               (c) Article 1 for the sole purposes of interpreting the
obligations and liabilities between the Parties surviving termination of this
Agreement.

          9.5.2 Expiration or termination of this Agreement for any reason will
not release either Party from any obligation that has accrued prior to
expiration or such termination, including without limitation any obligation of a
Party to pay any amount which became due and payable under the terms and
conditions of this Agreement prior to expiration or such termination.
Termination of this Agreement will not preclude either Party from claiming any
other damages, compensation, or relief that it may be entitled, whether in law
or in equity, upon such termination.

10.  CONFIDENTIALITY

     10.1 Confidential Information. "Confidential Information" means, except as
provided below in this Section 10.1, the terms and conditions of this Agreement
as well as confidential and proprietary information of a Party, whether in
written, printed, verbal, or electronic form, and whether disclosed before or
after the Effective Date, including research and development

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       45

<PAGE>

activities, Product design details and specifications, technology and know-how,
sales and marketing plans, finances and business forecasts, procurement
requirements and vendor information, customer lists, personnel information and
strategic plans. Confidential Information will not include information that: (a)
is now, or hereafter becomes, generally known or available to the public through
no act or failure to act on the part of the receiving Party; (b) was acquired by
the receiving Party before receiving such information from the disclosing Party
through no breach of any duty of confidentiality owed to the disclosing Party
and without restriction as to use or disclosure; (c) is hereafter rightfully
furnished to the receiving Party by a Third Party without any breach of any duty
of confidentiality owed to the disclosing Party and without restriction as to
use or disclosure; or (d) is information that the receiving Party can document
was independently developed by the receiving Party without any use of the
disclosing Party's Confidential Information.

     10.2 Non-Disclosure of Confidential Information. Each Party, when it is the
receiving Party, agrees: (a) to hold the disclosing Party's Confidential
Information in strict confidence and not to disclose such Confidential
Information to any other Third Party without the prior written consent of the
disclosing Party; (b) not to use, at any time following the Effective Date, any
Confidential Information of the disclosing Party for its own benefit or for the
benefit of any Third Party for any purpose other than for the express purposes
permitted under this Agreement or any other agreement between the Parties and/or
their respective Affiliates relating to Product; and (c) to limit the disclosure
of Confidential Information to Permitted Persons. For purposes hereof, the term
"Permitted Person" will mean the receiving officers and employees of the
receiving Party or of an Affiliate of the receiving Party who have a need to
know in order to carry out the obligations under this Agreement; provided each
has agreed in writing to maintain the confidentiality of the Confidential
Information in a manner no less protective than that set forth herein. The
receiving Party will use Confidential Information of a disclosing Party solely
to exercise its rights and perform its obligations under this Agreement
(including without limitation the right to use and disclose such Confidential
Information in Regulatory Approval Applications and regulatory filings), unless
otherwise mutually agreed in writing. The receiving Party will take the same
degree of care with Confidential Information of a disclosing Party that it uses
to protect its own confidential and proprietary information of a similar nature
and importance (but in any event no less than reasonable care).

     10.3 Legal Disclosure. In the event a receiving Party is required to
disclose Confidential Information of the disclosing Party by any Applicable Law,
it may do so only to the extent required thereby; provided, however, that the
receiving Party will (a) use reasonable efforts under the circumstances to
provide advance notice to the disclosing Party of the required disclosure to
allow the disclosing Party an opportunity to take steps to object to, prevent,
or limit its disclosure or obtain a protective or other similar order with
respect to the required disclosure and (b) restrict disclosure to only that
portion of the Confidential Information that is required to be disclosed.

     10.4 Remedies. The receiving Party agrees that its obligations hereunder
are necessary and reasonable to protect the disclosing Party's business
interests and that the unauthorized

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       46

<PAGE>

disclosure or use of Confidential Information of a disclosing Party would cause
irreparable harm and significant injury, the degree of which may be difficult to
ascertain. The receiving Party further acknowledges and agrees that in the event
of any actual or threatened breach of this Agreement, the disclosing Party may
have no adequate remedy at law and, accordingly, that the disclosing Party will
have the right to seek an immediate injunction enjoining any breach or
threatened breach of this Agreement, as well as the right to pursue any and all
other rights and remedies available at law or in equity for such breach or
threatened breach.

     10.5 Return of Confidential Information. Upon the request of the disclosing
Party, the receiving Party will promptly return to the disclosing Party or, upon
the disclosing Party's written approval, destroy all material embodying
Confidential Information of the disclosing Party in its possession or under its
control, including all copies thereof; provided that each Party may, at such
Party's expense, make and retain one (1) copy of the other Party's Confidential
Information for legal archival purposes only.

     10.6 Disclosure of Agreement, Publicity, and Publications. Except as
expressly provided otherwise in Section 10.3, neither GSK nor ALLERGAN will
release to any Third Party or publish in any way any non-public information with
regard to the terms of this Agreement or concerning their cooperation without
the prior written consent of the other, which consent will not be unreasonably
withheld or delayed. Subject to the foregoing, the Parties will issue a joint
press release, public statement, or disclosure regarding this Agreement in the
Territory, which joint press release, public statement or disclosure will be
mutually agreed upon by the Parties. Nothing in the foregoing, however, will
prohibit a Party from making disclosures to the extent deemed necessary under
applicable federal or state securities laws or any rule or regulation of any
nationally recognized securities exchange. In such event, however, the
disclosing Party will use good faith efforts to consult with the non-disclosing
Party prior to such disclosure and will request confidential treatment to the
extent available. Each Party acknowledges and agrees that the other will have
the right to submit manuscripts relating to Product for scientific publications.
A copy of any scientific abstract or manuscript of results from any clinical
trial that is submitted for publication will be provided by to the other Party
within thirty (30) days after such submission. ALLERGAN acknowledges and agrees
that GSK may publish the results of clinical trials conducted by GSK with the
Product after the Effective Date on GSK's Clinical Trial Register and that such
publication will not be a breach of the confidentiality obligations provided in
Section 10.2. ALLERGAN agrees to cooperate with GSK in such effort as further
determined by the TJCC, including using Commercially Reasonable Efforts to
provide GSK with the protocols, results, data, and other information relating to
all clinical trials conducted by GSK with the Product in ALLERGAN's possession
that GSK reasonably requires to be published on GSK's Clinical Trial Register.

     10.7 ALLERGAN Data Protections. GSK agrees and understands that
Confidential Information of ALLERGAN, including but not limited to data,
disclosed to GSK through the TJCC or otherwise and arising under or related to
Product, is very sensitive and ALLERGAN would not enter into this Agreement
without additional assurances from GSK with respect to GSK's use of such
Confidential Information or possible disclosure of such Confidential

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       47

<PAGE>

Information to ALLERGAN's competitors. Accordingly, GSK will not use any
Confidential Information in connection with any botulinum toxin research and/or
development other than as provided under this Agreement.

     10.8 Termination. All obligations of confidentiality and non-use imposed
under this Article 10 will expire *** after the date of expiration or
termination of this Agreement, except that Article 10 obligations of
confidentiality and non-use will continue thereafter with respect to
manufacturing and regulatory information, including without limitation filings
with regulatory bodies.

11.  GENERAL PROVISIONS

     11.1 Governing Law. Notwithstanding its place of execution or performance,
this Agreement, and all claims arising out of or relating to this Agreement,
will be governed by and construed in accordance with the laws of the State of
New York, irrespective of its laws regarding choice or conflict of laws. The
Parties hereby agree that for the purposes of resolving any Disputes hereunder,
in accordance with Section 11.4, that the Parties hereby submit to the exclusive
jurisdiction of the courts of New York.

     11.2 Further Assurances. Each Party will, at its own expense, furnish,
execute, and deliver all documents and take all actions as may reasonably be
required to effect the terms and purposes of this Agreement

     11.3 Assignment. This Agreement is binding upon and inures to the benefit
of the Parties, and to their permitted successors and assigns. No Party may
assign or delegate any or all of its rights or obligations under this Agreement
without the prior written consent of the other Party except to an Affiliate. Any
assignment or delegation, or any other transfer or change of control by sale,
acquisition, merger, or otherwise, or attempt at the same, other than to an
Affiliate, made in the absence of such prior written consent will be void and
without effect; provided, however, that in the event of the foregoing, such
written consent will not be unreasonably withheld. If a Party assigns this
Agreement to an Affiliate, such Party will also promptly inform the other Party
and guarantee the performance by its Affiliate of all of such Party's
obligations under this Agreement. Either Party may, however, with notice, but
without consent and at its sole discretion, assign all of the rights and
obligations under this Agreement (excluding however, with regard to ALLERGAN,
any of its rights under Section 7.5) to a Third Party in connection the transfer
or sale of all or substantially all of its business, or in the event of its
merger or consolidation or change in control or similar transaction.

     11.4 Dispute Resolution. Except with regard to any matters or disputes
between the Parties that are to be resolved by the TJDC or TJCC as set forth in
this Agreement, if a dispute or controversy regarding any other matter under
this Agreement, arises between the Parties which they are unable to resolve (a
"Dispute"), each of the Parties will (subject to any cure period as set forth in
this Agreement), be entitled to submit to the other Party written notice of such
Dispute, with such notice setting forth in reasonable detail the nature of the
Dispute (the "Dispute Notice"). For a period of thirty (30) calendar days after
the date of the receiving Party's receipt

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       48

<PAGE>

of the Dispute Notice, the Parties will seek to resolve such Dispute by good
faith negotiation between the President Japan Pharmaceuticals for GSK or his/her
designee and the President, Pharmaceuticals of ALLERGAN or his/her designee. If
at the end of such thirty (30) calendar day period the Dispute remains
unresolved, the Parties may seek relief for such Dispute using any appropriate
administrative or judicial mechanism which may be available, subject to Section
11.1. The provisions of this Section 11.4 will not restrict in any way the
Parties' rights to seek preliminary injunctive or other equitable relief from
any court having jurisdiction.

     11.5 Legal Fees. If any Party to this Agreement resorts to any legal action
in connection with this Agreement, the prevailing Party will be entitled to
recover reasonable fees of attorneys and other professionals in addition to all
court costs which that Party may incur as a result.

     11.6 No Use of Names. Except as otherwise required under Applicable Law, or
as otherwise permitted under this Agreement, neither Party will use the name of
the other in its advertising, press releases or promotional materials without
the prior written consent of such other Party.

     11.7 Notices. Any notice to be given under this Agreement must be in
writing and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address
given below, or at any address such Party has previously designated by prior
written notice to the other. Notice will be deemed sufficiently given for all
purposes upon the earlier of: (a) the date of actual receipt; (b) if mailed,
three (3) calendar days after the date of postmark; or (c) if delivered by
overnight courier, the next business day the overnight courier regularly makes
deliveries.

          If to GSK, notices must be addressed to:

               Glaxo Group Limited
               Glaxo Wellcome House, Berkeley Avenue,
               Greenford, Middlesex, UB6 0NN, England
               Attention: Company Secretary
               Telephone:
               Facsimile:

          With a copy to:

               Smith Kline Beecham Corporation d/b/a GlaxoSmithKline
               2301 Renaissance Boulevard
               King of Prussia, PA 19406-2772
               Attention: Vice President and Associate General Counsel,
                          R&D Legal Operations, Business Development
                          Transactions Team
               Facsimile: 610-787-7084

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       49

<PAGE>

          If to ALLERGAN, notices must be addressed to:

               ALLERGAN, INC.
               2525 Dupont Drive
               Irvine, California  92612 U.S.A.
               Attention: General Counsel
               Telephone:
               Facsimile:

     11.8 Integration; Modification. This Agreement by and between the Parties
hereto, is both a final expression of the Parties' agreement and a complete and
exclusive statement with respect to all of its terms. The exhibits and schedules
referred to in this Agreement are incorporated herein and made a part of this
Agreement by this reference. This Agreement supersedes all prior and
contemporaneous agreements and communications, whether oral, written or
otherwise, concerning any and all matters contained herein; provided, however,
that the confidentiality provisions of Article 10 are in addition to and do not
supersede the terms and conditions of the Confidential Disclosure Agreement
between Allergan Inc. and GlaxoSmithKline Research & Development Limited, an
Affiliate of GSK, dated October 6, 2004, and any amendments thereto. No rights
or licenses are granted or deemed granted hereunder or in connection herewith,
other than those rights expressly granted in this Agreement. No trade customs,
courses of dealing, or courses of performance by the Parties will be relevant to
modify, supplement, or explain any term used in this Agreement. This Agreement
may only be modified, altered, amended, or supplemented in a writing expressly
stated for such purpose and signed by the Parties to this Agreement.

     11.9 No Waiver. The failure of a Party to exercise, enforce, or insist upon
strict performance of any provisions of this Agreement, or rights of or arising
out of this Agreement, will neither impair that provision or right nor
constitute a waiver of that provision or right, in whole or in part, and will
not be construed to be a waiver of such rights or provisions, or a waiver by
such Party to thereafter enforce such rights or provision or any other rights or
provisions hereunder. No waiver will be effective unless made in writing and
signed by the waiving Party.

     11.10 Severability. If, for any reason, any part of this Agreement is
adjudicated invalid, unenforceable, or illegal by a regulatory authority or
court of competent jurisdiction, such adjudication will not affect or impair, in
whole or in part, the validity, enforceability, or legality of any remaining
portions of this Agreement. All remaining portions will remain in full force and
effect as if the original Agreement had been executed without the invalidated,
unenforceable, or illegal part.

     11.11 Relationship Between the Parties. The Parties have no ownership
interest in the other and their relationship, as established by this Agreement,
is solely that of independent

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       50

<PAGE>

contractors. This Agreement does not create any partnership, joint venture, or
similar business relationship between the Parties. Neither Party is a legal
representative of the other Party, and neither Party can assume or create any
obligation, representation, warranty, or guarantee, express or implied, on
behalf of the other Party for any purpose whatsoever.

     11.12 No Third Party Beneficiaries. This Agreement is neither expressly nor
impliedly made for the benefit of any Person other than those executing it.

     11.13 Force Majeure. Without prejudice to any rights of GSK set out in the
Supply Agreement, each Party will be excused from liability for the failure or
delay in performance of any obligation under this Agreement by reason of any
event beyond such Party's reasonable control, which materially impacts the
performance of the relevant Party's obligations under this Agreement including
but not limited to acts of God, fire, flood, earthquake, or other natural
forces, war, terrorism, civil unrest, or any other event similar to those
enumerated above (a "Force Majeure Event"). Such excuse from liability will be
effective only to the extent and duration of the Force Majeure Event causing the
failure or delay in performance and provided that the Party has not caused such
Force Majeure Event to occur. Notice of a Party's failure or delay in
performance due to a Force Majeure Event must be given to the other Party within
*** after its occurrence. All performance timelines under this Agreement that
have been affected by a Force Majeure Event will be suspended for the duration
of such Force Majeure Event.

     11.14 Interpretation.

          11.14.1 Captions and Headings. The captions and headings of clauses
contained in this Agreement preceding the text of the articles, sections,
subsections, and paragraphs hereof are inserted solely for convenience and ease
of reference only and will not constitute any part of this Agreement, or have
any effect on its interpretation or construction.

          11.14.2 Singular and Plural. All references in this Agreement to the
singular will include the plural where applicable, and all references to gender
will include both genders and the neuter.

          11.14.3 Articles, Sections, and Subsections. Unless otherwise
specified, references in this Agreement to any article will include all
sections, subsections, and paragraphs in such article; references in this
Agreement to any section will include all subsections and paragraphs in such
sections; and references in this Agreement to any subsection will include all
paragraphs in such subsection.

          11.14.4 Days. All references to days in this Agreement will mean
calendar days, unless otherwise specified.

          11.14.5 The word "including" or any variation thereof means "including
without limitation" and the word "including" or any variation thereof will not
be construed to limit any general statement which it follows to the specific or
similar items or matters immediately following it.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       51

<PAGE>

          11.14.6 Ambiguities. Ambiguities and uncertainties in this Agreement,
if any, will not be interpreted against either Party, regardless of which Party
may be deemed to have authored the ambiguous provision or caused the ambiguity
or uncertainty to exist.

     11.15 Performance by Affiliates. The Parties recognize that each Party may
perform some or all of its obligations under this Agreement through Affiliates,
provided, however, that each Party will remain responsible for the performance
by its Affiliates and will cause its Affiliates to comply with the provisions of
this Agreement in connection with such performance. Each Party hereby expressly
waives any requirement that the other Party exhaust any right, power or remedy,
or proceed against an Affiliate, for any obligation or performance hereunder
prior to proceeding directly against such Party.

     11.16 JFTC Approval. Except as set forth below, each Party will use
Commercially Reasonable Efforts to obtain JFTC clearance for this Agreement. GSK
and/or its Affiliate in the Territory will file all necessary documents with the
JFTC in accordance with Article 16 of the Anti-Monopoly Law of Japan, including,
without limitation, those documents set forth in this Section 11.16 which are
received from ALLERGAN or its Affiliate. ALLERGAN will, and will cause its
Affiliates to, co-operate with GSK or its Affiliate in the Territory in
complying with all filing requirements and any request received by the JFTC
pursuant to Article 16 of the Anti-Monopoly Law of Japan, including, without
limitation, by promptly after the Execution Date, providing the following
documents to GSK or its Affiliate in the Territory, and any other documents
reasonably requested by GSK or its Affiliate in the Territory:

          11.16.1 JFTC Form 12, appropriately completed by ALLERGAN'S Affiliate
in the Territory, or accompanied with the appropriate materials to enable GSK to
complete such form;

          11.16.2 The most recent Articles of Association for ALLERGAN'S
Affiliate in the Territory, which have been duly certified to be an original
copy by such Affiliate's representative director;

          11.16.3 The most recent financial statements, including, business
report, profit and loss statement and balance sheet for ALLERGAN'S Affiliate in
the Territory;

          11.16.4 Minutes of the shareholder's meeting and board of directors
meeting approving the execution of this Agreement; and

          11.16.5 A executed copy of the Distribution Agreement by ALLERGAN'S
Affiliate in the Territory.

Neither Party will take any action inconsistent with this Agreement (or its
effect if clearance is obtained) while the Parties are seeking JFTC clearance
for this Agreement. The Parties agree that all necessary documents to be filed
with the JFTC in accordance with Article 16 of the Anti-Monopoly Law of Japan
will be filed within five (5) business days after the Effective Date; provided,
however, that such documents will have been reviewed and the content thereof
agreed

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       52

<PAGE>

upon by each of the Parties prior to such filing. The Parties will use best
efforts to resolve any concerns that may be raised by the JFTC regarding
clearance. For the purposes of this Agreement, "best efforts" means as to GSK,
efforts and resources that would normally be used by an Affiliate of GSK in the
Territory, in the exercise of its reasonable business and legal discretion, to
obtain Regulatory Approval of such Affiliate's in-license of co-exclusive rights
to develop and commercialize a product which is of similar market potential in
the Territory as Product. For the purposes of this Agreement, "best efforts"
means as to ALLERGAN, efforts and resources normally used by ALLERGAN, in the
exercise of its reasonable business and legal discretion, to obtain Regulatory
Approval to out-license co-exclusive rights to develop and commercialize a
product which is of similar market potential as Product. In the event that JFTC
clearance is not possible, or has not been obtained within twelve (12) months
after the Effective Date, GSK at its option will have a right to continue as
ALLERGAN's distributor of Product under the terms and conditions of the
Distribution Agreement or immediately terminate this Agreement, unless otherwise
agreed in writing by the Parties.

     11.17 Counterparts. This Agreement may be executed in one or more
counterparts (which may be delivered via facsimile), each of which will be
deemed an original document, and all of which, together with this writing, will
be deemed one instrument.

     IN WITNESS WHEREOF, ALLERGAN and GSK have executed this Botox(R) Japan
License Agreement by their respective duly authorized representatives.

ALLERGAN, INC.                         GLAXO GROUP LIMITED

By: /s/ DAVID PYOTT                    By: /s/ LORRAINE DAY
    ---------------------------------      ------------------------------------
Name: David Pyott                      Name: Lorraine Day
      -------------------------------        ----------------------------------
                                             For and on behalf of
                                             Edinburgh Pharmaceutical Industries
                                             Limited

Title: Chairman and Chief Executive    Title: Corporate Director
       Officer                                ---------------------------------
       ------------------------------

ALLERGAN SALES, LLC

By: /s/ JEFFREY L. EDWARDS
    ---------------------------------
Name: Jeffrey L. Edwards
      -------------------------------
Title: Vice President and
       Chief Financial Officer
       ------------------------------

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       53

<PAGE>

                                    Exhibit A

                ALLERGAN Patent Rights Not Subject to the Option

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       54

<PAGE>

                                   Exhibit A-1

                  ALLERGAN Patent Rights Subject to the Option

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       55

<PAGE>

                                    Exhibit B

                           ALLERGAN Product Trademarks

<TABLE>
<CAPTION>
ID    MARK   CLASSES   REG. OWNER   APP. #   APP. DT   REG. #   REG. DT   STATUS
---   ----   -------   ----------   ------   -------   ------   -------   ------
<S>   <C>    <C>       <C>          <C>      <C>       <C>      <C>       <C>
***    ***     ***         ***        ***      ***       ***      ***       ***
</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       56

<PAGE>

                                    Exhibit C

                          ALLERGAN Corporate Trademarks

<TABLE>
<CAPTION>
ID    MARK   CLASSES   REG. OWNER   APP. #   APP. DT   REG. #   REG. DT   STATUS
---   ----   -------   ----------   ------   -------   ------   -------   ------
<S>   <C>    <C>       <C>          <C>      <C>       <C>      <C>       <C>
***    ***     ***         ***        ***      ***       ***      ***       ***
</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       57

<PAGE>

                                   Exhibit D

                      Principles and Terms for Co-Promotion

-    ALLERGAN will ensure that sales personnel are adequately trained in
     accordance with GSK policies and have the background, experience, and skill
     sets customarily expected to promote the Product in the Field in the
     Territory.

-    Such sales force deployment will conform to the commercial Product
     strategy, deployment plan, marketing objectives, and promotional guidelines
     designed and implemented by GSK from time to time during the Co-Promotion
     Term in the Territory and reviewed by the TJCC.

-    GSK will be solely responsible for pricing, distributing and booking sales
     of Product during the Co-Promotion Term.

-    Allergan will provide periodic (not less than once per Calendar Quarter)
     reports of its detailing efforts, as directed by the TJCC, which reports
     will include, without limitation, the number of details performed.

-    ALLERGAN will arrange for such number of details, which details will be in
     the secondary position as defined by the TJCC, to be provided for Product
     in each Calendar Year during the Co-Promotion Term, pro rated as necessary,
     as determined by the TJCC. A "detail" means a face-to-face meeting, in an
     individual or group practice setting, between one (1) or more physicians
     identified by the TJCC, during which a complete Product presentation is
     communicated (a) describing in a fair and balanced manner, the
     MHLW-approved indicated uses, and other relevant characteristics, of the
     Product, and (b) using the TJCC approved promotional materials in an effort
     to increase the prescribing preferences of the Product for its
     MHLW-approved indicated uses.

-    GSK will be entitled to periodically (not less than once per Calendar Year
     during the Co-Promotion Term) to audit ALLERGAN's records relating to its
     detailing efforts relating to Product in the Territory.

-    GSK will deliver promotional materials to ALLERGAN during the Co-Promotion
     Term. ALLERGAN will be responsible for all costs and expenses in
     distributing such promotional materials to its sales force.

-    ALLERGAN will be responsible for all costs and expenses incurred in its
     co-promotion of Product in the Territory, including, without limitation,
     sales force costs (salaries, bonuses, training costs) and all costs
     incurred in promotion activities provided during the Co-Promotion Term.

-    Final approval authority and ultimate decisions responsibility related to
     all aspects of commercialization and promotion of Product in the Field of
     Use in the Territory will be determined by a majority vote of the TJCC.

-    Final approval authority and ultimate decisions responsibility related to
     all aspects of sales deployment and sales execution of ALLERGAN sales
     representatives will be determined by

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       58

<PAGE>

ALLERGAN provided that any such decisions will be made by ALLERGAN in a manner
consistent with any marketing plan and policies approved by the TJCC.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       59

<PAGE>

                                    Exhibit E

Summary Description and Activities for Product Improvements and Enhancements and
              Research and Pre-Clinical Support of New Indications

A.   GENERAL SCOPE. On-going and planned ALLERGAN efforts in development and
     modification of *** used in the formulation of Product.

                                       ***

     B. SPECIFIC ACTIVITIES.

     I. ***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       60

<PAGE>

                                    Exhibit F

                  Product Improvement and Enhancement Payments

Product Improvement and Enhancement Payments (in U.S. dollars):

<TABLE>
<CAPTION>
YEAR         '05   '06   '07   '08   '09
----------   ---   ---   ---   ---   ---
<S>          <C>   <C>   <C>   <C>   <C>
Annual
Payment to
ALLERGAN     ***   ***   ***   ***   ***
</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       61

<PAGE>

                                    Exhibit G

                          Distribution Agreement Terms

     1. The term of the Distribution Agreement will commence on a date that is
no later than fourteen (14) calendar days after the Effective Date (referred to
in the Agreement as the "GSK Distribution Commencement Date") and terminate on
the date on which the Regulatory Authorities approve GSK as the MAH for Product
in the Territory.

     2. During the term of the Distribution Agreement, ALLERGAN or its Affiliate
in the Territory will appoint GSK or its Affiliate to co-exclusively distribute
and promote Product in the Territory. In this regard, neither ALLERGAN nor its
Affiliates, agents or distributors will promote, sell, distribute, import or use
Product in the Territory during the term of the Distribution Agreement, except
as otherwise agreed by GSK in writing.

     3. ALLERGAN Responsibilities under the Distribution Agreement during the
Distribution Agreement Term:

          (a) ALLERGAN will remain the MAH for Product in the Territory and will
retain all legal responsibility for Product in the Territory, including, without
limitation as provided in Exhibit H, legal responsibility for conducting post
marketing surveillance for Product, pharmacovigilance activities, product
testing and release and quality assurance activities.

     4. GSK Responsibilities under the Distribution Agreement during the term of
the Distribution Agreement.

          (a) Upon the effective date of the Distribution Agreement, GSK or its
Affiliate will commence the distribution of Product in the Field of Use in the
Territory;

          (b) Within a reasonable period of time after the Closing Date, GSK
will hire such number of employees as may be necessary to, on behalf of
ALLERGAN, promote Product in the Territory.

          (c) GSK will book all sales of Product during the term of the
Distribution Agreement, and the Parties acknowledge and agree that GSK will not
owe any royalties or payments of any other kind to ALLERGAN on Net Sales of
Stock Product during the term of the Distribution Agreement.

          (d) Upon the effective date of the Distribution Agreement, GSK or its
Affiliate will be responsible for direct, non-personnel (of ALLERGAN) costs and
expenses, and any indirect costs and expenses incurred in connection with
promotion and marketing of the Product in the Territory, including, for example,
travel and other costs related to such activities. Allergan will not conduct any
promotional and/or marketing activities in the Territory relating to

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       62

<PAGE>

Product without obtaining the prior written agreement from GSK. For clarity,
neither GSK nor any of its Affiliates will be responsible in any way for any
salaries, pensions, benefits or compensation of any other kind whatsoever
payable to agents and employees of ALLERGAN.

     5. Purchase of Product.

          (a) GSK will purchase from ALLERGAN *** Units of Product which are
labeled with the ALLERGAN Corporate Trademark (the "Stock Product"), as a
one-time sale, promptly after the effective date of the Distribution Agreement;
provided, that each such Unit of Stock Product, as of the date of purchase, will
have an expiration date not earlier than *** and will meet such other quality
criteria of GSK.

          (b) GSK will purchase such Stock Product from ALLERGAN at a transfer
price of *** per Unit of Stock Product.

          (c) Terms of payment by GSK to ALLERGAN for this one-time sale of
Stock Product will be thirty (30) calendar days from the date GSK first takes
physical possession of such Stock Product from ALLERGAN. ALLERGAN will ship not
less than *** Units of Stock Product within three (3) business days after the
effective date of the Distribution Agreement and the remaining Units of Stock
Product within four (4) weeks after the effective date of the Distribution
Agreement.

          (d) During the term of the Distribution Agreement, GSK and its
Affiliates will not be obligated to purchase any Product from the Manufacturer
under the Supply Agreement unless and until GSK or its Affiliate sells all Stock
Product purchased from ALLERGAN as provided in 5(a) and (b) herein. In the event
that ALLERGAN is required to sell additional stock of Product to GSK during the
period of the Distribution Agreement, such sales will be made at a price of ***
per vial. ***.

          (e) With respect to the inventory of Product with the wholesalers as
of the effective date of the Distribution Agreement, ALLERGAN and GSK will
negotiate in good faith on methods to liquidate such inventory with minimum
financial impact to both Parties, which agreed methodology will be included in
the Distribution Agreement.

     6. In the event of any conflict between the terms of the Distribution
Agreement and this Agreement, the terms of this Agreement will control.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       63

<PAGE>

                                    Exhibit H

                              Co-Development Terms

1.   During the Transition Period, ALLERGAN will

     -    Remain the MAH for Product in the Territory and retain all legal
          responsibility for Product in the Territory, including, without
          limitation, sponsorship of ongoing clinical studies (specifically
          study 909 for the use of Product for the Cosmetic Indication) legal
          responsibility for conducting post marketing surveillance for Product,
          pharmacovigilance activities, product testing, and release and quality
          assurance activities.

     -    At its sole cost and expense complete the study 909 for the use of
          Product for the Cosmetic Indication until the study database is
          locked, including, without limitation, maintaining all
          investigator/site agreements relating to the study 909.
          Notwithstanding anything to the contrary contained herein, if the
          Transition Period expires (i.e., GSK or its Affiliate becomes the MAH)
          prior to the study 909 database being locked, ALLERGAN will, at its
          sole cost and expense (including, without limitation, all costs and
          expenses related to salaries, payroll, pension benefits and other
          compensation payable to employees and agents of ALLERGAN working on
          the study 909), continue to be responsible for completing the study
          909 as provided herein, however, if any time GSK employees, including
          for example R&D and regulatory affairs personnel, assist in completing
          work on study 909, the cost and expense of such GSK employees will be
          borne by GSK. All costs and expenses incurred in connection with study
          909 after the study 909 database is locked will be borne by GSK. All
          costs and expenses incurred by ALLERGAN in connection with the study
          909 prior to the date on which the study 909 database is locked, even
          if such costs and expenses are accrued after the date on which the
          study 909 database is locked, will be borne by ALLERGAN.

     -    At its sole cost and expense, maintain all required facility leases
          including such leases for the facilities where its employees as
          provided in the paragraph above will be located, and such leases for
          space where certain Product release testing equipment is located.
          Further, GSK will be permitted to use such facilities during the
          Transition Period and thereafter if agreed to by the Parties, but in
          no event for a term extending after December 31, 2005, at no cost to
          GSK.

     -    Be responsible for facilitating all required communications with the
          MHLW relating to the development and commercialization of Product in
          the Territory and to the extent permitted under Applicable Law, will
          permit GSK or its Affiliate to participate in all such communications

     -    Retain such number of employees as may be required by Japanese law by
          a MAH for a prescription pharmaceutical product in the Territory.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       64

<PAGE>

2. Within a reasonable period of time after the Closing Date, GSK will hire such
number of employees as may be necessary to develop Product in the Territory, and
conduct post marketing surveillance activities, quality assurance activities,
release testing, and pharmacovigilance activities for Product in the Territory.
When hiring of such personnel is complete, GSK will become operationally
responsible for all development activities for Product in the Territory,
including completion and, to the extent permitted under Applicable Law,
submission of the applicable Regulatory Approval Application to commercialize
Product for the Cosmetic Indication in the Territory, even if the existing
Regulatory Approvals have not yet been transferred from ALLERGAN to GSK.

3. GSK will be solely responsible for all external costs and expenses relating
to post marketing surveillance agreements, which will be maintained by ALLERGAN
after the GSK Distribution Commencement Date and thereafter until (if so
requested by GSK) transferred to GSK. For clarity, ALLERGAN will continue to be
responsible for all costs and expenses related to salaries, payroll, pension
benefits and other compensation payable to employees and agents of ALLERGAN
associated with post marketing surveillance activities.

4. Notwithstanding that ALLERGAN will be responsible for facilitating all
required communications with the MHLW relating to the development and
commercialization of Product in the Territory during the term of the
Distribution Agreement, as provided above, GSK will be solely responsible for
all costs relating to Regulatory Approvals and Regulatory Approval Applications
for Product during the term of the Distribution Agreement.

5. When GSK becomes the MAH for the Product in the Territory, all commercial,
legal and regulatory responsibilities for the Product will transfer from
ALLERGAN to GSK; provided, however that ALLERGAN will maintain, at its sole cost
and expense, all current contracts with institutions participating in study 909
until the study database is locked (which ALLERGAN estimates to be December 13
2005).

6. Promptly after the locking of the database for study 909, ALLERGAN will, at
its sole cost and expense, transfer the study 909 database (electronic datasets)
to GSK or its Affiliate in the Territory along with all other study documents
and information required to allow GSK or its Affiliate in the Territory to
analyze the data, complete the clinical study report and, to the extent
permitted under Applicable Law, file the appropriate Regulatory Approval
Application to commercialize Product for the Cosmetic Indication in the
Territory.

7. GSK will be responsible for all reasonable and documented travel costs and
expenses incurred by ALLERGAN's employees in providing services to GSK as
provided herein during the Transition Period and will pay ALLERGAN for such
costs and expenses within thirty (30) calendar days after the date of an invoice
from ALLERGAN, but excluding, however, any expenses which are related to
participation in TJDC and TJCC meetings as provided in Article 5.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       65

<PAGE>

                                    Exhibit I

                           Pharmacovigilance Agreement

-    ALLERGAN will hold the global safety database for the Product.

-    ALLERGAN will be responsible for providing all relevant pharmacovigilance
     support for the Product to GSK's Affiliate in the Territory, including,
     without limitation, providing any non-domestic expedited or periodic
     reports necessary for local regulatory submission, signal detection and
     issue management.

-    GSK's Affiliate in the Territory will be responsible for collecting adverse
     event reports in the Territory and forwarding such reports to ALLERGAN.
     GSK's Affiliate in the Territory will also be responsible for submitting
     relevant reports to the appropriate Regulatory Authority.

-    GSK will not be obligated to maintain a central safety and
     pharmacovigilance department to provide support for, or involvement in,
     pharmacovigilance activities conducted pursuant to this Agreement or the
     Pharmacovigilance Agreement

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       66

<PAGE>

                                    Exhibit J

                             Product Integrity Plan

PRODUCT INTEGRITY PLAN OBJECTIVE:

Protect the safety of patients and maintain the loyalty of physician customers
by assuring that patients seeking treatment with Product continue to get
Product, appropriately handled for safe and effective treatment.

REQUIREMENTS FOR SUCCESSFUL IMPLEMENTATION:

          -    Each Party will designate a Person in the Territory as Product
               Integrity Manager in accordance with Section 5.8.

          -    All personnel promoting Product in the Territory are trained to
               recognize current approved packaging of Product in the Territory.

          -    Personnel promoting Product are trained to promptly report
               suspected counterfeit or imported product to the Product
               Integrity Manager.

          -    Examples (or photos) of counterfeit product packaging obtained by
               personnel of a Party should be sent to the Product Integrity
               Manager for such Party.

          -    The Party's Product Integrity Manager will file complaint the
               TJCC chairman and such Party's local team, in accordance with
               internal procedures, with evidence of suspected counterfeit or
               imported product.

          -    GSK will use Commercially Reasonable Efforts to send "cease and
               desist" warning letter to the suspected importer within *** after
               completing an internal investigation regarding the suspected
               importer.

          -    If the illegal activity is not discontinued within *** after the
               date of the cease and desist warning letter, GSK may report the
               importer to the appropriate Regulatory Authorities.

          -    ALLERGAN will determine origin of counterfeit product and request
               assistance from ALLERGAN'S Regional President to shut down supply
               of such counterfeit product.

          -    ALLERGAN will respond to GSK's Product Integrity Manager within
               30 days of result of regional efforts to limit supply of such
               counterfeit product.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       67

<PAGE>

                                    Exhibit K

                           Competing Business Entities

                                       ***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Act of 1934,
     as amended.

                                       68<PAGE>
                                                                   Exhibit 10.53

                             CO-PROMOTION AGREEMENT

                                 BY AND BETWEEN

              SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE

                                       AND

                                 ALLERGAN, INC.

                                       AND

                               ALLERGAN SALES LLC

                               SEPTEMBER 30, 2005

<PAGE>

                             CO-PROMOTION AGREEMENT

     This Co-Promotion Agreement (the "Co-Promotion Agreement" or this
"Agreement"), dated September 30, 2005 (the "Effective Date"), is made by and
between SmithKline Beecham Corporation d/b/a GlaxoSmithKline, a corporation
organized and existing under the laws of the Commonwealth of Pennsylvania and
having a place of business at One Franklin Plaza, Philadelphia, PA 19101
("GSK"), Allergan, Inc., a corporation organized and existing under the laws of
the State of Delaware and having a principal place of business at 2525 Dupont
Drive, Irvine, Ca 92612-1599 ("Allergan, Inc.") and Allergan Sales LLC, a
limited liability company organized and existing under the laws of the state of
Delaware and having a principal place of business at 2525 Dupont Drive, Irvine,
Ca 92612-1599 ("Allergan LLC"), ("Allergan LLC" and, together with Allergan,
Inc., "Allergan").

                                    RECITALS

     WHEREAS, GSK owns or controls all rights to the Product (as defined below)
in the Territory (as defined below);

     WHEREAS, GSK and Allergan each have an internal sales and marketing
organization to promote certain products to physicians and other health care
professionals; and

     WHEREAS, GSK desires to engage Allergan to co-promote and detail the
Product to selected physicians and other health care professionals within the
Territory upon the terms and conditions contained herein.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein
and other good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Parties hereto agree as follows:

                                    ARTICLE 1

                                   DEFINITIONS

     As used in this Agreement, the following capitalized terms have the
following meanings:

     1.1 "ADDITIONAL NEURO PRODUCT" means the Imitrex(R) (sumatriptan succinate)
STATdose System(R), which has been approved by the FDA for the treatment of
migraine and cluster headaches, and which is sold by GSK or its Affiliates in
the Territory, or such other branded, non-generic prescription pharmaceutical
products as determined by GSK in its sole discretion which are sold by GSK or
its Affiliates under the Imitrex(R) trademark in the Territory.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       1

<PAGE>

     1.2 "ADDITIONAL NEURO PRODUCT BASELINE" means the ***, which is calculated
using the methodology set forth in EXHIBIT A of this Agreement ***.

     1.3 "ADDITIONAL NEURO PRODUCT FAILURE" will have the meaning set forth in
SECTION 7.1.3(B) (ADDITIONAL NEURO PRODUCT FAILURE).

     1.4 "ADDITIONAL NEURO PRODUCT NET SALES" means Net Sales of Additional
Neuro Product achieved from prescriptions from the Neurologist Segment and those
primary care physicians who comprise the Additional Neuro Product Target
Audience and calculated using the Allocation Factors listed in EXHIBIT A to this
Agreement.

     1.5 "ADDITIONAL NEURO PRODUCT TARGET AUDIENCE" means as to the Additional
Neuro Product (i) certain of those physicians in the Neurologist Segment and
(ii) primary care physicians, both of whom meet the profile of target physicians
established by the JCC and set forth in the Marketing Plan, which Target
Audience may be modified *** by the JCC. As of sixty (60) days after the
Effective Date, the Parties will agree on fewer than *** primary care physicians
to comprise the Target Audience, in addition to certain of those physicians in
the Neurologist Segment.

     1.6 "AFFILIATE" of a Person means any individual, sole proprietorship,
firm, partnership, corporation, trust, joint venture or other entity, whether de
jure or de facto, which, directly or indirectly, controls, is controlled by or
is under common control with such Person. As used in this definition, "control"
means the possession, directly or indirectly, of the power to direct or cause
the direction of the policies and management of a person or entity, whether by
the ownership of stock, by contract or otherwise.

     1.7 "AGREEMENT" will have the meaning set forth in the Preamble.

     1.8 "ALLERGAN" will have the meaning set forth in the Preamble.

     1.9 "ALLERGAN MINIMUM DETAILS COMMITMENT" has the meaning set forth in
SECTION 3.2.5(A) (ALLERGAN PRODUCT MINIMUM DETAIL COMMITMENTS).

     1.10 "ALLERGAN PSR" means a member of Allergan's sales force.

     1.11 "ALLIANCE MANAGER" as to either of GSK or Allergan, as the case may
be, means a full time employee of either GSK or Allergan, as the case may be,
having primary oversight responsibility for the implementation of that Party's
obligations under this Agreement.

     1.12 "ANTI-KICKBACK STATUTE" means the Medicare and Medicaid Anti-Kickback
Statute set forth at 42 U.S.C. Section 1320a-7b(b).

     1.13 "APPLICABLE COMMERCIAL PRACTICES POLICIES" means the portions as
identified by GSK of the Commercial Practices Policies of GSK applicable to the
marketing, sale, promotion and detailing of pharmaceutical products, as amended
or supplemented from time to time, a copy

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       2

<PAGE>

of which will be delivered to Allergan by GSK prior to or simultaneously with
the execution of this Agreement.

     1.14 "APPLICABLE LAW" means all applicable provisions of any and all
federal, national, state, provincial, and local statutes, laws, rules,
regulations, administrative codes, ordinances, decrees, orders, decisions,
injunctions, awards, judgments, permits and licenses of or from any governmental
authorities relating to or governing the use or regulation of the subject item
or action, including, without limitation, the Anti-Kickback Statute, the FD&C
Act, and HIPAA.

     1.15 "CALENDAR QUARTER" means each of the three (3) month periods ending
March 31, June 30, September 30 and December 31; provided, however, that the
first Calendar Quarter of the Term will extend from the Effective Date to the
end of the first complete Calendar Quarter thereafter.

     1.16 "COMMERCIALLY REASONABLE EFFORTS" means efforts and resources normally
used by a Party in the Territory relating to a prescription pharmaceutical
product owned by it or to which it has rights, which is of similar market
potential and at a similar stage in its development or product life, taking into
account issues of safety and efficacy, product profile, the competitiveness of
the marketplace, the proprietary position of the compound or product, the
regulatory structure involved, the profitability of the applicable products and
other relevant factors including, without limitation, technical, legal,
scientific and/or medical factors.

     1.17 "COMMITMENT YEAR" means, for the first Commitment Year, the period
beginning on the Effective Date and ending on December 31, 2006, and for each
Commitment Year thereafter, each successive period beginning on January 1 and
ending twelve (12) consecutive calendar months later on December 31; provided,
however, that the last Commitment Year may be for a term of less than twelve
(12) months until the end of the Commitment Term.

     1.18 "COMMITMENT TERM" will have the meaning set forth in SECTION 3.2.5(C)
(COMMITMENT TERM).

     1.19 "CONFIDENTIAL INFORMATION" will have the meaning set forth in SECTION
9.2 ("CONFIDENTIAL INFORMATION").

     1.20 "CO-PROMOTION AGREEMENT" will have the meaning set forth in the
Preamble.

     1.21 "CO-PROMOTION COMMENCEMENT DATE" means the date on which Allergan
commences the Promotion and Detailing of Product in the Territory in accordance
with the Marketing Plan and the terms and conditions of this Agreement, which
Co-Promotion Commencement Date will not be more than *** after the Effective
Date.

     1.22 "DETAIL" means a face-to-face meeting, in an individual or group
practice setting, between one (1) or more physicians in the Primary Product
Target Audience or Additional Neuro Product Target Audience, as the case may be,
and one GSK PSR or Allergan PSR, as the case

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                        3

<PAGE>

may be, during which a complete Product presentation is communicated (a)
describing in a fair and balanced manner, the FDA-approved indicated uses, and
other relevant characteristics, of the Product, and (b) using the Product
Promotional Materials in an effort to increase the prescribing preferences of
the Product for its FDA-approved indicated uses. When used as a verb, "Detail"
means to engage in a Detail.

     1.23 "DIRECT DETAILING EXPENSES" means the following costs and expenses
associated with a Party's PSRs, District Managers and Sales Management Team: all
costs and expenses of salary, benefits and employment taxes (including but not
limited to base salary and incentive compensation); all costs and expenses of
recruiting and hiring; all costs and expenses of automobiles, equipment and
supplies; and all travel costs and expenses. Direct Detailing Expenses do not
include the costs and expenses associated with marketing, Promotion, sales and
Product Promotional Materials, and Samples.

     1.24 "DISTRICT MANAGER" means a full time employee of either GSK or
Allergan, as the case may be, who is responsible for supervising the respective
Party's PSRs.

     1.25 "EFFECTIVE DATE" will have the meaning set forth in the Preamble.

     1.26 "FDA" means the United States Food and Drug Administration and any
successor agency thereto.

     1.27 "FD&C ACT" means the Food, Drug, and Cosmetic Act as amended, and the
regulations promulgated thereunder from time to time.

     1.28 "GSK" will have the meaning set forth in the Preamble.

     1.29 "HIPAA" means the Healthcare Insurance Portability & Accountability
Act of 1996 as amended, and the regulations promulgated thereunder from time to
time.

     1.30 "JCC" has the meaning set forth in SECTION 2.1 (JOINT
COMMERCIALIZATION COMMITTEE).

     1.31 "GSK PROMOTIONAL REVIEW COMMITTEE" has the meaning set forth in
SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS).

     1.32 "GSK PSR" means a member of GSK's sales force.

     1.33 "MARKET" means, when used as a verb, to market, sell, distribute,
Promote or advertise a product.

     1.34 "MARKETING PLAN(S)" means one (1) or more plans detailing the
activities to be performed by each Party in the Territory during the Commitment
Term, as more fully detailed in ARTICLE 2 (GOVERNANCE AND MARKETING PLAN) of
this Agreement.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       4

<PAGE>

     1.35 "NET SALES" means, with respect to a given period of time, gross sales
of Primary Product and/or Additional Neuro Product by GSK, its Affiliates, and
sublicensees in the Territory in such period, as the case may be, less the
following deductions from such gross amounts which are actually incurred,
allowed, paid, accrued or specifically allocated:

          (A) credits or allowances actually granted for damaged Product,
returns or rejections of Product, price adjustments and billing errors;

          (B) governmental and other rebates (or equivalents thereof) granted to
managed health care organizations, health management organizations, pharmacy
benefit managers (or equivalents thereof), federal, state/provincial, local and
other governments, their agencies and purchasers and reimbursers or to trade
customers;

          (C) normal and customary trade, cash and quantity discounts,
allowances and credits actually allowed or paid;

          (D) commissions allowed or paid to Third Party distributors, brokers
or agents other than sales personnel, sales representatives and sales agents
employed by GSK;

          (E) transportation costs, including insurance, for outbound freight
related to delivery of the Product to the extent included in the gross amount
invoiced;

          (F) sales taxes, value added taxes (VAT), and other taxes directly
linked to the sales of Product to the extent included in the gross amount
invoiced;

          (G) the actual amount of any write offs for bad debt directly relating
to sales of Product in such period; and

          (H) any other items actually deducted from gross sales amounts as
reported by GSK in its financial statements in accordance with the International
Financial Reporting Standards ("IFRS"), applied on a consistent basis.

Sales between or among GSK and its Affiliates or sublicensees will be excluded
from the computation of Net Sales, but the subsequent final sales to Third
Parties by such Affiliates or sublicensees will be included in the computation
of Net Sales.

GSK shall apply the Allocation Factors listed in EXHIBIT A to this Agreement to
arrive at Net Sales to the Neurologist Segment and to identified Primary Care
Physicians.

     1.36 "NEUROLOGIST SEGMENT" means physicians who are neurologists or have
specialty training in neurology in the Territory.

     1.37 "PARTY" means either of GSK or Allergan and "Parties" means both of
them.

     1.38 "PDMA" means the Prescription Drug Marketing Act of 1987 as amended,
and the regulations promulgated thereunder from time to time.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                        5

<PAGE>

     1.39 "PRIMARY PRODUCT PERFORMANCE PAYMENT" has the meaning set forth in
SECTION 7.1.1(B) (PRIMARY PRODUCT PERFORMANCE PAYMENT).

     1.40 "PERSON" means an individual, a corporation, a partnership, an
association, a trust or other entity or organization, including a government or
political subdivision or an agency or instrumentality thereof.

     1.41 "PERSONNEL" has the meaning set forth in SECTION 3.2.12(A) (STATUS OF
ALLERGAN AND ITS PERSONNEL).

     1.42 "PHRMA CODE" means the PhRMA Code on Interactions with Health Care
Professionals, as amended from time to time.

     1.43 "PRIMARY DETAIL" means a Detail in which the Product information that
is communicated by a GSK PSR or Allergan PSR, as the case may be, to a
physician(s) in the Primary Product Target Audience or Additional Neuro Product
Target Audience, as the case may be, is the first product information
communicated by such GSK PSR or Allergan PSR.

     1.44 "PRIMARY PRODUCT" means Amerge(R) or any prescription branded
non-generic prescription pharmaceutical product containing naratriptan
hydrochloride as the sole therapeutically active ingredient, in any dosage form
for human prescription use and for all indications, which is sold by GSK or its
Affiliates in the Territory.

     1.45 "PRIMARY PRODUCT BASELINE" means the ***, which is calculated using
the methodology set forth in EXHIBIT A of this Agreement ***.

     1.46 "PRIMARY PRODUCT FAILURE" will have the meaning set forth in SECTION
7.1.3(A)(I).

     1.47 "PRIMARY PRODUCT NET SALES" means Net Sales of Primary Product
achieved from prescriptions from the Neurologist Segment and those primary care
physicians who comprise the Primary Product Target Audience and calculated using
the Allocation Factors listed in EXHIBIT A to this Agreement.

     1.48 "PRIMARY PRODUCT TARGET AUDIENCE" means as to the Primary Product (i)
certain of those physicians in the Neurologist Segment and (ii) primary care
physicians, both of whom meet the profile of target physicians established by
the JCC and set forth in the Marketing Plan, which Primary Product Target
Audience may be modified *** by the JCC. As of sixty (60) days after the
Effective Date, the Parties will agree on fewer than *** primary care physicians
to comprise the Primary Product Target Audience, in addition to certain of those
physicians in the Neurologist Segment.

     1.49 "PRODUCT" when used alone means either or both the Primary Product and
the Additional Neuro Product.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                        6

<PAGE>

     1.50 "PRODUCT PROMOTIONAL GUIDELINES" has the meaning set forth in SECTION
2.5.2 (PLAN CONTENTS AS TO THE PRIMARY PRODUCT).

     1.51 "PRODUCT PROMOTIONAL MATERIALS" has the meaning set forth in SECTION
3.3.1 (PRODUCT PROMOTIONAL MATERIALS).

     1.52 "PROMOTION" means those activities, including, without limitation,
detailing and distributing samples of a product, normally undertaken by a
pharmaceutical company's sales force to implement marketing plans and strategies
aimed at encouraging the purchase and appropriate use of a particular
prescription pharmaceutical product. When used as a verb, "Promote" means to
engage in such activities.

     1.53 "PROMOTIONAL EXPENSES" means all costs and expenses of Allergan
allocated to the Primary Product, less all of Allergan Direct Detailing
Expenses.

     1.54 "PSR" means Professional Sales Representative, either a Allergan PSR
or a GSK PSR, and "PSRs" means both Allergan PSRs and GSK PSRs.

     1.55 "RESIDUAL TERM" has the meaning set forth in SECTION 12.1.3 (RESIDUAL
TERM).

     1.56 "RESIDUAL TERM ROYALTY" has the meaning set forth in SECTION 7.1.2
(RESIDUAL TERM PAYMENTS).

     1.57 "SALES CALL" means an interaction between a PSR and a physician or
other health care provider in which the Product is the subject of a Detail.

     1.58 "SALES CALL PLAN" means a plan established from time to time by the
JCC and set forth in the Marketing Plan that sets forth, at a minimum, the
profile of Primary Product Target Audience and Additional Neuro Product Target
Audience, and the Detailing reach (i.e., number of physicians) and frequency
(i.e., number of Details per physician and the relevant timing of such Details)
objectives for the PSRs in a manner that reflects the promotional effort for the
Primary Product or Additional Neuro Product, as the case may be, as outlined in
the Marketing Plan and this Agreement. The Sales Call Plan may be modified from
time to time by the JCC.

     1.59 "SALES MANAGEMENT TEAM" means one (1) or more regional directors or
Vice Presidents of GSK or Allergan, as the case may be, each of whom will be (a)
full time employees of GSK or Allergan, as the case may be, and (b) primarily
responsible for supervising a group of the District Managers within a geographic
region of the Territory.

     1.60 "SALES TERRITORY" means one of the geographic regions within the
Territory, as established from time to time by the JCC and set forth in the
Marketing Plan, in which one or more PSRs will be assigned by GSK and/or
Allergan, as the case may be, to Promote the Primary Product. The Sales
Territories may be modified from time to time by the JCC.

     1.61 "SAMPLES" means individual physician sample units of the Product, the
amounts of which are for the Primary Product and Additional Neuro Product.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       7

<PAGE>

     1.62 "SAMPLE RECEIPT FORMS" means those multi-part paper or electronic
forms used for the purpose of recording Detail and Sample request and receipt
activity performed by PSRs during Sales Calls. These forms are also used as
Sample receipts on which to obtain a physician's signature in acknowledgment of
the physician's receipt of a Sample. The Sample Receipt Forms will be in a form
agreed to by the JCC.

     1.63 "SECONDARY DETAIL" means a Detail in which Product information is
communicated by a GSK PSR or Allergan PSR, as the case may be, to a physician(s)
in the Primary Product Target Audience or the Additional Neuro Product Target
Audience, as the case may be, and is the second product information communicated
by such GSK PSR or Allergan PSR.

     1.64 "TECHNICAL AGREEMENT" has the meaning set forth in SECTION 5.4
(GENERAL; ADVERSE DRUG EXPERIENCES AND PRODUCT COMPLAINTS; PRODUCT AUDITS).

     1.65 "TERM" has the meaning set forth in SECTION 12.1 (TERM).

     1.66 "TERRITORY" means the fifty (50) states of the United States of
America and the District of Columbia.

     1.67 "THIRD PARTY" means any Person other than a Party or any Party's
respective Affiliates.

     1.68 "TRADEMARK" has the meaning set forth in SECTION 3.4.2 (TRADEMARKS).

     1.69 "TRAINING PROGRAM" has the meaning set forth in SECTION 3.3.3(A)
(SALES TRAINING).

     1.70 "WORKING GROUP" has the meaning set forth in SECTION 2.2 (WORKING
GROUPS).

                                    ARTICLE 2

                         GOVERNANCE AND MARKETING PLANS

     2.1 JOINT COMMERCIALIZATION COMMITTEE (JCC).

          2.1.1 STRUCTURE. The Parties will establish a Joint Commercialization
Committee (the "JCC") during the Commitment Term, which will be comprised of at
least three (3) members from each Party, each with appropriate decision-making
authority. In addition, the JCC may from time to time include additional
non-voting, ad-hoc representatives from either Party on specific issues as the
need arises. The chairperson of the JCC will be one of the members of the JCC
and chairmanship of the JCC will rotate every six (6) months between a GSK JCC
member and an Allergan JCC member, commencing with a GSK JCC member. The
chairperson of the JCC will distribute a draft agenda prior to, and meeting
minutes reasonably promptly following, each meeting of the JCC. The JCC will
meet periodically as agreed by the Parties, but in no event less than once
during each Calendar Quarter during the Commitment

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       8

<PAGE>

Term, in person not more than twice per year (with locations to alternate
between the Parties), or by video teleconference or teleconference as mutually
agreed, to discuss matters within its purview. Each Party will bear all expenses
it incurs in regard to participating in any JCC meetings, including all travel
and living expenses as provided in SECTION 6.2.2 (ALLERGAN DETAIL RELATED COSTS
AND EXPENSES) and SECTION 6.3.2 (GSK DETAIL RELATED COSTS AND EXPENSES). At
least one (1) representative from each Party must be present at any meeting of
the JCC to represent a quorum for voting purposes. The members of the JCC will
seek to make all determinations to be made by them unanimously following full
discussion thereof (with each Party having one (1) vote). If the JCC is unable
to reach a unanimous decision on any matter for which it has responsibility as
set forth in this Agreement within ten (10) days after such matter is first
presented to the JCC, then GSK will make the final decision on any such matters
or disputes relating to the content of the Marketing Plans, Product strategy,
marketing, distribution and trade channels for Product, and all other Promotion
and marketing related topics relating to Product, which decision of GSK will be
binding upon both Parties; provided, however, that Allergan will have final say
on any disputes relating to Allergan PSRs Promotion strategy, deployment,
incentive compensation, tactics, or other Promotion execution or sales execution
related topics that are specifically related to Allergan's PSRs, provided that
Allergan will use good faith efforts to resolve any such disputes in a manner
consistent with the Marketing Plan and Applicable Law.

          2.1.2 DUTIES. The JCC will have the overall responsibility to manage
and coordinate all Promotion activities relating to the Product in the Territory
during the Commitment Term, to approve the Marketing Plans submitted by the
Parties for each Commitment Year as provided in SECTION 2.5 (MARKETING PLAN)
below, and to settle any disputes between the Parties relating to the
preparation of any such Marketing Plans prior to their submission to the JCC for
review and approval. In addition, the JCC will coordinate the activities of the
Parties to implement and execute each such Marketing Plan, which activities will
include, without limitation with respect to the Primary Product, developing
advertising, marketing and promotional strategies for the Primary Product in the
Territory, developing and establishing all Product Promotional Guidelines, Sales
Call Plans, Sales Territories and Target Physician lists. The JCC will also be
responsible for overseeing all Working Groups (if any) of the JCC. For the
avoidance of doubt, unless provided otherwise by this Agreement, the JCC has no
authority to (i) modify any material term or condition of this Agreement or (ii)
create or provide for any financial obligation of either Party.

     2.2 WORKING GROUPS. From time to time during the Commitment Term, the JCC
may establish and delegate duties to other committees, sub-committees, or
directed teams (each, a "WORKING GROUP") on an "as needed" basis to oversee
particular projects or activities. Each such Working Group will be constituted
and will operate as the JCC determines; provided that each Working Group will
have equal representation from each Party except as otherwise mutually agreed by
the Parties. Working Groups may be established on an ad hoc basis as the JCC
will determine. Each Working Group and its activities will be subject to the
oversight, review and approval of, and will report to the JCC. In no event will
the authority of the Working Group exceed that specified for the JCC under this
ARTICLE 2 (GOVERNANCE AND MARKETING PLANS).

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       9

<PAGE>

     2.3 MANAGED CARE. Subject to SECTION 3.2.6 (MANAGED CARE AND
REIMBURSEMENT), the Parties agree, that periodically with respect to managed
care formularies for the Primary Product, they will discuss in good faith
potential establishment and active initiation of a managed care penetration
strategy for the Primary Product.

     2.4 ALLIANCE MANAGERS. Each Party will appoint and notify the other Party
of its respective Alliance Manager, including any changes in such designation
from time to time during the Commitment Term. Further, the Parties acknowledge
and agree that each Party may designate their respective Alliance Manager to be
a member of the JCC.

     2.5 MARKETING PLAN.

          2.5.1 MARKETING PLAN. The principal mechanism by which the Parties
will coordinate their respective Promotion activities for Product under this
Agreement will be through the Marketing Plans, each (with the exception of the
initial Marketing Plan as described below) to be prepared jointly by GSK and
Allergan, and each (including the initial Marketing Plan as described below) to
be reviewed and approved by the JCC and periodically updated as set forth
herein. No later than thirty (30) days after the Effective Date, GSK will submit
the initial Marketing Plan, which was prepared by GSK prior to the Effective
Date, to the JCC for review and approval. The initial Marketing Plan will cover
the first (1st) Commitment Year. GSK and Allergan will be jointly responsible
for preparing drafts of all Marketing Plans subsequent to the initial Marketing
Plan, which will be presented to the JCC for review and approval on an annual
basis, and each such Marketing Plan will cover a full Commitment Year,
commencing with the second Commitment Year which will commence January 2007.
Each draft annual Marketing Plan will be ready for presentation to the JCC not
later than sixty (60) days prior to the end of each Commitment Year, and will be
approved by the JCC not later than the end of each Commitment Year. If the
Parties can not agree on the content of any such Marketing Plan, then such
matter will be resolved by the JCC as provided in SECTION 2.1.1 (STRUCTURE)
prior to the commencement of the relevant Commitment Year.

          2.5.2 PLAN CONTENTS AS TO THE PRIMARY PRODUCT. Each Marketing Plan
will, at a minimum, include: a review of the triptan marketplace in the
Territory and more specific detail of the long acting triptans and the
positioning of the Primary Product in the Territory against Third Party long
acting triptan competition, provided, however, that GSK will not be obligated to
provide to Allergan, or include in the Marketing Plan, any strategic information
on GSK neurological products other than the Products; Marketing and Promotion
objectives/strategies for the Primary Product in the Territory for the relevant
Commitment Year; clinical and publication support plans and plans (if any) for
Phase IIIb/IV studies and investigator-sponsored studies; delineation of Sales
Force efforts for the Primary Product in the Territory for the relevant
Commitment Year, including a profile of the Primary Product Target Audience, a
Sales Call Plan, and a Samples plan; general delineation of Sales Territories;
budgets for Marketing and Promotion of the Primary Product in the Territory for
the relevant Commitment Year; a non-binding multi-Commitment Year projection of
plans and budgets for the Marketing and Promotion of, and forecasts for, the
Primary Product in the Territory; desired call frequency and reach; revenue and
expense forecasts for the Primary Product in the Territory for the relevant

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       10

<PAGE>

Commitment Year; and the overall level of anticipated resource commitments on
the part of each Party under this Agreement relating to the Primary Product in
the Territory for the relevant Commitment Year. The Marketing Plan will also
contain promotional guidelines for the Primary Product (the "PRODUCT PROMOTIONAL
GUIDELINES"), which will be updated from time to time as necessary or desirable
by the JCC as provided in SECTION 3.2.1 (MARKETING AND PROMOTION PLANNING,
STRATEGY AND CONTENT). Such Marketing Plan will be in a form generally
consistent with the outline attached hereto as EXHIBIT B.

          2.5.3 MARKETING PLAN CONTENTS AS TO ADDITIONAL NEURO PRODUCT. Each
Marketing Plan will also include such contents, as determined by the Parties and
agreed to by the JCC, which pertain to the Detailing and Promotion of the
Additional Neuro Product by the Parties in the Territory, which contents will
include a review of the triptan marketplace in neurology for both short-acting
and long-acting triptans, a Sales Call Plan, a budget for the Detailing and
Promotion of the Additional Neuro Product, sampling requirements promotional
guidelines for the Additional Neuro Product, the allocation of Details between
Primary Details and Secondary Details for the Additional Neuro Product, and the
Additional Neuro Product Target Audience. Allergan will have no marketing and
Promotion spend commitments for the Additional Neuro Product. The Marketing Plan
will also include an explanation of GSK's co-positioning of the Products
relative to GSK PSR detailing efforts within the triptan marketplace.

          2.5.4 MARKETING AND PROMOTION COSTS. GSK and Allergan will be
responsible for Marketing and Promotion costs and expenses incurred in
accordance with the Primary Product Marketing Plan in accordance with SECTION
6.1 (JOINT MARKETING AND PROMOTION COSTS AND EXPENSES), which costs will be part
of the budget in the Marketing Plan and approved by the JCC as provided in
SECTION 2.1.1 (STRUCTURE).

                                   ARTICLE 3

                PROMOTIONAL MATERIAL DELIVERABLES AND OBLIGATIONS

     3.1 PRIMARY PRODUCT CO-EXCLUSIVE CO-PROMOTION ARRANGEMENT; ADDITIONAL NEURO
PRODUCT NON-EXCLUSIVE CO-PROMOTION ARRANGEMENT; RESTRICTIVE COVENANT.

          (A) GSK hereby engages Allergan, on a co-exclusive basis (with GSK),
and Allergan agrees, to Promote and Detail the Primary Product to the Primary
Product Target Audience in the Territory, commencing on the Co-Promotion
Commencement Date continuing thereafter during the Commitment Term, in
accordance with the Marketing Plan as directed by the JCC and the terms and
conditions of this Agreement. Notwithstanding the previous sentence, (i) GSK may
enter into co-promotion arrangements with respect to the Primary Product at any
time during the Term with (a) its Affiliates; provided that it will notify
Allergan in writing of any such Affiliate arrangement, and (b) Third Parties
with respect to physicians other than those included in the Primary Product
Target Audience; and (ii) GSK will at all times during the Term have a right to
Market, Detail and Promote the Product (a) outside of the Primary Product Target
Audience wherever and to whomever it chooses or (b) within the Primary Product
Target Audience as determined in writing by the JCC. For purposes of
clarification, any such

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       11

<PAGE>

promotional efforts by GSK will not affect or alter GSK's Fixed Payment, Primary
Product Performance Payment or Additional Neuro Product Performance Payment
obligations under SECTION 7.1.1 (COMMITMENT TERM PAYMENTS).

          (B) GSK hereby engages Allergan, on a non-exclusive basis, and
Allergan agrees, to Promote and Detail the Additional Neuro Product to the
Additional Neuro Product Target Audience in the Territory, commencing on the
Co-Promotion Commencement Date and continuing thereafter during the Commitment
Term, in accordance with the Marketing Plan as directed by the JCC and the terms
and conditions of this Agreement. For clarity, the Parties acknowledge and agree
that, (i) GSK may enter into co-promotion arrangements with respect to the
Additional Neuro Product with (a) its Affiliates, and (b) Third Parties; and
(ii) GSK will at all times during the Term have a right to promote the
Additional Neuro Product wherever and to whomever it chooses.

          (C) Allergan will have no right to sublicense any of its rights under
this Agreement, including, without limitation, its rights under SECTIONS 3.1(A)
and (B) above, to any Affiliate or Third Party without the prior written consent
of GSK. Notwithstanding anything in this Agreement to the contrary, either Party
may contract or agree with one or more of its Affiliates to have such Affiliate
perform any of such Party's obligations herein. In no event, will such use of an
Affiliate be deemed to relieve a Party of its liabilities or obligations to the
other Party under this Agreement. Each Party expressly acknowledges and agrees
that it will remain fully and unconditionally obligated and responsible for the
full and complete performance of all of its obligations under the terms and
conditions of this Agreement whether or not such performance is carried out by
such Party or any of its Affiliates.

          (D) During the Term, Allergan will not, and will cause its Affiliates
not to, directly or indirectly detail, promote, market and/or sell any
prescription pharmaceutical product in the Territory in which at least one
active component of such product may be included in the Triptan class of drugs
(selective 5-HT1 (serotonin) receptor agonists) (a "Competing Product"), or
acquire directly or indirectly any rights or interest in or to a Competing
Product which is being detailed, promoted, marketed and/or sold in the
Territory.

     3.2 CO-PROMOTION OBLIGATIONS

          3.2.1 MARKETING AND PROMOTION PLANNING, STRATEGY AND CONTENT. During
the Commitment Term, the JCC will have exclusive responsibility with respect to
Promotion planning and strategy applicable to the Parties for the Product in the
Territory during the Commitment Term and the content of Product Promotional
Guidelines. The JCC will have final authority for the Product's Promotion
strategies and plans as to the Parties, identification of Primary Product Target
Audience and the Additional Neuro Product Target Audience, Sales Call Plans, and
the strategies and plans with respect to the Product Promotional Materials;
provided, however, that prior to first use, the form and content of any and all
Product Promotional Materials will be subject to the approval of GSK as provided
in SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS) below.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       12

<PAGE>

          3.2.2 CO-PROMOTION. As of the Effective Date and thereafter during the
Commitment Term, Allergan will, at its sole expense and pursuant to SECTION
6.2.1 (ALLERGAN CO-PROMOTION COSTS AND EXPENSES) use Commercially Reasonable
Efforts to Promote the Product in the Territory in accordance with Promotion
strategies determined by the JCC under SECTION 3.2.1 (MARKETING AND PROMOTION
PLANNING; STRATEGY AND CONTENT) and set forth in the then-current JCC-approved
Marketing Plan, and the terms and conditions of this Agreement. During the
Commitment Term, neither Party will engage in any activities with respect to the
Product in the Territory that are outside of or inconsistent with the
then-current JCC-approved Marketing Plan for the Product, except with prior
express written approval of the JCC.

          3.2.3 PROFESSIONAL SALES REPRESENTATIVES (PSRS).

               (A) GENERALLY. In connection therewith, as of the Effective Date
and thereafter during the Commitment Term, Allergan will maintain, in the
Territory, a well-trained sales force consisting of full-time PSRs to Promote
and Detail the Products using Product Promotional Materials generated and
approved as provided in SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS) below
prior to first use. Allergan will supervise its PSRs, District Managers and
Sales Management Team and be responsible for its remuneration, incentives and,
subject to SECTION 3.2.4 (SALES MANAGEMENT) below, and general sales training.
The Allergan PSRs, District Managers and Sales Management Team will remain
exclusively under the authority of Allergan.

               (B) MINIMUM PSR'S. Allergan will Promote and Detail the Product
in the Territory during the Commitment Term with such minimum number Allergan
PSRs actively Promoting and Detailing, or in a position to Promote and Detail,
Product as provided herein: (i) at least *** PSRs as of, and for *** after, the
Co-Promotion Commencement Date, and (ii) at least *** PSRs at all times during
the Commitment Term after *** the Co-Promotion Commencement Date.

          3.2.4 SALES MANAGEMENT. Each Party will be responsible for supervising
its PSRs. In connection therewith, as of the Effective Date and thereafter
during the Commitment Term, Allergan will provide a sufficient number of full
time employees to serve as District Managers. Allergan may, but will not be
obligated to, designate one (1) or more full time employees to serve as regional
directors having the responsibility for supervising a group of Allergan's
District Managers in a particular geographic region of the Territory. Allergan
will provide GSK with contact information for Allergan's District Managers and
regional directors (if any) and will update that information periodically or as
requested by GSK from time to time during the Commitment Term. For the avoidance
of doubt, each Party's regional directors and District Managers may communicate
directly with their counterparts of the other Party to support each Party's
obligations under this Agreement.

          3.2.5 DETAILS. After the Effective Date and thereafter during the
Commitment Term (defined below), Allergan will Detail and Promote the Product in
the Territory in accordance with the applicable JCC-approved Marketing Plan
under SECTION 2.5.1 (MARKETING PLAN) and JCC-approved strategies and tactics
under SECTION 3.2.1 (MARKETING AND PROMOTION

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       13

<PAGE>

PLANNING; STRATEGY AND CONTENT), including by satisfying the specific
commitments set forth in this SECTION 3.2.5.

               (A) ALLERGAN PRODUCT MINIMUM DETAIL COMMITMENTS. After the
Co-Promotion Commencement Date and thereafter during the Commitment Term,
Allergan, at its own expense pursuant to SECTION 6.2.2(A) (ALLERGAN DETAIL
RELATED COSTS AND EXPENSES), will be required to deliver the Details indicated
in the table below to this Agreement for the Product per Commitment Year to the
Primary Product Target Audience and the Additional Neuro Product Target
Audience, which Detail amounts will be prorated for any partial calendar year
comprising a Commitment Year ("ALLERGAN MINIMUM DETAILS COMMITMENT"). The
Allergan Minimum Details Commitment for the Primary Product will be comprised of
*** Primary Details in *** the Commitment Term and *** Primary Details in ***
the Commitment Term, with all remaining Details being at least Secondary
Details. Subject to the immediately preceding sentence, the JCC will determine
in good-faith the Primary/Secondary Detail Commitment split for the Primary
Product for Allergan for *** of the Commitment Term.

<TABLE>
<CAPTION>
                                                 ADDITIONAL
                  TOTAL MINIMUM # OF   PRIMARY      NEURO
COMMITMENT YEAR         DETAILS        PRODUCT     PRODUCT
---------------   ------------------   -------   ----------
<S>               <C>                  <C>       <C>
      ***                 ***            ***         ***
</TABLE>

The Parties may, not later than ninety (90) days prior to the commencement of
any Commitment Year, agree in writing to change the distribution of Allergan
Minimum Details Commitment amounts between the Primary Product and Additional
Neuro Product from that as set forth in the table above. In the event that the
Parties cannot agree as to any such change in the distribution of Allergan
Minimum Details Commitment amounts between the Primary Product and Additional
Neuro Product for a Commitment Year within such ninety (90) day period, the
Allergan Minimum Details Commitment amounts set forth in the table above for the
Primary Product and Additional Neuro Product will remain in place during such
Commitment Year.

               (B) SALES DEPLOYMENT COSTS. Each Party will be responsible for
its own costs and expenses for sales deployment and internal distribution of
Product Promotional Materials pursuant to and as further set forth in SECTION
6.2.2(B) (ALLERGAN DETAIL RELATED COSTS AND EXPENSES as to Allergan and SECTION
6.3.2(A) (GSK DETAIL RELATED COSTS AND EXPENSES) as to GSK.

               (C) COMMITMENT TERM. The Allergan Minimum Details Commitment will
commence as of the Co-Promotion Commencement Date and will terminate
automatically on the fifth (5th) year anniversary of the Co-Promotion
Commencement Date (the "COMMITMENT TERM"). The Commitment Term may be extended
under SECTION 12.1.2 (EXTENSION OF COMMITMENT TERM) in twelve (12) month
increments by the mutual written agreement of the Parties, on prior written
request to the JCC by either Allergan or GSK, provided, however, that Allergan
will have first met the Allergan Minimum Details Commitment

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       14

<PAGE>

in each year of the Commitment Term as set forth in SECTION 3.2.5(A) (ALLERGAN
PRODUCT MINIMUM DETAIL COMMITMENTS) above before the JCC can consider any such
request.

               (D) NO AGENCY. In no event will any PSR or any member of the
Sales Management Team for one Party at any time identify, either expressly or
through implication, themselves as a an employee or agent of the other Party.

          3.2.6 MANAGED CARE AND REIMBURSEMENT. During the Term, the managed
care strategy for Product in the Territory including, without limitation,
contracting with, and pricing for, managed care customers, will be defined and
approved exclusively by GSK. All costs and expenses arising from managed care,
Medicare/Medicaid execution, personnel, and other related costs associated with
Product in the Territory will be the sole responsibility and obligation of GSK
as set forth in SECTION 6.3.4(B) (OTHER GSK COSTS AND EXPENSES).

          3.2.7 DATA COLLECTION AND REPORTING SYSTEMS. As soon as practicable,
but in any event prior to the Co-Promotion Commencement Date, Allergan, at no
expense to GSK, will establish and, during the Term and the three (3)-year
period following the expiration or earlier termination of this Agreement,
maintain true and accurate data collection and reporting systems for both
Details performed and Samples distributed by Allergan's PSRs, District Managers
or any member of Allergan's Sales Management Team during the Commitment Term.

          3.2.8 SALES FORCE INCENTIVE PLAN. As soon as practicable, but in any
event prior to the Co-Promotion Commencement Date, Allergan will establish and,
throughout the Commitment Term, maintain, a sales force incentive plan for its
PSRs, District Managers and Sales Management Team responsible for the Promotion
of the Product in the Territory, which in each case will be consistent with the
incentive plan and promotional strategy determined by the JCC and set forth in
the Marketing Plan.

          3.2.9 QUARTERLY REPORTS. Starting as of the Co-Promotion Commencement
Date for Allergan, at the end of each Calendar Quarter during the Commitment
Term, Allergan will provide to the JCC a quarterly written report providing
information on the numbers of Details and Samples distributed by its PSRs,
District Managers and Sales Management Team. Starting as of the Co-Promotion
Commencement Date for GSK, at the end of each Calendar Quarter during the Term,
GSK will provide to the JCC information on Net Sales as provided in SECTION
7.2.1 (PAYMENT OF COMPENSATION PAYMENTS), as well as updates on managed care
contracting with respect to the Primary Product, GSK advertising, overall brand
strategy and tactics in the Territory relating to the Primary Product that is
directly relevant to the Primary Product Target Audience, and Primary Product
improvements and enhancements, if any. Promptly after the Effective Date, the
Parties will agree on mutually acceptable quarterly written report/statement
formats; provided that each Party may reasonably request in writing report
modifications and/or additional Product-related information from time to time to
satisfy accounting, regulatory or legal requirements, including, but not limited
to, the Sarbanes-Oxley Act of 2002, as amended and all United States Securities
an Exchange Commission (SEC) rules and regulations relating thereto. Each Party
will provide their respective quarterly

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       15

<PAGE>

reports/statements as referenced above within sixty (60) days after the end of
such applicable Calendar Quarter.

          3.2.10 EMPLOYMENT QUALIFICATIONS. At all times during the Commitment
Term, *** of all Allergan PSRs will have prior experience and training in
pharmaceutical or other medical product sales and *** of Allergan's District
Managers will have sales management experience in the pharmaceutical industry.
Each member of Allergan's Sales Management Team will have sales management
experience in the pharmaceutical industry. Each Allergan PSR, District Manager
and Sales Management Team member will possess a Bachelor of Science or Bachelor
of Arts degree from an accredited four (4) year college or university, will be
professional in manner and appearance, and will be recruited and hired in
accordance with all applicable Federal and state laws. At the time each Allergan
PSR is hired, and at all times subsequent thereto, each such Allergan PSR will
have any and all licenses, permits, and insurance or other coverage as may be
required to enable the Allergan PSR to Promote and Detail the Product as
contemplated under this Agreement. Allergan will hire only competent PSRs,
District Managers and Sales Management Team members. Before hiring any
individual in connection with this Agreement, Allergan will ensure that such
individuals have (i) at least two satisfactory references, provided such
individuals have given written Allergan permission to obtain such references,
(ii) passed a criminal background check conducted by Allergan, (iii) not been
debarred, nor be currently under investigation by the FDA for debarment action
or pursuant to the Generic Drug Enforcement Act, (iv) passed a drug screening
test administered by Allergan, and (v) successfully passed a driving record
screening conducted by Allergan. In addition, before hiring any individuals in
connection with this Agreement that have former experience as a GSK (or any of
its predecessor companies such as SmithKline Beecham or Glaxo Wellcome Inc.)
employee or contractor, Allergan will notify GSK of such individuals so that GSK
may confirm employment history.

          3.2.11 INELIGIBLE PERSONS. During the Commitment Term, Allergan will
use Commercially Reasonable Efforts to not hire or employ an Ineligible Person
as either an employee or contractor to Allergan to Promote Product as
contemplated under this Agreement. For the purposes of this SECTION 3.2.11
(INELIGIBLE PERSONS), the term "INELIGIBLE PERSON" means a Person who is
currently excluded, debarred, suspended or otherwise ineligible to participate
in the Federal health care programs or in Federal procurement or nonprocurement
programs, or has been convicted of a criminal offense that falls within the
ambit of 42 U.S.C. 1320a-7(a), but has not yet been excluded, debarred,
suspended or otherwise declared ineligible. To prevent the hiring or engaging of
Ineligible Persons, Allergan will screen all prospective employees and
contractors prior to engaging their services by (i) requiring such persons to
disclose to Allergan whether there are Ineligible Persons; and (ii)
appropriately querying the General Administrative Services Administration's List
of Parties Excluded from Federal Programs (currently available through the
Internet at http://oig.hhs.gov) (these lists of excluded persons hereinafter
referred to as the "Exclusion Lists"), and will review its list of employees and
contractors against the Exclusion Lists prior to January 1st of each Commitment
Year. Prior to the execution of this Agreement, and by January 1st of each
Commitment Year, Allergan will provide GSK with a written certification that
Allergan has performed its obligations relating to Ineligible Persons under this
SECTION 3.2.11 (INELIGIBLE PERSONS) in a format acceptable to GSK. In addition,

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       16

<PAGE>

Allergan represents and warrants to GSK that Allergan has policies and
procedures in effect that require, and that it will otherwise require, all
employees and contractors to immediately disclose to Allergan any debarment,
exclusion, suspension or other event that may make such employee or contractor
an Ineligible Person. Upon learning or acquiring knowledge of any facts and
circumstances which may lead to an employee or contractor of Allergan providing
services under this Agreement becoming an Ineligible Person, Allergan will
immediately disclose such facts to GSK. If Allergan has actual notice that one
of its employees or contractors providing services under this Agreement has
become or is likely to become an Ineligible Person, Allergan will remove such
Person from any responsibility associated with this Agreement and the Product
Promoted hereunder. If Allergan has actual notice that one of its employees or
contractors is charged with a criminal offense related to any Federal health
care program, or is proposed for exclusion, Allergan will take all appropriate
action to ensure that the responsibilities of such Person has not and will not
in the future adversely affect this Agreement and the Product Promoted
hereunder. Allergan will promptly provide to GSK all data requested by GSK for
purposes of complying with disclosure, reporting or compliance obligations under
Federal and state laws relating to reporting obligations for Ineligible Persons.

          3.2.12 STATUS OF ALLERGAN AND ITS PERSONNEL.

               (A) GSK is engaging Allergan hereunder, and Allergan will perform
its obligations hereunder, strictly as an "independent contractor." PSRs, Sales
Management Team and any other employee or agent that is involved in performing
Allergan's obligations under this Agreement (collectively, "PERSONNEL") will not
be, and will not be considered or deemed to be, employees of GSK for any
purpose. GSK will not have any responsibility for the hiring, termination,
compensation, benefits or other conditions of employment or engagement of the
Personnel of Allergan.

               (B) Personnel of Allergan are not eligible to participate in any
benefits programs offered by GSK to its employees, or in any pension plans,
profit sharing plans, insurance plans or any other employee benefits plans
offered from time to time by GSK to its employees. Allergan acknowledges and
agrees that GSK does not, and will not, maintain or procure any workers'
compensation or unemployment compensation insurance for or on behalf of
Allergan's Personnel. Allergan acknowledges and agrees that it will be solely
responsible for paying all salaries, wages, benefits and other compensation
which its Personnel may be entitled to receive in connection with the
performance of the services hereunder and that Allergan will be liable for all
taxes, excises, assessments and other charges levied by any governmental agency
on, or because of, the services to be provided by Allergan under the terms of
this Agreement.

          3.2.13 COMPLIANCE WITH LAWS AND REGULATIONS. In connection with the
Promotion and Detailing of the Product in the Territory and all other activities
under this Agreement, each Party will comply and will cause each of its
respective Personnel, including, without limitation, each PSR, to comply with
all applicable Federal and state laws and regulations in the Territory,
including but not limited to all Federal and State Medicare and Medicaid
anti-kickback statutes and regulations, PDMA and regulations thereunder, FD&C
Act and regulations thereunder, and HIPAA and regulations thereunder.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       17

<PAGE>

     3.3 RESPONSIBILITIES OF THE PARTIES.

          3.3.1 PRODUCT PROMOTIONAL MATERIALS. All advertising, promotional,
educational and communication materials used by either Party in the Marketing
and/or Promotion of the Product in the Territory pursuant to this Agreement, in
any format, including, without limitation, audio, visual, digital or computer
formats (collectively, the "PRODUCT PROMOTIONAL MATERIALS"), will be generated
by or on behalf of the JCC and subject to the review and approval by an internal
working committee at GSK responsible for reviewing and approving such Product
Promotional Materials (the "GSK PROMOTIONAL REVIEW COMMITTEE") prior to being
used by Allergan in the Territory. The JCC will submit any proposed Product
Promotional Materials to the GSK Promotional Review Committee at least thirty
(30) days prior to the next meeting of the GSK Promotional Review Committee for
review and approval, which submitted materials will be reviewed at such next GSK
Promotion Review Committee meeting. Notwithstanding the foregoing, the Parties
will immediately cease using any previously approved Product Promotional
Materials in connection with the Promotion of Product in the Territory upon the
request of GSK, which request may be made at any time during the Commitment Term
but must be reasonably explained to the JCC.

               GSK, at its sole expense pursuant to SECTION 6.3.2(B) (GSK DETAIL
RELATED COSTS AND EXPENSES), will be responsible for the production of all
Product Promotional Materials for the Product. All Product Promotional Materials
will comply with the Product Promotional Guidelines set forth in the
then-current Marketing Plan, and neither Allergan nor GSK will distribute or
permit any use of any materials within the above definition of Product
Promotional Materials that are not approved by the JCC and GSK Promotional
Review Committee as provided herein. Each Party will be responsible, at its own
expense, for distributing Product Promotional Materials to their respective
PSRs, District Managers and Sales Management Team, and for ensuring use only of
Product Promotional Materials approved as provided hereunder. Product
Promotional Materials will be used only for the purposes of this Agreement and
all unused quantities of such Product Promotional Materials or any Product
Promotional Materials which can no longer be used in the Promotion of Product
per the request of GSK as provided above, will in each case be properly returned
to GSK or destroyed by Allergan, as determined by GSK in its sole discretion,
upon expiration or earlier termination of this Agreement.

          3.3.2 CME AND GRANTS. GSK will have sole responsibility, in its sole
discretion, for conducting or arranging for the conducting of any continuing
medical education (CME) and/or grant programs relating in any way to Product
during the Term. GSK will advise Allergan through the JCC of any CME and/or
grant programs relating to Product during the Commitment Term. Notwithstanding
the foregoing, GSK will in no way have any obligation to conduct or arrange for
the conducting of any CME and/or grant programs relating in any way to Product
during the Term. For the avoidance of doubt, Allergan will not conduct or
arrange for the conducting of any CME and/or grant programs relating in any way
to Product during the Term.

          3.3.3 SALES TRAINING.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       18

<PAGE>

               (A) GSK will be responsible for planning and conducting all
training for the Allergan PSRs, District Managers and Allergan's Sales
Management Team relating to the Product and the Promotion thereof approved by
the JCC (the "TRAINING PROGRAM"). Such Training Program will be comparable to
and no more burdensome to Allergan PSRs than training that GSK provides to its
own PSRs. As soon as practicable, but in any event prior to the Co-Promotion
Commencement Date one hundred twenty (120) days of the Effective Date, Allergan
will organize and conduct the first Training Program (referred to herein as the
"initial Training Program") at a time, date and location mutually agreed to by
the Parties, using GSK trainers to educate the Allergan PSRs, District Managers
and Allergan's Sales Management Team on the Product and the Promotion thereof,
the Applicable Commercial Practices Policies and such other sales training as
GSK or Allergan reasonably deems necessary and appropriate. GSK will provide the
training materials and will provide Allergan with an up-to-date programmed
learning system for the Product to be sent to each of Allergan's PSRs, District
Managers and Sales Management Team members for the "Homestudy Program" prior to
the commencement of the Training Program. Upon completion of the Training
Program, Allergan PSR, District Manager and Sales Management Team member will,
at GSK's sole discretion, be required to sign a certificate(s) acknowledging
their participation in the Training Program, and certifying and acknowledging
their understanding of the foregoing policies and statutes and the specified
acts prohibited thereunder.

               (B) Allergan will cause all of the Allergan PSRs, District
Managers and each member of Allergan's Sales Management Team to attend and
successfully complete a GSK Training Program prior to Promoting the Product as
contemplated in this Agreement, and to successfully complete GSK's programmed
learning system for the Product prior to the commencement of the Training
Program. After the initial Training Program, GSK will periodically conduct
additional Training Programs for newly hired Allergan PSRs, Allergan District
Managers and Allergan Sales Management Team members during the Commitment Term.
GSK will be responsible for all costs and expenses associated with the Training
Program pursuant to and as further set forth in SECTION 6.3.2(D) (GSK DETAIL
RELATED COSTS AND EXPENSES), and Allergan will be responsible for all costs and
expenses associated with the training activities pursuant to and as further set
forth in SECTION 6.2.2(D) (ALLERGAN DETAIL RELATED COSTS AND EXPENSES).

               (C) In order for any Allergan's PSRs, District Managers or Sales
Management Team members to Promote the Product in the Territory as contemplated
herein, such PSRs, District Managers and Sales Management Team members must
demonstrate thorough knowledge of the Product and the laws, rules, guidelines
and policies applicable to the Promotion of the Product by passing GSK's product
certifications. Such product certifications will be administered to each PSR,
District Manager and Sales Management Team member during the Training Program
and the scores of such certifications will be verified to the satisfaction of
GSK. GSK reserves, and will at all times have, the right to review any and all
product certifications taken by Allergan's PSRs, District Managers and Sales
Management Team members. Any Allergan PSR, District Manager or Sales Management
Team member failing to pass GSK's Homestudy Program product certifications with
at least an eighty percent (80%) score (or the same standards as GSK's internal
requirements for newly hired GSK PSRs, District

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       19

<PAGE>

Managers and Sales Management Team members) on each such certification may be
removed from Detailing the Product by Allergan.

          3.3.4 PROMOTIONAL CLAIMS. Allergan and GSK each agree to limit the
claims of efficacy and safety for the Product made by the Parties' respective
PSRs and Sales Management Teams to those that are consistent with FDA-approved
labeling for the Product in the Territory. Neither Party will add, delete or
modify claims of efficacy or safety in its Promotion of the Product nor make any
changes in Product Promotional Materials approved by the GSK Promotional Review
Committee pursuant to SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS) above. Each
Party's Detailing and Promotion of the Product will be in strict adherence to
all regulatory, professional and legal requirements including, without
limitation, FDA regulations and guidelines concerning the advertising of
prescription drug products, the American Medical Association's Guidelines on
Gifts to Physicians, the PhRMA Code, the Anti-Kickback Statute, the Applicable
Commercial Practices Policies and the Product Promotion Guidelines in the
then-current JCC-approved Marketing Plan for the Product, and any approved
updates thereto.

          3.3.5 COMMUNICATIONS WITH SALES REPRESENTATIVES. Each Party will have
full responsibility for the dissemination of information regarding the Product
to its Sales Management Team, District Managers and PSRs based on the Training
Program, Product Promotional Guidelines and the Product Promotional Materials
approved by GSK pursuant to SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS) above.
All written communications from Allergan to Allergan's Sales Management Team and
the Allergan PSRs concerning the Promotion of the Product to Primary Product
Target Audience and the Additional Neuro Product Target Audience, other than
communications described in the next sentence, will be subject to prior written
approval by the JCC or the GSK Promotional Review Committee, as the case may be.
Prior approval will not be required for communications that do not contain any
drug information other than Product name, and other routine business reports
that do not contain any substantive drug information about the Product.

          3.3.6 PRICING. GSK will have exclusive responsibility and authority
with respect to the pricing of the Product. If GSK desires to modify pricing for
the Primary Product, GSK will inform Allergan prior to implementation and
discuss any implications of such modification to this Agreement.

          3.3.7 MANUFACTURING; DISTRIBUTION; AND SALE OF PRODUCT. GSK will be
solely responsible for all activities relating to manufacture, supply and
distribution of the Product (including Samples) in the Territory, including,
without limitation, order processing, inventory warehousing, delivery to
customers, invoicing and collection of receivables. Costs and expenses for the
foregoing activities will be borne exclusively by GSK pursuant to SECTION
6.3.3(B) (GSK MANUFACTURING, DISTRIBUTION, SALE AND SAMPLE COSTS AND EXPENSES).
GSK will have the sole right and responsibility to arrange for all distribution
of the Product in the Territory, and to effect and account for all sales and to
establish and modify the terms and conditions with respect to the sale of the
Product, including any terms and conditions relating to or affecting the price
at which the Product will be sold, any discount attributable to payments on
receivables, distribution of the Product, credit to be granted or refused and
the like. GSK will process, administer and pay

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       20

<PAGE>

pursuant to SECTION 6.3.3(B) (GSK MANUFACTURING, DISTRIBUTION, SALE AND SAMPLE
COSTS AND EXPENSES) any and all rebates, chargebacks and discounts.

               During the Term, GSK will use its Commercially Reasonable Efforts
to manufacture, supply and distribute sufficient Product (including Samples with
adequate shelf life as specified in SECTION 4.1 (PROVISION OF SAMPLES)) to
satisfy the Allergan Minimum Detail Commitments and support the then-current
JCC-approved Marketing Plan and JCC-approved strategies under SECTION 3.2.1
(MARKETING AND PROMOTION PLANNING; STRATEGY AND CONTENT) above. GSK agrees to
discuss with Allergan through the JCC any reasonable concerns of Allergan
relating to manufacture, supply or distribution capacity and/or quality of
Product in the Territory as provided under this Agreement.

          3.3.8 PROCESS CHANGES BY GSK. GSK will provide written notice to
Allergan of any material changes contemplated or proposed by GSK to any material
manufacturing processes that will impact the safety, strength, purity,
integrity, or quality (SSPIQ) of the Product.

          3.3.9 ON-GOING DEVELOPMENT AND LINE EXTENSIONS. GSK will use its
Commercially Reasonable Efforts to continue existing (as of the Effective Date)
and planned pre-clinical and clinical development and line extensions of the
Primary Product, including, integrating and applying GSK's RT technology, which
may enhance the dispersion and dissolution of the Primary Product even in the
presence of gastric stasis. Any and all costs and expenses associated with such
activities will be the sole and exclusive responsibility of GSK pursuant to
SECTION 6.3.4(D) (OTHER GSK COSTS AND EXPENSES). GSK will keep Allergan
reasonably informed of such efforts and will communicate such efforts to
Allergan regularly.

     3.4 OWNERSHIP OF PRODUCT.

          3.4.1 OWNERSHIP OF PRODUCT. GSK retains, and will during the Term
retain, all proprietary and property interests in and to the Product until the
point of sale. GSK's National Drug Code (NDC) number will at all times remain on
the Product. Allergan will not have nor represent that it has any control over,
or proprietary or property interests in, the Product. Nothing contained in this
Agreement will be deemed to grant to Allergan or its Affiliates any license,
right, title or interest in or to any patent, trademark, copyright, trade secret
or other similar property of GSK, including without limitation, any Product
Promotional Materials and training materials used in the Training Program.

          3.4.2 TRADEMARKS. The Product will be Promoted by Allergan in
accordance with the terms and conditions of this Agreement under the trademark
"AMERGE(R)" or "IMITREX(R)", as the case may be, (the "TRADEMARK"). Allergan
will use Trademark, other trademarks, trade names, and copyrighted materials of
GSK only as authorized by GSK and will take all reasonable precautions to ensure
the protection of GSK's rights in such materials. It is understood by Allergan
that GSK is not by this Agreement granting any right or license to Allergan or
to any other Person to use any trademarks, trade names, designs, logos, slogans,
taglines, or trade dress of GSK or its Affiliates or to utilize any information,
know-how, data or

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       21

<PAGE>

patent rights GSK or its Affiliates may have or may secure in the future
regarding the manufacture, use, and sale of the Product or any components
thereof except such limited licenses to use the Trademark, subject to any other
applicable provisions of this Agreement, as are necessary to fulfill the
obligations of Allergan hereunder with respect to Detailing and Promoting the
Product in the Territory pursuant to the terms and conditions contained in this
Agreement. Notwithstanding the foregoing, Allergan will not at any time use the
Trademark, other trademarks, trade names and copyrights of GSK in a manner
inconsistent with their established policy for use of such intellectual property
unless otherwise authored by GSK. All use of the Trademark by Allergan at all
times inures to the benefit of GSK, as licensee of the Trademark, and Glaxo
Group Limited, GSK's Affiliate and owner of the Trademark. GSK consents to the
use of Allergan's logo on all Product Promotional Materials ,but not on Product
packaging. GSK's logo will be used on all Product Promotional Materials and all
Product packaging.

     3.5 PATENTS. This Agreement does not grant to Allergan any license, right,
title or interest in or to any patent applications or patents of GSK, except to
the extent necessary to allow Allergan to Promote the Product in accordance with
the terms and conditions of this Agreement.

     3.6 NO DISTRIBUTION BY ALLERGAN. The Parties recognize that Allergan may
from time to time receive orders for the Product directly from Third Parties. In
such event, Allergan will promptly advise the customer that Allergan is not
authorized to accept orders for the Product and it will use its Commercially
Reasonable Efforts to provide the customer with adequate information to complete
the customer's order directly with GSK.

                                    ARTICLE 4

                                     SAMPLES

     4.1 PROVISION OF SAMPLES. GSK will use Commercially Reasonable Efforts to
provide Samples to Allergan in such quantities and pursuant to such timings as
set forth in the then current Marketing Plan, which quantities and timings will
be determined by the JCC and will be provided at GSK's cost and expense, for use
by Allergan in Promoting the Product to Primary Product Target Audience and the
Additional Neuro Product Target Audience in accordance with the Marketing Plan
as directed by the JCC and the terms and conditions of this Agreement.
Notwithstanding the foregoing, during each Commitment Year, GSK will provide
Allergan with such quantity of Samples of Primary Product that is equal to ***.
The JCC may, at any time during the Term, agree to increase the number of sample
packs of Primary Product provided to Allergan for each Detail comprising the
Allergan Minimum Detail Commitment amount for such Commitment Year.

Allergan will cause, and will maintain written procedures to ensure that all of
its PSR's, District Managers and Sales Management Team members comply with all
Applicable Laws relating to the distribution of, and accountability for,
Samples. All Samples provided by GSK under this Agreement will at the time of
delivery by GSK to Allergan hereunder, have *** of remaining shelf life based on
Product labeling and the relevant date of manufacture.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       22

<PAGE>

     4.2 SHIPPING OF SAMPLES. GSK will deliver Samples to Allergan FCA shipping
point (Incoterms 2000) at a single location designated by Allergan, which
location will be designated by Allergan on a quarterly basis, for distribution
by Allergan to a Third Party or the Allergan PSRs and Allergan's District
Managers. The storage by Allergan, the Allergan PSRs and Allergan's District
Managers of such Samples will be at Allergan's expense and Allergan will be
responsible for storing such Samples or causing such Samples to be stored under
label conditions and with adequate security to maintain the integrity and
usability of such Samples. All Samples that are in the possession of Allergan,
the Allergan PSRs or Allergan's District Managers and that are undistributed by
their expiration date will be returned by Allergan, at its expense, to GSK's
preferred destruction vendor, and destruction of such outdated Samples will be
at Allergan's expense; provided, however, that if GSK delivers Samples that do
not meet the shelf life requirements under SECTION 4.1 (PROVISION OF SAMPLES),
all return and destruction will be at GSK's expense.

     4.3 COMPLIANCE WITH PDMA.

          4.3.1 Allergan will be an "Authorized Distributor of Record" for the
Product for purposes of the requirements of the PDMA and will comply with the
PDMA, FDA regulations and applicable State law requirements regarding the
Marketing, sale and distribution of the Product, including, without limitation,
applicable wholesale drug distribution licensing guidelines and requirements.
GSK will have the right to audit the records and inspect the facilities of any
warehouse or distribution agent identified by Allergan under SECTION 4.2
(SHIPPING OF SAMPLES) for the storage and distribution of Samples, on advance
written notice to Allergan and during regular business hours. Upon request by
GSK, Allergan will provide GSK with copies of such agent's State registration
certificate as a licensed distribution center and State board of pharmacy
inspection report. Allergan understands that no Samples will be shipped until
such agent is verified by GSK to be in PDMA compliance.

          4.3.2 Each Party will take all steps necessary to ensure that each
Party's PSRs, District Managers and Sales Management Team members comply with
the requirements of the PDMA, all regulations promulgated thereunder and each
State's companion PDMA statutes and regulations that relate to the distribution
of Samples of a prescription drug product. This compliance includes, but is not
limited to, obtaining written requests, obtaining the licensed healthcare
professional's signature for all Samples delivered, ensuring validity of the
practitioner's State license, storage of all Samples at label conditions and
sending all documentation to the Party in a timely manner for retention.

          4.3.3 Each Party will take all steps necessary to ensure that each
Party's PSR and District Manager, and each member of its Sales Management Team
complies with all applicable Federal and state rules and policies concerning all
aspects of the storage, handling and distribution of Samples. This compliance
includes, but is not limited to, distribution to all PSRs, District Managers and
all members of Sales Management Teams an appropriate "Sample Accountability
System," adherence to the provisions contained therein, and attendance by each
Party's PSRs, District Managers, and Sales Management Team at training classes
on procedures for storage, handling and distribution of Samples.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       23

<PAGE>

          4.3.4 Sample Receipt Forms, final reconciliation reports, signature
audit data and findings, and for-cause investigation reports and associated data
with respect to Samples distributed in the Territory or otherwise for
distribution to customers in the Territory for free, where the purpose of the
free supply is to maximize sales and market share during the Term, will be
generated from compliance reports, accountability cards and the like produced by
Allergan, and will be maintained by Allergan for a period of not less than three
(3) years. All such information of Allergan will be considered GSK property.
Allergan will fully cooperate with GSK in the production and delivery of any
such documentation as may be requested or required by FDA and/or other
governmental agencies. Allergan will compile Sample reports on the Sample
Receipt Forms that are completed and returned by each Allergan PSR, and will
share such reports with GSK. Further, GSK will, at all times, have the right to
inspect and copy such documentation upon reasonable notice to Allergan. In the
event that GSK receives a request for any of such documentation from any Federal
or state authority, Allergan will provide copies to GSK of said requested
documentation within fifteen (15) days of written or verbal notice from GSK. In
the event that Allergan receives a request for any of such documentation from
any Federal or state authority to the extent that it relates to the Product or
this Agreement, Allergan will immediately notify GSK of such request. At GSK's
option, on a case by case basis, GSK may participate in the process to respond
to such authority. Copies of any and all reports, notices and the like with
respect to the Samples which Allergan is required to file by any Federal or
state authority will be submitted to GSK prior to the delivery of said documents
to the relevant authorities. GSK may, at its option, offer comments to such
reports and notice, and Allergan will include such comments in the filings. The
rights and obligations of the Parties under this SECTION 4.3.4 will survive the
expiration or termination of this Agreement.

          4.3.5 GSK agrees that Allergan may develop its own, or with a Third
Party, Sample systems, policies, procedures and documentation (including Sample
Receipt Forms), subject to GSK's prior review and approval for use with the
Product.

          4.3.6 Allergan will notify GSK promptly upon learning that any Samples
shipped by GSK to Allergan have been lost or have not been received as
scheduled. All reports regarding Sample accountability filed with the FDA will
be prepared and submitted to the FDA by GSK, regardless of whether such theft or
significant loss occurred with respect to GSK's or Allergan's PSRs, District
Managers or Sales Management Teams. For the purposes of filing such reports with
the FDA, Allergan agrees to fully cooperate and provide all relevant information
to GSK so that GSK, in turn, may comply with its reporting requirements to the
FDA.

          4.3.7 Allergan will notify GSK promptly upon learning that any of the
subject Samples had not been properly handled or had been handled in a manner
prohibited by law. Allergan will take all steps necessary to aid and support GSK
in a full investigation of any suspected mishandling of Samples.

          4.3.8 If Allergan or any of its PSRs fails to comply or causes GSK to
fail to comply with applicable Federal or state legal requirements and as a
direct result a penalty(ies) is assessed against GSK or any of its Affiliates or
employees, then, subject to ARTICLE 11

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       24

<PAGE>

(INDEMNIFICATION AND INSURANCE), Allergan will hold harmless and indemnify GSK,
its Affiliates or its employees from any such civil or criminal penalty or other
damages or losses related thereto, including reasonable attorneys' fees, costs
and expenses as provided in SECTION 11.1 (INDEMNIFICATION BY ALLERGAN).

     4.4 ADDITIONAL REQUIREMENTS. Allergan will maintain and provide to GSK,
upon request, an updated written list of full names and addresses of each
Allergan PSR and each member of Allergan's Sales Management Team as well as the
address of each site where Samples are stored. GSK will keep this information
confidential and will use this information solely to satisfy applicable legal or
regulatory requirements under this Agreement and for no other purpose.

     4.5 RETURN OF SAMPLES. Within forty-five (45) days following the
termination or expiration of the Commitment Term, Allergan will cause and ensure
that all of its PSRs and District Managers send all Samples back to Allergan or
Allergan's distribution agent. During such time period, GSK will provide Sample
disposition instructions to Allergan. Upon receipt of such instructions,
Allergan will, at its expense, comply with such Sample disposition instructions
within forty-five (45) days. Allergan will prepare and provide a detailed Sample
reconciliation report within sixty (60) days following termination or expiration
of the Commitment Term. GSK must receive and approve the Sample reconciliation
report prior to being obligated to pay, and Allergan being entitled to receive,
any of the Residual Term Royalty.

                                    ARTICLE 5

                              REGULATORY COMPLIANCE

     5.1 MARKETING AUTHORIZATION AND REGULATORY MATTERS. GSK will have the sole
right and responsibility between the Parties to take, and will use Commercially
Reasonable Efforts to maintain the authorization to Market the Product as a
pharmaceutical product in the United States. GSK will own or hold legal
responsibility and maintain the new drug application with respect to the Product
and will retain responsibility for all regulatory filings for the Product as
required under the FD&C Act and Applicable Law.

     5.2 RECALLS. GSK will promptly notify Allergan if GSK determines, in its
sole discretion, to authorize a Product recall in the Territory. The Parties
will allocate responsibilities between them for any such recall, such as, for
example, distributing notices of the recall and collecting samples. At GSK's
request and expense, Allergan will reasonably assist GSK in handling any recalls
of the Product. GSK will manage effecting any such recall of Product in the
Territory. Allergan will make available to GSK, upon request and at GSK's
expense, all pertinent records of Allergan that GSK may reasonably request to
assist GSK in effecting any such recall of Product in the Territory.

          5.2.1 MANUFACTURING RECALLS. In the event of any manufacturing-related
recall of Product (including Samples, will) hereunder, the provisions of SECTION
7.1.3(A) (PRIMARY PRODUCT FAILURE) and SECTION 7.1.3(B) (ADDITIONAL NEURO
PRODUCT FAILURE) will apply.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       25

<PAGE>

     5.3 RETURNS. Any Product returned to Allergan will be shipped as directed
by GSK to GSK's nearest facility, with any reasonable, documented direct cost to
be paid by GSK.

     5.4 GENERAL; ADVERSE DRUG EXPERIENCES AND PRODUCT COMPLAINTS; PRODUCT
AUDITS. GSK will be solely responsible for processing all adverse event reports
and Product complaints as required under Applicable Law. Both Parties will
collaborate in developing procedures for providing GSK information related to
adverse events and Product complaints, with such agreed upon procedures to be
evidenced by a separate agreement attached not later than sixty (60) days after
the Effective Date as an addendum to this Agreement (the "TECHNICAL AGREEMENT")
(attached as EXHIBIT C). The Technical Agreement will also contain procedures
for providing Allergan information related to adverse events and Product
complaints.

     5.5 PRODUCT INQUIRIES. If Allergan, or any Allergan PSR, receives any
inquiries about the Product, Allergan's responsibilities will be as follows:

          5.5.1 For questions that Allergan PSRs are unable to answer concerning
Product identification, Product availability or general inquiries, Allergan will
contact GSK Customer Service at ***, (or such other Person, at the address and
phone number as GSK may designate from time to time by written notice to
Allergan).

          5.5.2 For medical inquiries, including those related to information
outside of labeling or which Allergan PSRs are unable to answer, such medical
inquiries will go to GSK's Medical Information Department.

     5.6 COMMUNICATIONS WITH FDA. All communications with the FDA concerning the
Product will be the sole responsibility of GSK and will be initiated solely by
GSK. GSK will keep Allergan informed of any material interactions with FDA with
respect to the Product. Allergan, at its own expense, will provide reasonable
assistance to GSK to the extent deemed necessary by GSK.

     5.7 ADDITIONAL RESPONSIBILITIES OF THE PARTIES.

          5.7.1 The Parties will keep each other advised of significant market,
economic, regulatory and other developments that may affect the Promotion of the
Product in the Territory by the Parties pursuant to this Agreement.

          5.7.2 Each Party will report promptly to the other Party all other
significant information concerning any complaint of any kind regarding the
Product, its labeling, quality or packaging, including, without limitation, any
adverse drug experience not reported under the Technical Agreement.

                                    ARTICLE 6

                               COSTS AND EXPENSES.

     6.1 JOINT MARKETING AND PROMOTION COSTS AND EXPENSES.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       26

<PAGE>

          6.1.1 During each Commitment Year, excluding GSK's cost and expense
obligations in SECTION 6.3. below, Allergan will be responsible for all budgeted
Promotion costs and expenses set forth in the Marketing Plan for such Commitment
Year for the Primary Product only, which expenses are ***, pro rated as
necessary, which costs and expenses will be paid for directly by Allergan.
During each Commitment Year, GSK may be responsible for a share of all budgeted
Promotion costs and expenses set forth in the Marketing Plan for such Commitment
Year for the Primary Product only, which are ***, if any.

          6.1.2 During each Commitment Year, GSK will be responsible for
production and provision of all Product Promotional Materials and Sample costs
as set forth below in SECTION 6.3 (GSK COSTS AND EXPENSES) and for all Promotion
and Marketing costs and expenses for the Additional Neuro Product as set forth
in the Marketing Plan for such Commitment Year.

     6.2 ALLERGAN COSTS AND EXPENSES. Allergan will be responsible for the
following costs and expenses which are incurred by Allergan in each Commitment
Year:

          6.2.1 ALLERGAN CO-PROMOTION COSTS AND EXPENSES. All other costs and
expenses incurred by Allergan in its Promotion of the Product in the Territory
pursuant to SECTION 3.2.2 (CO-PROMOTION) that are not included in Allergan's
obligations pursuant to SECTION 6.1 (JOINT MARKETING AND PROMOTION COSTS AND
EXPENSES).

          6.2.2 ALLERGAN DETAIL RELATED COSTS AND EXPENSES.

               (A) All costs and expenses associated with the delivery of
Details with respect to the Allergan Minimum Details Commitment pursuant to
SECTION 3.2.6 (DETAILS).

               (B) All costs and expenses related to Allergan's own sales
deployment and internal distribution of Product Promotional Materials under this
Agreement, including its Direct Detailing Expenses, but excluding costs for
Samples.

               (C) All costs and expenses related to Allergan's distribution of
the Product Promotional Materials to its PSRs and Sales Management Team and
Allergan's efforts to ensure use only of Product Promotional Materials approved
as provided under this Agreement pursuant to SECTION 3.3.1 (PRODUCT PROMOTIONAL
MATERIALS).

               (D) All costs and expenses incurred in connection with Allergan's
participation at any JCC meetings as set forth in SECTION 2.1.1 (STRUCTURE).

               (E) All costs and expenses incurred in connection with an
Allergan employee's attendance at any Training Program pursuant to SECTION 3.3.3
(SALES TRAINING), including without limitation air and rail travel, hotel
accommodations and meals.

          6.2.3 OTHER ALLERGAN COSTS AND EXPENSES.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       27

<PAGE>

               (A) All costs and expenses related to Allergan's obligations to
compile and generate all reports, including, without limitation, under SECTION
3.2.7 (DATA COLLECTION AND REPORTING SYSTEMS) and SECTION 3.2.9 (QUARTERLY
REPORTS).

               (B) All payments of net wages, incentive compensation and fringe
benefits, if any, to Allergan's Personnel as well as costs and expenses
associated with liability and Workers' Compensation insurance coverage
applicable to such Personnel.

               (C) All costs and expenses of Allergan incurred in complying with
SECTION 3.2.10 (EMPLOYMENT QUALIFICATIONS) and SECTION 3.2.11 (INELIGIBLE
Persons).

               (D) All costs and expenses of Allergan as set forth in SECTION
4.2 (SHIPPING OF SAMPLES).

               (E) Subject to GSK's obligation to co-fund such costs in SECTION
6.3.2(H) below, all costs and expenses incurred by Allergan in connection with
obtaining national and territory/physician level Primary Product Target
Audience, Additional Neuro Product Target Audience and Neurologist Segment total
and new prescription data, which data is in addition to what is purchased by GSK
in the ordinary course of business prior to the Effective Date.

     6.3 GSK COSTS AND EXPENSES. GSK will be responsible for the following costs
and expenses which are incurred by GSK in each Commitment Year:

          6.3.1 GSK CO-PROMOTION COSTS AND EXPENSES. All other costs and
expenses incurred by GSK in its Promotion of the Product in the Territory
pursuant to SECTION 3.2.2 (CO-PROMOTION) that are not included in GSK's
obligations pursuant to SECTION 6.1 (JOINT MARKETING AND PROMOTION COSTS AND
EXPENSES).

          6.3.2 GSK DETAIL RELATED COSTS AND EXPENSES.

               (A) All costs and expenses related to GSK's own sales deployment
and internal distribution of Product Promotional Materials under this Agreement,
including its Direct Detailing Expenses.

               (B) All costs and expenses related to GSK's production and
provision of the Product Promotional Materials to either GSK or Allergan PSRs
for the Product as set forth in SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS).

               (C) All costs and expenses related to GSK's distribution of the
Product Promotional Materials to its PSRs and Sales Management Team provided
under this Agreement pursuant to SECTION 3.3.1 (PRODUCT PROMOTIONAL MATERIALS).

               (D) All costs and expenses incurred in connection with the
training of any GSK employee or agent regarding the Promotion of Product in the
Territory.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       28

<PAGE>

               (E) All costs and expenses related to GSK's conducting of the
Training Program pursuant to SECTION 3.3.3 (SALES TRAINING), including the cost
of producing and distributing training materials to Allergan, and the costs of
its designated training personnel.

               (F) All costs and expenses incurred in connection with compiling
and generating all GSK reports required under this Agreement, including, without
limitation, as set forth in SECTION 3.2.9 (QUARTERLY REPORTS).

               (G) All costs and expenses incurred in connection with GSK's
participation at any JCC meetings as set forth in SECTION 2.1.1 (STRUCTURE).

               (H) All costs and expenses incurred by GSK in connection with
obtaining national and territory/physician level Primary Product Target
Audience, Additional Neuro Product Target Audience and Neurologist Segment total
and new prescription data, and *** costs and expenses incurred by Allergan under
SECTION 6.2.3(E) above directly related to Allergan's acquisition of
territory/physician level Primary Product Target Audience, Additional Neuro
Product Target Audience and Neurologist Segment total and new prescription data,
***.

          6.3.3 GSK MANUFACTURING, DISTRIBUTION, SALE AND SAMPLE COSTS AND
EXPENSES.

               (A) All costs and expenses related to GSK's distribution and
provision of Samples to Allergan pursuant to ARTICLE 4 (SAMPLES).

               (B) All costs and expenses related to GSK's obligations under
SECTION 3.3.7 (MANUFACTURING; DISTRIBUTION; AND SALE OF PRODUCT). Such costs and
expenses include those incurred by the activities relating to manufacture,
supply and distribution of the Product (including Samples, which, manufacturing
and supply costs will be at GSK's expense) in the Territory, including, without
limitation, order processing, inventory warehousing, delivery to customers,
invoicing and collection of receivables. In addition, GSK will pay any and all
rebates, chargebacks and discounts that have been approved by GSK.

          6.3.4 OTHER GSK COSTS AND EXPENSES.

               (A) All costs and expenses related to GSK's obligations to
compile and generate statements under this Agreement, including, without
limitation under SECTION 7.2.1 (PAYMENT OF COMPENSATION PAYMENTS; STATEMENTS).

               (B) All costs and expenses arising from managed care,
Medicare/Medicaid execution, personnel, and other related costs associated with
Product in the Territory as set forth in SECTION 3.2.6 (MANAGED CARE AND
REIMBURSEMENT).

               (C) All payments of net wages, incentive compensation and fringe
benefits, if any, to GSK's Personnel as well as costs and expenses associated
with liability and Workers' Compensation insurance coverage applicable to such
Personnel.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       29

<PAGE>

               (D) Any and all costs and expenses associated with the efforts of
GSK to continue existing and planned pre-clinical and clinical development and
line extensions of the Product, pursuant to SECTION 3.3.9 (ON-GOING DEVELOPMENT
AND LINE EXTENSIONS).

               (E) All costs and expenses of GSK relating to regulatory
compliance as set forth in ARTICLE 5 (REGULATORY COMPLIANCE).

     6.4 ADDITIONAL COSTS AND EXPENSES. In addition to the costs and expenses
set forth in this ARTICLE 6, unless otherwise provided in this Agreement,
Allergan and GSK will be responsible for all other costs and expenses associated
with their respective obligations under this Agreement.

                                    ARTICLE 7

                                  COMPENSATION.

     7.1 COMPENSATION ARRANGEMENT.

          7.1.1 COMMITMENT TERM PAYMENTS. Subject to the provisions of this
SECTION 7.1, during the Commitment Term, GSK hereby agrees to compensate
Allergan by paying the sum of the Annual Fixed Payment in SECTION 7.1.1(A)
(FIXED PAYMENT) below plus the Primary Product Performance Payment in SECTION
7.1.1(B) (PRIMARY PRODUCT PERFORMANCE PAYMENT) and the Additional Neuro Product
Performance Payment in SECTION 7.1.1(C) (ADDITIONAL NEURO PRODUCT PERFORMANCE
PAYMENT) below, each payable in four (4) Calendar Quarter installments per
Commitment Year as provided in SECTION 7.2 (PAYMENT TERMS).

               (A) FIXED PAYMENT. Beginning as of the Co-Promotion Commencement
Date and subject to SECTION 7.2 (PAYMENT TERMS), GSK will pay Allergan on a
Calendar Quarter bases an amount based on a yearly minimum reimbursement payment
for its Promotion of Product as provided in this Agreement equal to *** per
Commitment Year, pro rated as necessary (i.e. ***) per Calendar Quarter, pro
rated as necessary); provided Allergan has met the Allergan Minimum Details
Commitment for Primary Product and Additional Neuro Product for such Commitment
Year as provided in SECTION 3.2.5 (DETAILS).

               (B) PRIMARY PRODUCT PERFORMANCE PAYMENT. Subject to SECTION 7.2
(PAYMENT TERMS), GSK will pay to Allergan, on a Calendar Quarter basis, an
amount based on actual Primary Product Net Sales for each Commitment Year, which
are above the Primary Product Baseline for each such Commitment Year (the
"PRIMARY PRODUCT PERFORMANCE PAYMENT") according to the following non-cumulative
schedule, provided that Allergan has satisfied the Allergan Product Minimum
Detail Commitments for the Primary Product for such Commitment Year, as provided
in SECTION 3.2.5 (DETAILS):

<TABLE>
<CAPTION>
PRIMARY PRODUCT NET SALES IN EACH    PRIMARY PRODUCT PERFORMANCE PAYMENT*
         COMMITMENT YEAR                    IN EACH COMMITMENT YEAR
---------------------------------    -----------------------------------
<S>                                  <C>

</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       30

<PAGE>

<TABLE>
<CAPTION>
PRIMARY PRODUCT NET SALES IN EACH    PRIMARY PRODUCT PERFORMANCE PAYMENT*
         COMMITMENT YEAR                    IN EACH COMMITMENT YEAR
---------------------------------    ------------------------------------
<S>                                  <C>
               ***                                    ***
</TABLE>

*    by way of example only, ***. Such Primary Product Performance Payment is
     subject to SECTION 7.2 (PAYMENT TERMS) and would be paid on a Calendar
     Quarter basis as provided therein.

               (C) ADDITIONAL NEURO PRODUCT PERFORMANCE PAYMENT. Subject to
SECTION 7.2 (PAYMENT TERMS), GSK will pay to Allergan, on a Calendar Quarter
basis, an amount based on actual Additional Neuro Product Net Sales for each
Commitment Year that are above the Additional Neuro Product Baseline for each
such Commitment Year (the "ADDITIONAL NEURO PRODUCT PERFORMANCE PAYMENT")
according to the following non-cumulative schedule, provided that Allergan has
satisfied the Allergan Product Minimum Detail Commitments for the Additional
Neuro Product for such Calendar Quarter, as set forth in the Marketing Plan
based upon the Commitment Year Detail requirements as provided in SECTION 3.2.5
(DETAILS):

<TABLE>
<CAPTION>
ADDITIONAL NEURO PRODUCT NET SALES IN   ADDITIONAL NEURO PRODUCT PERFORMANCE
         EACH COMMITMENT YEAR             PAYMENT IN EACH COMMITMENT YEAR*
-------------------------------------   ------------------------------------
<S>                                     <C>
                 ***                                    ***
</TABLE>

***

*    by way of example only, ***. Such Additional Neuro Product Performance
     Payment is subject to SECTION 7.2 (PAYMENT TERMS) and would be paid on a
     Calendar Quarter basis as provided therein..

          7.1.2 RESIDUAL TERM PAYMENTS. Subject to SECTION 4.5 (RETURN OF
SAMPLES) and SECTION 7.2 (PAYMENT TERMS), Allergan will, in further
consideration for the Promotion and Detailing of Product as provided herein, be
entitled to a payment during the Residual Term after the Commitment Term (the
"RESIDUAL TERM ROYALTY"); provided that Allergan has satisfied the Allergan
Product Minimum Detail Commitments for *** during the Commitment Term for the
Primary Product, as provided in SECTION 3.2.5 (DETAILS). Such Residual Term
Royalty will be based on Net Sales from the Primary Product Target Audience
during the Residual Term, according to the schedule below.

<TABLE>
<CAPTION>
YEAR DURING THE RESIDUAL TERM   ROYALTY AS % OF PRIMARY PRODUCT TARGET AUDIENCE NET
                                  SALES IN EXCESS OF THE PRIMARY PRODUCT BASELINE
-----------------------------   ---------------------------------------------------
<S>                             <C>
             ***                                        ***
</TABLE>

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       31

<PAGE>

          7.1.3 ADJUSTMENTS FOR FAILURE OF THE PARTIES TO MEET CERTAIN
OBLIGATIONS.

               (A) PRIMARY PRODUCT FAILURE.

                    (i) If (A) GSK is unable to fulfill at least *** of
outstanding purchase orders from Third Parties for Primary Product in the
Territory as provided in SECTION 3.3.7 (MANUFACTURING; DISTRIBUTION; AND SALE OF
PRODUCT) or supply at least *** of the quantities Samples for Primary Product
that Allergan is entitled to receive as set forth in the Marketing Plan, (in
each case other than as a result of an event arising under SECTION 13.9 (FORCE
MAJEURE), any direct or indirect act or omission of Allergan, or any action of
any governmental agency or authority or court injunction), including, but not
limited to, any manufacturing recall, or, if (B) GSK is otherwise prevented or
prohibited from marketing, distributing or selling the Primary Product in the
Territory for any reason (other than as a result of an event arising under
SECTION 13.9 (FORCE MAJEURE), any direct or indirect act or omission of
Allergan, or any action of any governmental agency or authority or court
injunction), including, without limitation, as a result of any action of any
Primary Product safety concerns on the part of GSK (each situation in (A) and
(B) referred to as a "PRIMARY PRODUCT FAILURE"), then as to each Primary Product
Failure set forth in (A) and (B), GSK will have *** from the commencement date
of such Primary Product Failure to cure such Primary Product Failure. If after
such *** period, such Primary Product Failure has not been cured and solely as a
result of such Primary Product Failure (e.g., not because Allergan is in breach
of this Agreement, such as, by way of example only, failing to have the minimum
number of PSRs as provided in SECTION 3.2.3(B) (MINIMUM PSRS)), Allergan does
not meet the Allergan Minimum Detail Commitments for the Commitment Year for the
Primary Product during the period when any such Primary Product Failure
occurred, Allergan will be deemed to have met the Allergan Minimum Detail
Commitments for Primary Product for the purposes of SECTION 7.1.1(A) (FIXED
PAYMENTS) during such period. In addition, GSK will pay Allergan, for each
Calendar Quarter during which such Primary Product Failure exists until another
Neurology product has been selected to replace the Primary Product or the
Details for the Primary Product have been reallocated to Additional Neuro
Product as provided in SECTION 7.1.3(A)(II), the Primary Product Performance
Payment amount owed for the Calendar Quarter immediately preceding the Calendar
Quarter in which the Primary Product Failure occurred, pro-rated as necessary to
apply solely to the period of such Primary Product Failure.

                    (ii) If a Primary Product Failure exists with respect to
Product as referenced in (A) in SECTION 7.1.3(A)(I) above during each month of a
*** period during the Commitment Term, or if a Primary Product Failure with
respect to Samples as referenced in (A) in SECTION 7.1.3(A)(I) above during each
month of a *** period during the Commitment Term, or if a Primary Product
Failure exists with respect to Product as referenced in (B) in SECTION
7.1.3(A)(I) above during each month of a *** period during the Commitment Term,
then at such time, Allergan may require, through the JCC, that GSK in its sole
discretion either (A) substitute another agreed upon Neurology product to
replace the Primary Product, or (B) reallocate the Allergan Minimum Detail
Requirements for the Primary Product to the Additional Neuro Product for the
remainder of the Commitment Term and create a new performance structure that

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       32

<PAGE>

would enable Allergan to earn at least the same Primary Product Performance
Payment as it received in the immediately preceding Commitment Year with respect
to the Primary Product.

                    (iii) If there is not at least one valid and enforceable
patent claiming the Primary Product in the Territory, or if there is not
regulatory exclusivity covering (e.g., pediatric exclusivity) the Primary
Product in the Territory, in either case at any time during the Commitment Term,
then at such time, Allergan may require, through the JCC, that GSK in its sole
discretion either (A) substitute another agreed upon Neurology product to
replace the Primary Product, or (B) reallocate the Allergan Minimum Detail
Requirements for the Primary Product to the Additional Neuro Product for the
remainder of the Commitment Term and create a new performance structure that
would enable Allergan to earn at least the same Primary Product Performance
Payment as it received in the immediately preceding Commitment Year with respect
to the Primary Product.

               (B) ADDITIONAL NEURO PRODUCT FAILURE. If (A) GSK is unable to
fulfill at least *** of outstanding purchase orders from Third Parties for
Additional Neuro Product in the Territory as provided in SECTION 3.3.7
(MANUFACTURING; DISTRIBUTION; AND SALE OF PRODUCT) or supply at least *** of the
quantities Samples for Additional Neuro Product that Allergan is entitled to
receive as set forth in the Marketing Plan, (in each case other than as a result
of an event arising under SECTION 13.9 (FORCE MAJEURE), any direct or indirect
act or omission of Allergan, or any action of any governmental agency or
authority or court injunction), including, but not limited to, any manufacturing
recall, or, (B) GSK is otherwise prevented or prohibited from marketing,
distributing or selling the Additional Neuro Product in the Territory for any
reason (other than as a result of an event arising under SECTION 13.9 (FORCE
MAJEURE), any direct or indirect act or omission of Allergan, or any action of
any governmental agency or authority or court injunction), including, without
limitation, as a result of any action of any Additional Neuro Product safety
concerns on the part of GSK (each situation in (A) and (B) referred to as a
"ADDITIONAL NEURO PRODUCT FAILURE"), then as to each Additional Neuro Product
Failure set forth in (A) and (B), GSK will have forty-five (45) consecutive days
from the commencement date of such Additional Neuro Product Failure to cure such
Additional Neuro Product Failure. If after such forty-five (45) consecutive day
period, such Additional Neuro Product Failure has not been cured and solely as a
result of such Additional Neuro Product Failure (e.g., not because Allergan is
in breach of this Agreement, such as, by way of example only, failing to have
the minimum number of PSRs as provided in SECTION 3.2.3(B) (MINIMUM PSRS)),
Allergan does not meet the Allergan Minimum Detail Commitments for the
Commitment Year for the Additional Neuro Product during the period when any such
Additional Neuro Product Failure occurred, Allergan will be deemed to have met
the Allergan Minimum Detail Commitments for Additional Neuro Product for the
purposes of SECTION 7.1.1(A) (FIXED PAYMENTS) during such period. Further, GSK
will pay Allergan, for each Calendar Quarter during which such Additional Neuro
Product Failure exists, the Additional Neuro Product Performance Payment amount
owed for the Calendar Quarter immediately preceding the Calendar Quarter in
which the Additional Neuro Product Failure occurred, pro-rated as necessary to
apply solely to the period of such Additional Neuro Product Failure.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       33

<PAGE>

               (C) FAILURE BY ALLERGAN TO MEET MINIMUM COMMITMENTS. If Allergan
does not meet the Allergan Minimum Details Commitment as defined in SECTION
3.2.5 (DETAILS) of this Agreement for any Commitment Year for reasons unrelated
to a Primary Product Failure or an Additional Neuro Product Failure, the
following in this SECTION 7.1.3(C) will apply. For every *** Details below the
Minimum Details Commitment which are not performed by Allergan for a given
Commitment Year, Allergan will pay to GSK, or GSK will be entitled to reduce the
Fixed Payment by, an amount equal to ***, pro rated as necessary.

          7.1.4 EFFECT OF TERMINATION ON PAYMENTS.

               (A) TERMINATION PRIOR TO END OF COMMITMENT TERM. In the event
that Allergan terminates this Agreement prior to the end of the Commitment Term
for any reason, other than for cause under SECTION 12.2 (TERMINATION OF CAUSE),
effective as of the effective date of such termination, Allergan will not be
entitled to receive further payments under this SECTION 7.1 except for
previously owed or accrued amounts that have not yet been paid to Allergan (if
any).

               (B) TERMINATION AFTER COMMITMENT TERM. In the event that this
Agreement has not been terminated pursuant to ARTICLE 12 (TERM AND TERMINATION)
prior to the end of the Commitment Term, Allergan will be compensated according
to the Residual Term Royalty in SECTION 7.1.2 (RESIDUAL TERM ROYALTY) above.

     7.2 PAYMENT TERMS.

          7.2.1 PAYMENT OF COMPENSATION PAYMENTS. Subject to the other terms of
this Agreement, GSK will make any compensation payments owed to Allergan in
United States Dollars, within sixty (60) days following the end of each Calendar
Quarter during the Commitment Term using the wire transfer provisions of SECTION
7.2.3 (WIRE TRANSFERS). With respect to the first Commitment Year (and for
information purposes for each subsequent Commitment Year), each compensation
payment will be accompanied by a written statement for the Calendar Quarter
covered by such statement, specifying: the Net Sales in the Territory showing
deductions specified in SECTION 1.35 (NET SALES); the applicable compensation
rate under this Agreement, applying the terms of SECTION 7.1 (COMPENSATION
ARRANGEMENT); and the compensation payments payable in United States Dollars.
The Fixed Payment component of such Calendar Quarter payment will be *** and
will be subject to reduction by GSK at the end of each Commitment Year pursuant
to SECTION 7.1.3(C) (FAILURE BY ALLERGAN TO MEET MINIMUM COMMITMENTS).

               (A) During each Commitment Year, the portion of the Primary
Product Performance Payment due after each Calendar Quarter will be based on a
comparison of actual Net Sales reported in the above statement, during such
Calendar Quarter to twenty five percent (25%) of the Primary Product Baseline
and applying the difference on an quarterly basis to the schedule in SECTION
7.1.1(B) (PRIMARY PRODUCT PERFORMANCE PAYMENT). At the end of each Commitment
Year the Parties will determine the actual Primary Product Performance Payment

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       34

<PAGE>

due for such Commitment Year based on actual Net Sales for such Commitment Year
and adjust the final Calendar Quarter Payment for such Commitment Year
accordingly.

               (B) During each Commitment Year, the portion of the Additional
Neuro Product Performance Payment due after each Calendar Quarter will be based
on a comparison of actual Net Sales reported in the above statement, during such
Calendar Quarter to twenty five percent (25%) of the Additional Neuro Product
Baseline and applying the difference on an quarterly basis to the schedule in
SECTION 7.1.1(C) (ADDITIONAL NEURO PRODUCT PERFORMANCE PAYMENT). At the end of
each Commitment Year the Parties will determine the actual Additional Neuro
Product Performance Payment due for such Commitment Year based on actual Net
Sales for such Commitment Year and adjust the final Calendar Quarter Payment for
such Commitment Year accordingly.

               (C) An example of the calculation of the Primary Product
Performance Payments on a Calendar Quarter basis and annual true up described in
SECTION 7.2.1(A) above is provided in EXHIBIT D to this Agreement. The
calculation for the Additional Neuro Product Net Sales on a Calendar Quarter
basis and annual true up as described in Section 7.2.1(a) would be performed in
the same manner as provided in the example in Exhibit D using the Additional
Neruo Product Baseline.

          7.2.2 TAXES. GSK may withhold taxes, duties, levels fees or charges if
revenue authorities in such country require the withholding of taxes, duties,
levies, fees or charges on any amounts paid or owed by GSK hereunder. GSK will
deduct any such taxes, duties, levies, fees or charges from such payment and
will pay such taxes, duties, levies, fees or charges to the property taxing
authority on behalf of the payee. GSK agrees to assist and, to the extent
provided by the relevant taxing authority, provide evidence of payment of such
tax promptly to Allergan in claiming exemption from such deductions or
withholdings under any applicable double taxation or similar agreement or
treaty.

          7.2.3 WIRE TRANSFERS. All payments hereunder will be made to Allergan
by bank wire transfer in immediately available funds to Allergan in accordance
with the wire instructions set forth below, which may be changed only by written
notice to GSK from the Chief Financial Officer of Allergan under SECTION 13.7
(NOTICES).

               ***

          7.2.4 OVERDUE COMPENSATION PAYMENTS. Subject to the other terms of
this Agreement, compensation payments not paid to Allergan within the time
period set forth in this ARTICLE 7 will bear interest at an annual rate of ***.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       35

<PAGE>

                                    ARTICLE 8

                      RECORD KEEPING; REPORTING AND AUDITS

     8.1 DETAILS AND SAMPLES. The Parties will keep complete and accurate
records of (i) all Details delivered by the PSRs and the District Managers, and
(ii) with respect to Samples delivered by the PSRs, the quantity and dates of
delivery of such Samples to each physician. Each Party also will keep its copies
of the completed Sample Receipt Forms. In addition, Allergan will keep complete
and accurate records of all of its costs and expenses for Promotion under this
Agreement (except for Direct Detailing Expenses).

     8.2 COMPENSATION PAYMENTS. GSK and its Affiliates will keep, for at least
one (1) year from the end of the Commitment Year to which they pertain, complete
and accurate records of sales by GSK and its Affiliates of the Product in the
Territory, in sufficient detail to allow the accuracy of the compensation
payments to be confirmed as set forth in SECTION 8.3 (FINANCIAL AUDIT RIGHTS).

     8.3 FINANCIAL AUDIT RIGHTS.

          8.3.1 Subject to the other terms of this SECTION 8.3.1, at the request
of either Party upon at least thirty (30) business days' prior written notice
from the requesting Party to the other Party, not more than once in any calendar
year, and at the expense of the requesting Party (except as otherwise provided
herein), the other Party will permit an independent certified public accountant
reasonably selected by the requesting Party and reasonably acceptable to the
other Party to inspect (during regular business hours) the relevant records
required to be maintained by the other Party under this SECTION 8.3.1. At
Allergan's request, the accountant will be entitled to review the then-preceding
three (3) years of GSK's records as provided under SECTION 8.1 (DETAILS AND
SAMPLES) and the then-preceding one (1) year of GSK's records as provided under
SECTION 8.2 (COMPENSATION PAYMENTS) for purposes of (i) verifying Allergan's
compensation payments, including verification of GSK's Net Sales, and GSK's
determination of numbers of Details and Samples provided by GSK and its
Affiliates under SECTION 3.2.5 (DETAILS), or (ii) complying with the
Sarbanes-Oxley Act of 2002, as amended, including, but not limited to all United
States Securities an Exchange Commission (SEC) rules and regulations relating
thereto. At GSK's request, the accountant will be entitled to review the
then-preceding three (3) years of Allergan's records as provided under SECTION
8.1 (DETAILS AND SAMPLES) for purposes of verifying Allergan's costs and
expenses for Marketing and Promotion under this Agreement (except for Direct
Detailing Expenses) and determination of numbers of Details and Samples provided
by Allergan under SECTION 3.2.5 (DETAILS). In every case the accountant must
have previously entered into a confidentiality agreement with both Parties
substantially similar to the provisions of ARTICLE 9 (CONFIDENTIALITY) and
limiting the disclosure and use of such information by such accountant to
authorized representatives of the Parties and the purposes germane to this
SECTION 8.3.1. Results of any such review will be made available to both Parties
and will be binding on both Parties.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       36

<PAGE>

          If any review reveals a deficiency in the calculation of compensation
payments resulting from any underpayment by GSK, GSK will, within thirty (30)
days pay Allergan the amount remaining to be paid (plus interest thereon at the
rate provided in SECTION 7.2.4 (OVERDUE COMPENSATION PAYMENTS) above), and if
such underpayment is by *** or more, GSK will also pay all costs and expenses of
the review. If any review reveals an error in the calculation of compensation
payments resulting in an overpayment by GSK, Allergan will, within thirty (30)
days pay to GSK such overpayment. If any review reveals that Allergan has not
met the Allergan Minimum Details Commitment as defined in SECTION 3.2.5
(DETAILS) for any Commitment Year, then SECTION 7.1.3(C) (FAILURE BY ALLERGAN TO
MEET MINIMUM COMMITMENTS) will apply, and if any review reveals that Allergan
has not met its funding for Promotional expenses as set forth in SECTION 6.1
(JOINT MARKETING AND PROMOTION COSTS AND EXPENSES), then Allergan will, within
thirty (30) days pay to GSK the amount remaining to be paid.

          8.3.2 Subject to the other terms of this SECTION 8.3.2, at the request
of Allergan upon at least thirty (30) business days' prior written notice to
GSK, not more than once in any calendar year, and at the expense of Allergan
(except as otherwise provided herein), GSK will permit an independent auditor
reasonably selected by Allergan and reasonably acceptable to GSK to inspect
(during regular business hours) the relevant records required to be maintained
by GSK under this SECTION 8.3.2. At Allergan's request, the auditor will be
entitled to review the then-preceding two (2) years of GSK's records regarding
the allocation factors applied to the data obtained as provided in EXHIBIT A to
this Agreement, including all prescription source data for both the Neurologist
Segment and PCP's, *** as to the PCP allocation factor, in all cases for both
Primary Product and Additional Neuro Product for purposes of verifying GSK's Net
Sales during such period. The auditor must have previously entered into a
confidentiality agreement with both Parties substantially similar to the
provisions of ARTICLE 9 (CONFIDENTIALITY) and limiting the disclosure and use of
such information by such auditor to authorized representatives of Allergan and
the purposes germane to this SECTION 8.3.2. Results of any such review will be
made available to both Parties and will be binding on both Parties.

          If any review reveals a deficiency in the calculation Net Sales
attributable to the Neurologist Segment and to PCP's as set forth in Exhibit A
to this Agreement, resulting in any underpayment by GSK, GSK will, within thirty
(30) days, pay Allergan the amount remaining to be paid (plus interest thereon
at the rate provided in SECTION 7.2.4 (OVERDUE COMPENSATION PAYMENTS) above),
and if such deficiency in the calculation of Net Sales is *** or more, GSK will
also pay all costs and expenses of the review; provided, however, that if
notwithstanding a deficiency in the calculation of Net Sales that is *** or
more, Allergan is not entitled to receive any additional compensation from GSK
notwithstanding such deficiency (such as, for the purposes of example only, if
Primary Product Net Sales in a Commitment Year, even after such review, are
equal to or less than the Primary Product Baseline and Allergan would still not
be entitled to receive any Primary Product Performance Payment in such
Commitment Year), then GSK will not be obligated to pay any costs and expenses
of the review. If any review reveals an excess in the calculation of Net Sales
resulting in any overpayment by GSK, Allergan will, within thirty (30) days, pay
GSK any excess compensation payments received during such period.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       37

<PAGE>

     8.4 MONTHLY AND QUARTERLY REPORTS. Within fifteen (15) business days after
the end of each month during each Commitment Term, each Party will provide to
the other Party the raw data of Sales Call activity, and within forty (40) days
after the end of each month during the Commitment Term, each Party will provide
the other Party with Sample disbursements for the immediately preceding month,
all as provided in the remainder of this SECTION 8.4. All such monthly reports
will be in the form of a written report, and, at the other Party's option, an
electronic file, each formatted in such manner as may be reasonably requested by
the other Party (taking into account each Party's existing computer systems),
for each Sales Territory and on a cumulative basis for the entire Territory,
setting forth the following information (and such modifications and/or
additional Product-related information as either Party may reasonably request
from time to time, particularly to satisfy accounting, regulatory or legal
requirements):

          8.4.1 the number of Primary and Secondary Details delivered by each
PSR during such month and on a cumulative basis for all PSRs and District
Managers for such month;

          8.4.2 the number of Primary and Secondary Details delivered by the
PSRs to each physician during such month, sorted by delivery to physicians who
are and who are not included in the Primary Product Target Audience and
Additional Neuro Product Target Audience;

          8.4.3 the total number of Samples delivered by each PSR during the
preceding month and on a cumulative basis for all PSRs and District Managers
during the immediately preceding month;

          8.4.4 the number of Samples delivered to each physician by the PSRs
and District Managers during the immediately preceding month, which report will
also identify each such physician as either a Target Physician or a non-Target
Physician;

          8.4.5 the number of Samples remaining in inventory and in each PSRs
and each District Manager's inventory on the last day of the immediately
preceding month;

          8.4.6 the calculated percentage of total Details delivered by the PSRs
during such month which were Details to the Primary Product Target Audience and
the Additional Neuro Product Target Audience;

          8.4.7 from GSK only, a calculation of the estimated Net Sales and
estimated portion of the Primary Product Performance Payment and Additional
Neuro Product Performance Payment applicable for such month; and

          8.4.8 from GSK only, a statement of inventory returns to GSK from its
distributors for such month.

               After the end of each Calendar Quarter during the Commitment
Term, at the same time as the written statement from GSK set forth in SECTION
7.2.1 (PAYMENT OF COMPENSATION PAYMENTS) above, each Party will provide to the
other Party with a written report, and, at the other Party's option, an
electronic file, each formatted in such manner as may

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       38

<PAGE>

be reasonably requested by the other Party (taking into account each Party's
existing computer systems), for each Sales Territory and on a cumulative basis
for the entire Territory, setting forth the same information as the foregoing
SECTIONS 8.4.1 THROUGH 8.4.8 in this case covering the Calendar Quarter;
provided, however, that GSK's written report to Allergan will accompany its
written statement to Allergan under SECTION 7.2.1 (PAYMENT OF COMPENSATION
PAYMENTS; STATEMENTS) above.

     8.5 AUDIT OF WAREHOUSE AND DISTRIBUTION FACILITY. Upon request of GSK,
Allergan will permit GSK or its authorized representatives access to audit, on
an annual basis or more frequently as may be required by Applicable Law,
Allergan's or the Third Party's facility where Allergan stores Samples and
Promotional Materials for distribution to its PSRs, District Managers and Sales
Management Team members. GSK will use Commercially Reasonable Efforts not to
jeopardize or interfere with Allergan's ongoing business operations or
jeopardize Allergan trade secrets in conducting any such audit.

                                    ARTICLE 9

                                 CONFIDENTIALITY

     9.1 REQUIREMENTS.

          9.1.1 Each Party agrees not to use Confidential Information (as
hereinafter defined) furnished by the other Party for any purpose other than for
purposes of performing its obligations under this Agreement. Each Party will
treat Confidential Information furnished by the other Party with the same degree
of care as it treats its own proprietary information and will not disclose the
same, for a period of *** after the expiration or earlier termination of this
Agreement, to any Third Party without the prior written consent of the Party
which furnished such information.

          9.1.2 If, to carry out its obligations under this Agreement, a Party
must disclose Confidential Information of the other Party to a Third Party, such
disclosing Party will first require any such Third Party to be bound by the
confidentiality provisions of this Agreement by requiring such Third Party to
enter into an appropriate written confidentiality agreement. This provision will
not be applicable to confidential information disclosed by the Parties pursuant
to SECTION 9.2 (CONFIDENTIAL INFORMATION) below.

     9.2 CONFIDENTIAL INFORMATION. "Confidential Information" refers to all
proprietary technical, business and Marketing information of the other Party
(including, without limitation, the Marketing Plans and training materials
provided to Allergan by GSK as part of the Training Program, each of which will
constitute GSK Confidential Information) disclosed by one Party to the other
pursuant to this Agreement. Notwithstanding the foregoing or any other provision
in this Agreement to the contrary, a Party's Confidential Information will not
include:

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       39

<PAGE>

          9.2.1 information which at the time of disclosure is in the public
domain or thereafter becomes part of the public domain through no breach of this
Agreement by the receiving Party;

          9.2.2 information which the receiving Party can establish by competent
written proof was in its possession at the time of disclosure by the disclosing
Party and was not acquired, directly or indirectly, from the disclosing Party;

          9.2.3 information which the receiving Party receives from a Third
Party; provided, however, that such information was not obtained by said Third
Party, directly or indirectly from the disclosing Party; or

          9.2.4 information or data which is independently developed by the
receiving Party without the reference to or any other use of the disclosing
Party's Confidential Information.

     9.3 GSK DATA PROTECTIONS. Allergan agrees and understands that Confidential
Information of GSK, including but not limited to, data disclosed to Allergan
through the JCC or otherwise and arising under or related to Product, is very
sensitive and GSK would not enter into this Agreement without additional
assurances from Allergan with respect to Allergan's use of such Confidential
Information or possible disclosure of such Confidential Information to GSK's
competitors. Accordingly, Allergan will not use, and will cause its Affiliates
not to use, directly or indirectly, any Confidential Information of GSK in
connection with any neurology product other than as provided under this
Agreement.

     9.4 DISCLOSURE REQUIRED BY LAW. Notwithstanding anything else in this
Agreement, the receiving Party will not be prohibited from disclosing
Confidential Information of the disclosing Party to the extent such information
is required to be disclosed to governmental agencies or by legal process or
Applicable Laws, in which case the receiving Party will notify the disclosing
Party in writing of the need for such disclosure and will cooperate with the
disclosing Party to seek confidential treatment of the information.

     9.5 REMEDIES. The receiving Party agrees that its obligations hereunder are
necessary and reasonable to protect the disclosing Party's business interests
and that the unauthorized disclosure or use of Confidential Information of a
disclosing Party would cause irreparable harm and significant injury, the degree
of which may be difficult to ascertain. The receiving Party further acknowledges
and agrees that in the event of any actual or threatened breach of this
Agreement, the disclosing Party may have no adequate remedy at law and,
accordingly, that the disclosing Party will have the right to seek an immediate
injunction enjoining any breach or threatened breach of this Agreement, as well
as the right to pursue any and all other rights and remedies available at law or
in equity for such breach or threatened breach.

     9.6 RETURN OF CONFIDENTIAL INFORMATION. Upon termination of this Agreement
and upon the request of the disclosing Party, the receiving Party will return
all such Confidential

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       40

<PAGE>

Information and copies thereof in its possession; provided, however, that one
(1) copy of the disclosing Party's Confidential Information may be retained by
the legal department of the receiving Party solely for the purpose of
determining compliance with this ARTICLE 9.

     9.7 DISCLOSURE OF AGREEMENT, PUBLICITY AND PUBLICATIONS. Except as
expressly provided otherwise in SECTION 9.1 (REQUIREMENTS) or SECTION 9.3
(DISCLOSURE REQUIRED BY LAW), neither GSK nor Allergan will release to any Third
Party or publish in any way any non-public information with regard to the terms
of this Agreement or concerning their cooperation without the prior written
consent of the other, which consent will not be unreasonably withheld or
delayed. Subject to the foregoing, the Allergan will issue a press release,
public statement or disclosure regarding this Agreement, which press release,
public statement or disclosure will be mutually agreed upon by the Parties.
Nothing in the foregoing, however, will prohibit a Party from making disclosures
to the extent deemed necessary under applicable federal or state securities laws
or any rule or regulation of any nationally recognized securities exchange. In
such event, however, the disclosing Party will use good faith efforts to consult
with the non-disclosing Party prior to such disclosure and will request
confidential treatment to the extent available. Allergan acknowledges and agrees
that GSK will have the right, without obtaining Allergan's prior consent, to
submit manuscripts relating to the Product for scientific publications. A copy
of any scientific abstract or manuscript that is submitted for publication will
be provided by GSK to Allergan within thirty (30) days after such submission.
Allergan further acknowledges and agrees that GSK will have the right, without
obtaining Allergan's prior consent, to publish clinical trial results or
summaries of clinical trial results on GSK's Clinical Trial Registry.

                                   ARTICLE 10

                         REPRESENTATIONS AND WARRANTIES

     10.1 MUTUAL REPRESENTATIONS AND WARRANTIES. As of the Effective Date, each
of GSK and Allergan hereby represents, warrants and covenants to the other Party
hereto that:

          10.1.1 it is a corporation or entity duly organized and validly
existing under the laws of the State or other jurisdiction of its incorporation
or formation;

          10.1.2 the execution, delivery and performance of this Agreement by
such Party has been duly authorized by all requisite corporate action and does
not require any shareholder action or approval;

          10.1.3 it has the power and authority to execute and deliver this
Agreement and to perform its obligations hereunder and this Agreement
constitutes and when executed will constitute, its legal, valid and binding
obligation, enforceable in accordance with its terms, except as may be limited
by bankruptcy and equitable principles limiting specific performance;

          10.1.4 the execution, delivery and performance by such Party of this
Agreement and its compliance with the terms and provisions hereof does not and
will not conflict with or result in a breach of any of the terms and provisions
of or constitute a default under (i) a loan

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       41

<PAGE>

agreement, guaranty, financing agreement, agreement affecting a product or other
agreement or instrument binding or affecting it or its property; (ii) the
provisions of its charter or operative documents or bylaws; or (iii) any order,
writ, injunction or decree of any court or governmental authority entered
against it or by which any of its property is bound; and

          10.1.5 during the Term, it and its Affiliates will not, Market (in the
case of GSK only) or Promote the Product in violation of Applicable Law and
professional requirements in the Territory, including but not limited to the
Anti-Kickback Statute and any State Medicare and Medicaid anti-kickback statutes
and regulations, the PDMA and regulations thereunder, the FD&C Act and
regulations thereunder, HIPAA, FDA regulations and guidelines concerning the
advertising of prescription drug products, the American Medical Association's
Guidelines on Gifts to Physicians, the PhRMA Code , the Applicable Commercial
Practices Policies, and any approved updates thereto.

     10.2 REPRESENTATIONS AND WARRANTIES OF GSK. As of the Effective Date, GSK
hereby represents, warrants and covenants to Allergan that:

          10.2.1 it has the legal power to extend the rights granted to Allergan
in this Agreement necessary to enable Allergan to carry out its obligations and
exercise its rights under this Agreement, and has not made and will not make any
commitments to others inconsistent or in derogation of such rights.

     10.3 REPRESENTATIONS AND WARRANTIES OF ALLERGAN. As of the Effective Date,
Allergan hereby represents, warrants and covenants to GSK that:

          10.3.1 It is not legally prevented from Promoting or Detailing the
Product as contemplated under this Agreement. Allergan represents and warrants
to GSK that Allergan has the requisite Personnel, facilities, equipment,
expertise, experience and skill to perform its obligations hereunder and to
render the services contemplated hereby; and it covenants that it will perform
the services in a professional, timely, competent and efficient manner. Allergan
further covenants that it will abide by all laws, rules and regulations that
apply to the performance of the services to be performed hereunder (including,
without limitation, the Anti-Kickback Statute and the PDMA), and that in
performing the services to be performed hereunder it will not, nor will the
PSRs, District Managers or Sales Management Team members, engage in the
counseling or promotion of a business arrangement or other activity that
violates any State or Federal Law. When on GSK's premises or a GSK customer's
premises, Allergan personnel will comply with all of GSK's or GSK customer's
policies regarding the conduct of visitors.

          10.3.2 Neither Allergan, nor any PSR, District Manager or Sales
Management Team member or other employee or agent of Allergan (i) is currently
excluded, debarred, suspended, or otherwise ineligible to participate in the
Federal health care programs or in Federal procurement or non-procurement
programs; (ii) has been convicted of a criminal offense that falls within the
ambit of 42 U.S.C. Section 1320a-7(a) but has not yet been excluded, debarred,
suspended, or otherwise declared ineligible, or (iii) has been debarred, nor is
currently under

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       42

<PAGE>

investigation by the FDA for debarment action or pursuant to the Generic Drug
Enforcement Act.

                                   ARTICLE 11

                         INDEMNIFICATION AND INSURANCE.

     11.1 INDEMNIFICATION BY ALLERGAN. Allergan will indemnify, defend and hold
GSK, and its officers, directors, agents, employees, and Affiliates
(collectively, the "GSK INDEMNITEES"), harmless from any claims, damages, causes
of action, actions, liabilities, losses, costs and expenses, including costs of
investigation and reasonable attorneys' fees incurred hereunder (hereinafter,
collectively, "CLAIMS") of a Third Party arising out of or in connection with
(i) the material breach by Allergan of any of its representations, warranties,
covenants or obligations under this Agreement; (ii) any activities by any
Allergan Indemnitee that violate any Applicable Law or are inconsistent with the
Marketing Plan, the Product Promotional Materials or any guidelines approved by
the JCC; (iii) any Claims brought by or on behalf of any Allergan PSR, Allergan
District Manager or member of Allergan's Sales Management Team in connection
with their employment or the performance of Allergan's obligations under this
Agreement; and (iv) any negligent act or omission of any Allergan Indemnitee in
the performance of any obligation under this Agreement; provided, however, that
in each of (i) through (iv), Allergan will have no liability as set forth in
this SECTION 11.1 to the extent such Claims are the responsibility of GSK under
SECTION 11.2 (INDEMNIFICATION BY GSK).

     11.2 INDEMNIFICATION BY GSK. GSK will indemnify, defend and hold Allergan,
and its officers, directors, agents, employees, and Affiliates (collectively,
the "ALLERGAN INDEMNITEES"), harmless from any Claim of a Third Party arising
out of or in connection with (i) the material breach by GSK of any of its
representations, warranties, covenants or obligations under this Agreement; (ii)
any activities by any GSK Indemnitee that violate any Applicable Law or are
inconsistent with the Marketing Plan, the Product Promotional Materials or what
has been approved by the JCC; (iii) any theory of product liability concerning
the development, testing, manufacture, promotion (but only to the extent that
such Claims do not arise out of conduct covered by Allergan's indemnification
obligations set forth in SECTION 11.1 (INDEMNIFICATION BY ALLERGAN)), sale or
use of the Product by GSK, its Affiliates or its sublicensees; (iv) any Claims
brought by or on behalf of any GSK PSR, GSK District Manager or member of GSK's
Sales Management Team in connection with their employment or the performance of
GSK's obligations under this Agreement; (v) any negligent act or omission of any
GSK Indemnitee in the performance of any obligation under this Agreement; (vi)
any activities or omissions of any GSK Indemnitee unrelated to the Promotion of
Product under this Agreement, whether inside or outside the Territory; and (vii)
any Claims that relate to any GSK arrangement under this Agreement with an
Affiliate or a Third Party other than Allergan to co-promote the Product in the
Territory; provided, however, that in each of (i) through (vii), GSK will have
no liability as set forth in this SECTION 11.2 to the extent such Claims are the
responsibility of Allergan under SECTION 11.1 (INDEMNIFICATION BY ALLERGAN).

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       43

<PAGE>

     11.3 PROCEDURE. A Party asserting a claim for indemnification under this
ARTICLE 11 will notify the indemnifying Party in writing of any such claims as
follows: (a) within fifteen (15) days after receipt of service of process of the
commencement of suit, or (b) for non-litigated matters, within thirty (30) days
after receipt of notice thereof; provided, however, that failure to give such
notice will not relieve the indemnifying Party of its obligation to provide
indemnification hereunder except, if and to the extent that such failure
materially and adversely affects the ability of the indemnifying Party to defend
the applicable Claim. The indemnifying Party will be entitled to assume sole
control over the defense of any such claim at its own cost and expense;
provided, however, that the indemnitee will have the right to be represented by
its own counsel at its own cost in such matters. Neither the indemnifying Party
nor the indemnified Party will settle or dispose of any such matter in any
manner which would adversely affect the rights or interests of the other Party
without the prior written consent of the other Party, which will not be
unreasonably withheld or delayed. Each Party will reasonably cooperate with the
other Party and its counsel in the course of the defense of any such Claim, such
cooperation to include without limitation using reasonable efforts to provide or
make available documents, information and witnesses.

     11.4 LIMITATION OF LIABILITY. With respect to any claim by one Party
against the other arising out of the performance or failure of performance of
the other Party under this Agreement, the Parties expressly agree that the
liability of such Party to the other Party for such breach will be limited under
this Agreement or otherwise at law or equity to direct damages only. IN NO EVENT
WILL A PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INDIRECT, SPECIAL, PUNITIVE,
EXEMPLARY, INCIDENTAL OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION,
LOSS OF PROFIT, LOSS OF BUSINESS , LOSS OF SAVING OR OTHER LOSS. The limitations
set forth in this SECTION 11.4 will not apply with respect to the obligations of
either Party to indemnify the other under SECTIONS 11.1 (INDEMNIFICATION BY
ALLERGAN) or 11.2 (INDEMNIFICATION BY GSK) in connection with a Claim of a third
party.

     11.5 INSURANCE. Each Party hereby represents that it currently carries, in
full force and effect, commercial general liability insurance against claims
judgments, liabilities and expenses for which it is obligated to indemnify the
other Party under this ARTICLE 11 , in such amounts and with such deductibles as
are customary at the time for companies engaged in a similar business, and will
provide the other Party with written evidence of such insurance upon request as
well as a certificate of such insurance naming such other Party as an additional
insured. The Party carrying such insurance policy will require at least thirty
(30) days' notice to the other Party prior to cancellation or material change in
such policy.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       44

<PAGE>

                                   ARTICLE 12

                              TERM AND TERMINATION

     12.1 TERM. The term of this Agreement (the "TERM") will commence as of the
Effective Date and will include the Commitment Term and the Residual Term, as
such terms are defined in this Agreement.

          12.1.1 COMMITMENT TERM. The Commitment Term, as defined in SECTION
3.2.5 (DETAILS) above, will be effective as of the Effective Date and, if not
terminated earlier pursuant to another provision of this ARTICLE 12, will
continue until the fifth (5th) anniversary of the Co-Promotion Commencement
Date; subject to a possible extension as set forth in SECTION 12.1.2 below.

          12.1.2 EXTENSION OF COMMITMENT TERM. Once Allergan will have met its
Minimum Details Commitment in each Commitment Year during the Commitment Term,
the Parties will have the option to extend the Commitment Term by mutual written
agreement as more fully described in SECTION 3.2.5(C) (COMMITMENT TERM). Other
elements of SECTION 12.1.1 (COMMITMENT TERM) above will remain unchanged. The
Party desiring an extension will provide the other Party with written notice of
any proposed extension at least one hundred eighty (180) days before the end of
the Commitment Term in order to enable the Parties to cooperate on such
extension.

          12.1.3 RESIDUAL TERM. Upon the expiration of the Commitment Term and
this Agreement, Allergan will be entitled to the Residual Term Royalty described
in SECTION 7.1.2 (RESIDUAL TERM PAYMENTS) during the *** period immediately
following the expiration of the Commitment Term (the "RESIDUAL TERM"). As of
such commencement of the Residual Term, Allergan's obligations under SECTION
3.2.5 (DETAILS) and any other obligation related to Allergan Minimum Detail
Commitments will terminate. All other obligations of the Parties under this
Agreement will continue in full force and effect, including, but not limited to,
GSK's obligation to continue to compensate Allergan according to ARTICLE 7
(COMPENSATION).

     12.2 TERMINATION FOR CAUSE.

          12.2.1 MATERIAL BREACH. In the event of a material breach or default
of this Agreement by either Party that is not cured within *** after receipt of
notice thereof from the other Party, the non-breaching Party will be entitled to
terminate this Agreement by giving written notice to the other Party, such
termination to take effect immediately. The right to terminate this Agreement
will not be affected in any way by a waiver of, or failure to take action with
respect to, any previous default.

          12.2.2 BANKRUPTCY OR INSOLVENCY. Either Party will have the right to
terminate this Agreement effective upon written notice to the other Party in the
event the non-notifying Party becomes insolvent or makes an assignment for the
benefit of creditors, or in the event

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       45

<PAGE>

bankruptcy or insolvency proceedings are instituted against the non-notifying
Party or on the non-notifying Party's behalf.

     12.3 TERMINATION WITHOUT CAUSE. Allergan will have the right to terminate
this Agreement without cause upon one hundred eighty (180) days' advance written
notice to GSK.

     12.4 MUTUAL TERMINATION. This Agreement may be terminated at any time by
mutual written consent of the Parties.

     12.5 EFFECT OF TERMINATION. Upon any termination or expiration of this
Agreement, Allergan will immediately cease any and all Promotion of the Product
and Allergan will promptly destroy, or will cooperate with GSK in the collection
and return to GSK of, all Product Promotional Materials, scientific literature
relating to the Product, Samples, and other sales or sales training materials in
the possession of Allergan, any Allergan PSR, Allergan District Manager and/or
any member of Allergan's Sales Management Team, as promptly as practical after
the date thereof. The foregoing destruction and/or returns will be at GSK's
expense if this Agreement has been terminated by Allergan under SECTION 12.2
(MATERIAL BREACH) and otherwise will be at Allergan's expense. In the event that
Allergan terminates this Agreement prior to the end of the Commitment Term for
any reason, other than for cause under SECTION 12.2 (MATERIAL BREACH), effective
as of the effective date of such termination, Allergan will not be entitled to
receive further payments under SECTION 7.1 (COMPENSATION ARRANGEMENT) except for
previously owed or accrued amounts that have not yet been paid to Allergan (if
any).

     12.6 NO WAIVER OF REMEDIES. Termination of this Agreement will not preclude
either Party from (a) claiming any other damages, compensation or relief that it
may be entitled to upon such termination, (b) any right to receive any amounts
accrued under this Agreement prior to the termination date but which are unpaid
or become payable thereafter and (c) any right to obtain performance of any
obligation provided for in this Agreement which will survive termination.

     12.7 SURVIVAL OF CERTAIN PROVISIONS. Termination or expiration of this
Agreement for any reason will terminate all outstanding obligations and
liabilities between the Parties arising out of this Agreement, except:

          12.7.1 those described in Section 3.4 (Ownership of Product), Section
5.1 (Marketing Authorization and Regulatory Matters), Article 9
(Confidentiality), Article 11 (Indemnification and Insurance), Section 8.1
(Details and Samples), Section 8.2 (Compensation Payments), Section 8.3
(Financial Audit Rights), Section 12.5 (Effect of Termination), Section 12.6 (No
Waiver of Remedies), this Section 12.7 (Survival of Certain Provisions), Section
13.1 (Integration/ Modification), Section 13.3 (Non-Waiver), Section 13.6
(Severability), Section 13.7 (Notices), Section 13.10 (Dispute Resolution),
Section 13.12 (Jurisdiction and Governing Law), Section 13.13 (Interpretation)
and Section 13.16 (Non-Solicitation), all of which will survive termination or
expiration of this Agreement for the time specified in such Articles and
Sections; provided, however, that if no such time period is specified in such
Articles and Sections, they will all survive termination or expiration of this
Agreement indefinitely;

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       46

<PAGE>

          12.7.2 Article 1 (Definitions) for the sole purposes of interpreting
the obligations and liabilities between the Parties surviving termination or
expiration of this Agreement;

          12.7.3 and, to the extent applicable, and any remedies for the breach
thereof, will survive the expiration or any termination of this Agreement.

                                   ARTICLE 13

                                  MISCELLANEOUS

     13.1 INTEGRATION/MODIFICATION. This Agreement by and between the Parties
hereto, is both a final expression of the Parties' agreement and a complete and
exclusive statement with respect to all of its terms. The Exhibits referred to
in this Agreement are incorporated herein and made a part of this Agreement by
this reference. This Agreement supersedes all prior and contemporaneous
agreements and communications, whether oral, written or otherwise, concerning
any and all matters contained herein, provided, however, that the
confidentiality provisions of ARTICLE 9 (CONFIDENTIALITY) are in addition to and
do not supersede the terms and conditions of the Confidential Disclosure
Agreement between the Parties dated September 27, 2004. No rights or licenses
are granted or deemed granted hereunder or in connection herewith, other than
those rights expressly granted in this Agreement. No trade customs, courses of
dealing or courses of performance by the Parties will be relevant to modify,
supplement or explain any term(s) used in this Agreement. This Agreement may
only be modified or supplemented in a writing expressly stated for such purpose
and signed by the Parties to this Agreement.

     13.2 RELATIONSHIP BETWEEN THE PARTIES. The Parties have no ownership
interest in the other and their relationship, as established by this Agreement,
is solely that of independent contractors. This Agreement does not create any
partnership, joint venture or similar business relationship between the Parties.
Neither Party is a legal representative of the other Party, and neither Party
can assume or create any obligation, representation, warranty or guarantee,
express or implied, on behalf of the other Party for any purpose whatsoever.

     13.3 NON-WAIVER. The failure of a Party to insist upon strict performance
of any provision of this Agreement or to exercise any right arising out of this
Agreement will neither impair that provision or right nor constitute a waiver of
that provision or right, in whole or in part, in that instance or in any other
instance.

     13.4 ASSIGNMENT. This Agreement is binding upon and inures to the benefit
of the Parties, and to their permitted successors and assigns. No Party may
assign or delegate any or all of its rights or obligations under this Agreement
to any Person without the prior written consent of the other Party except that
GSK may assign this Agreement to an Affiliate without the prior written consent
of Allergan. Any assignment or delegation, or any other transfer or change of
control by sale, acquisition, merger, or otherwise, or attempt at the same,
(other than to an Affiliate in the case of GSK), made in the absence of such
prior written consent will be void and

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       47

<PAGE>

without effect; provided, however, that in the event of the foregoing, such
written consent will not be unreasonably withheld.

     13.5 NO THIRD PARTY BENEFICIARIES. This Agreement is neither expressly nor
impliedly made for the benefit of any Party other than those executing it.

     13.6 SEVERABILITY. If, for any reason, any part of this Agreement is
adjudicated invalid, unenforceable or illegal by a court of competent
jurisdiction, such adjudication will not affect or impair, in whole or in part,
the validity, enforceability or legality of any remaining portions of this
Agreement. All remaining portions will remain in full force and effect as if the
original Agreement had been executed without the invalidated, unenforceable or
illegal part.

     13.7 NOTICES. Any notice to be given under this Agreement must be in
writing and delivered either in person, by any method of mail (postage prepaid)
requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its
address(es) given below, or at any address such Party has previously designated
by prior written notice to the other. Notice will be deemed sufficiently given
for all purposes upon the earlier of: (a) the date of actual receipt; (b) if
mailed, three (3) days after the date of postmark; or (c) if delivered by
overnight courier, the next business day the overnight courier regularly makes
deliveries.

          If to GSK, notices must be addressed to:

               SmithKline Beecham Corporation d/b/a GlaxoSmithKline
               5 More Drive
               Research Triangle Park, North Carolina 27709
               Attention: Senior Vice President, US Pharmaceuticals RTP
               Facsimile:

          With a copy to:

               Smith Kline Beecham Corporation d/b/a GlaxoSmithKline
               2301 Renaissance Boulevard
               King of Prussia, PA 19406-2772
               Attention: Vice President and Associate General Counsel,
               R&D Legal Operations, Business Development Transactions Team
               Facsimile: 610-787-7084

     If to Allergan, notices must be addressed to:

                    Allergan Sales, LLC.
                    2525 Dupont Drive
                    Irvine, California 92612 U.S.A.
                    Attention: Vice President, Operations
                    Telephone: (714) 246-4767
                    Facsimile: (714) 246-6557

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       48

<PAGE>

     with a copy to:

                    Allergan, Inc.
                    2525 Dupont Drive
                    Irvine, Ca 92515 U.S.A.
                    Attention: General Counsel
                    Telephone: (714) 246-4658
                    Facsimile: (714) 246-6987

     In case of notices given pursuant to SECTION 11.5 (INSURANCE), with a copy
to:

                    Allergan, Inc.
                    2525 Dupont Drive
                    Irvine, Ca 92613 U.S.A.
                    Attention: Risk Management Department
                    Facsimile: (714) 246-4162

     13.8 COMPLIANCE WITH LAWS. Each Party will at all times comply with all
applicable Federal and state laws and regulations relating to its activities
under this Agreement.

     13.9 FORCE MAJEURE. Each Party will be excused from liability for the
failure or delay in performance of any obligation under this Agreement by reason
of any extraordinary, unexpected and/or unavoidable event, such as acts of God,
fire, flood, explosion, earthquake, or other natural forces, war, civil unrest,
accident, destruction or other casualty, any lack or failure of transportation
facilities, any lack or failure of supply of raw materials, any strike or labor
disturbance, or any other event similar to those enumerated above. Such excuse
from liability will be effective only to the extent and duration of the event(s)
causing the failure or delay in performance and provided that the Party has not
caused such event(s) to occur. Notice of a Party's failure or delay in
performance due to force majeure must be given to the other Party within ***
after its occurrence. All delivery dates under this Agreement that have been
affected by force majeure will be tolled for the duration of such force majeure.
In no event will any Party be required to prevent or settle any labor
disturbance or dispute. Notwithstanding the foregoing, but except as set forth
in SECTION 7.1.3(A) (FAILURE TO SUPPLY PRODUCT OR SAMPLES), should the event(s)
of force majeure suffered by a Party extend beyond a *** period, the other Party
may then terminate this Agreement by written notice to the non-performing Party.

     13.10 DISPUTE RESOLUTION. Except with regard to any matters or disputes
between the Parties that are to be resolved by the JCC as set forth in this
Agreement, if a dispute or controversy regarding any other matter under this
Agreement, arises between the Parties which they are unable to resolve (a
"DISPUTE"), each of the Parties will (subject to any applicable cure period as
set forth in this Agreement), be entitled to submit to the other Party written
notice of such Dispute, with such notice setting forth in reasonable detail the
nature of the Dispute (the "DISPUTE NOTICE"). For a period of thirty (30) days
after the date of the receiving Party's receipt of the Dispute Notice, the
Parties will seek to resolve such Dispute by good faith negotiation between the
President U.S. Pharmaceuticals for GSK or his/her designee and the President
U.S.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       49

<PAGE>

for Allergan or his/her designee. If at the end of such thirty (30) day period
the Dispute remains unresolved, the Parties may seek relief for such Dispute
using any appropriate administrative or judicial mechanism which may be
available, subject to SECTION 13.12 (JURISDICTION AND GOVERNING LAW). The
provisions of this SECTION 13.10 will not restrict in any way the Parties'
rights to seek preliminary injunctive or other equitable relief from any court
having jurisdiction.

     13.11 LEGAL FEES. If any Party to this Agreement resorts to any legal
action in connection with this Agreement, the prevailing Party will be entitled
to seek reasonable fees of attorneys and other professionals in addition to all
court costs which that Party may incur as a result.

     13.12 JURISDICTION AND GOVERNING LAW. Notwithstanding its place of
execution or performance, this Agreement will be governed by and construed in
accordance with the laws of the State of New York, irrespective of its laws
regarding choice or conflict of laws. The Parties hereby agree that for the
purposes of resolving any Disputes hereunder, in accordance with SECTION 13.10,
that the Parties hereby submit to the exclusive jurisdiction of the courts of
New York.

     13.13 INTERPRETATION.

          13.13.1 The captions and headings of clauses contained in this
Agreement preceding the text of the articles, sections, subsections and
paragraphs hereof are inserted solely for convenience and ease of reference only
and will not constitute any part of this Agreement, or have any effect on its
interpretation or construction.

          13.13.2 All references in this Agreement to the singular will include
the plural where applicable, and all references to gender will include both
genders and the neuter.

          13.13.3 Unless otherwise specified, references in this Agreement to
any article will include all sections, subsections, and paragraphs in such
article; references in this Agreement to any section will include all
subsections and paragraphs in such sections; and references in this Agreement to
any subsection will include all paragraphs in such subsection.

          13.13.4 All references to days in this Agreement will mean calendar
days, unless otherwise specified.

          13.13.5 The word "including" or any variation thereof means "including
without limitation" and the word "including" or any variation thereof will not
be construed to limit any general statement which it follows to the specific or
similar items or matters immediately following it.

          13.13.6 Ambiguities and uncertainties in this Agreement, if any, will
not be interpreted against either Party, irrespective of which Party may be
deemed to have caused the ambiguity or uncertainty to exist.

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       50

<PAGE>

     13.14 COUNTERPARTS. This Agreement may be executed in one or more
counterparts (which may be delivered via facsimile), each of which will be
deemed an original document, and all of which, together with this writing, will
be deemed one instrument.

     13.15 FURTHER ASSURANCES. Each Party to this Agreement will, at its own
expense, furnish, execute, and deliver all documents and take all actions as may
reasonably be required to effect the terms and purposes of this Agreement.

     13.16 NON-SOLICITATION. The Parties hereto recognize that each Party has a
substantial interest in preserving and maintaining confidential its Confidential
Information hereunder. Each Party hereto recognizes that certain of the other
Party's employees may have access to such Confidential Information of the other
Party. The Parties hereto therefore agree not to solicit or otherwise induce or
attempt to induce for purposes of employment, any PSRs from the other Party
during the Term of this Agreement and for a period of one (1) year thereafter.
Notwithstanding the foregoing, nothing herein will restrict or preclude either
Party's right to make generalized searches for employees by the issue of
advertising in the media or by engaging search firms to engage in searches that
are not targeted or focused on any PSR of the other Party.

                            [Signatures on next page]

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       51

<PAGE>

     IN WITNESS WHEREOF, the Parties hereto have caused this Co-Promotion
Agreement to be executed by their duly authorized officers as of the day and
year first above written.

SMITHKLINE BEECHAM CORPORATION          ALLERGAN, INC.
D/B/A GLAXOSMITHKLINE

By: /s/ DONALD E. PARMAN                By: /s/ DAVID PYOTT
    ---------------------------------       ------------------------------------
Name: Donald E. Parman                  Name: David Pyott
      -------------------------------         ----------------------------------
Title: Vice President and Secretary     Title: Chairman & CEO
       ------------------------------          ---------------------------------

                                        ALLERGAN SALES LLC

                                        By: /s/ JEFFREY L. EDWARDS
                                            ------------------------------------
                                        Name: Jeffrey L. Edwards
                                              ----------------------------------
                                        Title: Vice President and
                                               Chief Financial Officer
                                               ---------------------------------

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       52

<PAGE>

                                    EXHIBIT A

                        NET SALES CALCULATION ADJUSTMENTS

NEUROLOGIST SEGMENT ALLOCATION FACTOR

The Net Sales for the Primary Product and the Additional Neuro Product in the
Neurologist Segment will be based on ***.

PCP SEGMENT ALLOCATION FACTOR

The Net Sales for the Primary Product and Additional Neuro Product for
identified Primary Care Physicians (PCP's) will be obtained based on ***.

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       53

<PAGE>

                                    EXHIBIT B

                 MARKETING PLAN OUTLINE FOR THE PRIMARY PRODUCT

                     TO THE PRIMARY PRODUCT TARGET AUDIENCE

1)   Executive Summary

2)   Market Analysis as to the Primary Product Target Audience

3)   Product Profile

     -    Product Description

     -    Indications

     -    Clinical Experience and Program

     -    Formulation, Packaging and Administration

4)   SWOT Analysis

5)   One (1) - year Sales Forecasts of Net Sales from the Primary Product Target
     Audience

     -    Units, Dollars, Prescriptions, Market Share from the Primary Product
          Target Audience

6)   Objectives - In each case as to the Primary Product Target Audience

     -    Communication

     -    Sales

     -    Market Share

     -    Managed Care/Formulary - Message development only

7)   Key Issues

8)   Strategies

     -    Product Positioning

     -    Audiences - Primary Product Target Audience

     -    Sales Force

     -    Managed Care/Formulary - Message development only

9)   Tactics - In each case as to the Primary Product Target Audience

     -    Market Research

     -    Product Promotional Guidelines

     -    Personal Selling Materials/Program

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       54

<PAGE>

     -    Non-Independent Medical Education

     -    Publication Plan

     -    Physician Targets

     -    Sales Training

     -    Sales Force Incentive Plan

     -    Territory Sales Force Effort

     -    Sampling Plans and Forecasts

     -    Managed Care / Formulary

10)  Budget for Following Year

11)  Timelines

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

                                       55

<PAGE>

                                    EXHIBIT C

                               TECHNICAL AGREEMENT

     To be provided by GSK within thirty (30) days of the Effective Date

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

<PAGE>

                                    EXHIBIT D

                      QUARTERLY PERFORMANCE PAYMENT EXAMPLE

***

***  Certain confidential information contained in this document, marked with 3
     asterisks, has been omitted and filed separately with the Securities and
     Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act
     of 1934, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]